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ABSTRACT
NITRIC OXIDE AND CARDIAC MYOCYTE CONTRACTION
ADRIAN J.B. BRADY
Nitric oxide is involved in the function of many cell types, including nerve,
muscle, leucocytes and endothelium. Whether nitric oxide is implicated in the
contractile function of isolated cardiac ventricular myocytes forms the major part of
the work of this thesis.
Contracting guinea-pig cardiac myocytes were studied in isolation in vitro
using a videomicroscopy length detection system.
Studies are presented which establish that nitric oxide attenuates contractility
of cardiac ventricular myocytes, both when it is derived from exogenous sources, and
when nitric oxide is released from adjacent endothelium in coculture with cardiac
myocytes. The coronary microcirculation is in close proximity to cardiac myocytes
within the myocardium, thus endothelium-derived nitric oxide may have an important
tonic effect on myocardial contractility. This may be particularly important when the
diffusing distance from endothelial cell to myocyte is altered in disease states.
Myocardial contractility is impaired in endotoxic shock. The hypothesis that
this is caused by production of nitric oxide within cardiac myocytes is examined. A
model of endotoxic shock was developed. Contractility of cardiac myocytes was
substantially impaired. Much of this impairment was caused by nitric oxide
production within the cardiac myocytes themselves. Inhibition of nitric oxide
synthesis in these cells restored contractility towards normal. Healthy myocytes did
not produce effective amounts of nitric oxide. Induction of nitric oxide synthase
activity within cardiac myocytes may account for much of the depressed contractility
of endotoxic heart failure.
Myocardial contractility is impaired following ischaemia-reperfusion.
Experiments examining myocyte behaviour in this situation are presented, but whether
activation of nitric oxide synthase contributes to the impaired contractility of myocytes
following ischaemia is not established. Studies to define the direct action of
neutrophils on cardiac myocytes are presented, and reasons why these experiments
did not generate definitive answers are discussed.
Nitric oxide is an important modulator of cardiac myocyte contraction. It may
have a role in the regulation of myocardial contractility. Production of nitric oxide
within myocytes may contribute to the depressed contractility of endotoxic heart
failure.
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CHAPTER 1: INTRODUCTION
1.1 NITRIC OXIDE BIOLOGY
Nitric oxide is an inorganic radical gas. It is also one of the most important
modulators of cellular function in biology. Only since the 1970s has this importance
become apparent.
Its existence has long been known to chemists as a simple molecule: N=0,
with an unpaired electron. In its pure form, in solid or liquid phase, nitric oxide
exists as a dimer for chemical stability. In the environment, the odd electron makes
it a highly reactive species. Nitric oxide reacts readily with oxygen to form nitrogen
dioxide, a powerful oxidising agent. Nitric oxide and other reactive oxides of
nitrogen are produced by plants, by combustion of hydrocarbons in motor vehicles
and jet aircraft, and combustion of most other biological materials (Halliwell &
Gutteridge, 1993). This introduction begins with a brief history of how the discovery
of the importance of nitric oxide to biology evolved.
1.1.1. Discovery of the biological importance of nitric oxide
Four independent cornerstones of investigation led to the discovery of the
importance of nitric oxide in biological systems (Nathan, 1992), illustrated in
Figure 1.
(i) Mammalian cells generate a reactive nitrogen oxide from the guanidino end
of the amino acid, L-arginine.
(ii) These reactive nitrogen oxides mediate a physiological reaction in
macrophages. Chemically modified L-arginine analogues block the synthesis
of nitrogen oxides.
(iii) Another tissue, the endothelium, also produces the reactive nitrogen oxide,
nitric oxide. Its action within the vasculature had already been the subject of
intensive research by vascular biologists, who had identified some of its
functions but not its nature.
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(iv) Nitric oxide is produced by neural tissue and has properties of a
neurotransmitter.
Macrophages as a source of nitric oxide.
Interest in biological nitrates developed following the association of
nitrosamines with carcinoma of the stomach. Attempts to study this in animal models
and human subjects showed that mammals synthesise nitrates (Green et al., 1981b;
Green et al., 1981a). At first it was considered that intestinal bacteria were the sole
source of these nitrates. But studies with germ-free rats showed that these animals
also produced nitrogen oxides. An important observation was made when a human
subject became ill with intercurrent infection during one study (Green et al., 1981a).
Excretion of NQ3- became markedly elevated and this finding was confirmed in
2
animal experiments (Wagner et al., 1983; Stuehr & Marietta, 1985). It appeared that
macrophages accounted at least in part for the excess production of nitrogen oxides.
Explanted macrophages were able to secrete these substances (Stuehr & Marietta,
1985), generated from oxidation of a guanidino nitrogen from the amino acid, L-
arginine (Iyngar et al., 1987). This oxidation yielded the amino acid citrulline, and
a reactive compound, more reactive than either nitrite or nitrate, which could
nitrosate amines to toxic nitrosamines (Miwa et al., 1987). Thus the observation was
made that mammalian cells could generate reactive nitrogen oxides from L-arginine.
Independently, other researchers were studying the oxidative injury
macrophages cause to tumour cells and fungi. Hibbs et al had been studying this field
since the early 1970s (Hibbs et al., 1971; Hibbs et al., 1972; Hibbs et al., 1990b)
and showed in 1987 that macrophage cytotoxicity required L-arginine, and that
modification of the L-arginine molecule blocked both nitrite production and
cytotoxicity of macrophages (Hibbs et al., 1987). The production of nitrogen
compounds also required protein synthesis, implying induction of an enzyme within
the macrophages(Stuehr & Marietta, 1987). The development of analogues of L-
arginine which inhibit synthesis of nitrogen oxides paved the way for an explosion in
nitric oxide research.
Endothelium as a source of nitric oxide.
Furchgott and Zawadski had shown in 1980 (Furchgott & Zawadzki, 1980)
that endothelium was not merely an inert lining of a hollow tube, but that it
influenced its adjacent smooth muscle in the vascular wall. The identification of their
endothelial-derived relaxing factor (EDRF) as nitric oxide evolved over the following
eight years, although as early as 1977 Arnold et al had shown nitric oxide capable of
activating guanylate cyclase in different tissues, the enzyme now known to be the
target for nitric oxide in smooth muscle (Arnold et al., 1977). In mid-1986 Furchgott
and Ignarro independently suggested that EDRF might be nitric oxide (Ignarro et al.,
1988). In 1987, two groups showed that stimulated endothelium released a nitrogen
oxide (Palmer et al., 1987; Ignarro et al., 1987) which was neither nitrite or nitrate,
although a chemiluminescent assay failed to identify which nitrogen oxide was active
(Palmer et al., 1987). In 1988, Palmer et al and Schmidt et al then showed that
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EDRF release from cultured cells required L-arginine (Palmer et al., 1988a; Schmidt
et al., 1988), and that same year Palmer et al demonstrated that release of nitric oxide
from endothelium was inhibited by analogues of L-arginine (Palmer et al., 1988b).
Neural tissue as a source of nitric oxide.
Neurobiologists had known since the early 1970s that some neurotransmitters
elevated cyclic GMP in neural tissue (Ferrendelli et al., 1974). In 1977 Miki et al
showed that nitric oxide stimulated the guanylate cyclase enzyme in mouse cerebral
cortex (Miki et al., 1977). In 1982 L-arginine was shown to activate guanylate
cyclase in neuroblastoma cells (Deguchi & Yoshioka, 1982) and in 1988 cerebellar
tissue was shown to release a mediator with properties like nitric oxide, which both
elevated cyclic GMP and relaxed vascular smooth muscle (Garthwaite et al., 1988).
Release of nitric oxide and citrulline by neural tissue was inhibited by an analogue
of L-arginine, evidence that synaptic cells contained the nitric oxide synthase enzyme
(Knowles et al., 1989). Thus nervous tissue, as well as leucocytes and endothelium,
was shown to employ nitric oxide as a chemical mediator.
Moncada demonstrated recently the importance in terms of phylogenetics and
evolution of nitric oxide biology (invited lecture to the American Heart Association,
November 1991, Anaheim, USA). Not only do all mammals examined employ nitric
oxide as an intercellular mediator, but even primitive invertebrates use nitric oxide
in their circulatory "blood-like" cells as a chemical messenger, and probably as a
cytotoxic agent too.
1.1.2. Biosynthesis of nitric oxide.
Nitric oxide is synthesised from the amino acid, L-arginine. It was believed
that cells from different tissues had different synthetic pathways, but recent work has
resolved this. Figure 2 shows the pathway of nitric oxide production from L-arginine
(modified from Nathan)(Nathan, 1992). Both oxidation steps are catalysed by the
enzyme, nitric oxide synthase. NADPH donates three electrons and molecular
oxygen provides two more.
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L-arginine Nw-OH-L-arginine Nitric oxide L-citrulline
Figure 2
Different nitric oxide synthase enzymes have been isolated from diverse tissues
and species. At present, no nomenclature classifies them satisfactorily. Three
enzyme types for which cDNAs have been reported at this time are listed below
(Nathan, 1992), shown in Table 1.
constitutive NOS (cNOS) constitutive NOS (cNOS) inducible NOS
(iNOS)




elevated [Ca2+]i -» binding of
calmodulin





Activation of the constitutive nitric oxide synthase (cNOS) enzymes follows
elevation of [Ca2+];, which causes the calcium binding protein, calmodulin, to adhere
to and activate constitutive nitric oxide synthase (Busse & Mulsch, 1990; Nathan,
1992). These nitric oxide synthases are thus susceptible to agonists that elevate Ca2+,
and are termed Ca2+-dependent by some authors (Moncada et al., 1991).
Activation of mouse macrophage nitric oxide synthase is not controlled by
changes in [Ca2+];, since this type of nitric oxide synthase binds calmodulin tightly
at resting intracellular levels of calcium (Cho et al., 1992). Induction of new protein
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is required to synthesise this nitric oxide synthase, hence it is termed inducible (Xie
et al., 1992) whereas nitric oxide synthase in brain and endothelium exists in resting
cells and is termed constitutive (Moncada & Higgs, 1991). Human endothelial
constitutive nitric oxide synthase has recently been cloned by T Michels in Boston
(Nathan, 1992). It has 94% homology with the bovine constitutive nitric oxide
synthase amino acid sequence.
1.1.3. Distribution and activation of nitric oxide synthases
At the time of writing nitric oxide synthases have been divided broadly into
constitutive enzymes and inducible ones. As Table 2 below shows, constitutive nitric
oxide synthases are activated rapidly by a variety of inflammatory or pharmacological
stimuli. Inducible nitric oxide synthase enzymes require induction of mRNA and
protein synthesis and this process is stimulated by inflammatory cytokines.
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sources Endothelial cells
Some central neurons














Cardiac myocytes Cardiac myocytes*
rapid activators acetylcholine, bradykinin, ADP,
thrombin, endotoxin, FMLP,
leukotrienes, PAF, some amino










* The demonstration and function of nitric oxide synthase activity within cardiac
myocytes is the central finding of this thesis
Agents which stimulate nitric oxide production within seconds or minutes of
exposure act on existing constitutive nitric oxide synthase. Many of the rapid
activators listed elevate [Ca2+];, causing calmodulin to bind to nitric oxide synthase.
Tissues which contain inducible nitric oxide synthase take several hours to generate
nitric oxide. This process is blocked by inhibitors of DNA transcription or mRNA
translation, thus new protein synthesis occurs. Once induced, inducible nitric oxide
synthase generates nitric oxide for many hours or even days (Xie et al., 1992). How
this production is turned off is not known, but mechanisms to regulate nitric oxide
production once initiated likely exist, but have yet to be discovered.
A range of substances have been developed or discovered to inhibit nitric
oxide synthase. These include: -
(i) Substrate inhibitors (Moncada et al., 1991): (analogues of L-arginine)- N"-methyl-
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L-arginine (L-NMMA); N"-nitro-L-arginine; N"-nitro-L-arginine methyl ester (L-
NAME); N^-amino-L-arginine.
(ii) Flavoprotein binders (Stuehr et al., 1991). Diphenylene iodinium binds to
flavoprotein cofactors involved in nitric oxide synthase function. This agent also
binds to other cellular flavoproteins and is thus not a useful therapeutic agent.
(iii) Calmodulin binders (Bredt & Snyder, 1990). These pharmacological tools are
available but since calmodulin is involved in many cellular processes, they are not
useful therapeutically.
(iv) Carbon monoxide (Nathan, 1992). Nitric oxide synthase contains a haem moiety,
to which carbon monoxide can bind and render inactive. Clearly this is not useful
as therapy. Intriguingly, emerging evidence points to physiological roles for carbon
monoxide not dissimilar to those of nitric oxide. Both substances are simple gases,
both act like neurotransmitters, both bind to haemoglobin and both activate guanylate
cyclase (Verma et al., 1993). Much will be heard about carbon monoxide in the near
future.
Apart from the calmodulin binders the above inhibitors affect both constitutive
nitric oxide synthase and inducible nitric oxide synthase. Induction of inducible nitric
oxide synthase can be effectively prevented by corticosteroids (Di Rosa et al., 1990),
and by certain cytokines: transforming growth factor -fi (TGF-ft), and the interleukins
IL-4 and IL-10 (Ding et al., 1990).
1.1.4. Intracellular site of action of nitric oxide in the vasculature
In vascular tissue the principal target for nitric oxide is the soluble guanylate
cyclase enzyme (Ignarro, 1990). Guanylate cyclase is activated by nitrosation of its
haem moiety by nitric oxide. Elevation of intracellular cyclic GMP (cGMP)
concentrations brings about vasorelaxation by mechanisms which are partially
characterised, but which must ultimately involve cellular handling of cytosolic
calcium.
Free cytosolic Ca2+ causes smooth muscle contraction by binding to
calmodulin, and this complex binds to and activates myosin light chain kinase which
phosphorylates the myosin light chain, permitting activation of Mg2+-dependent
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ATPase on the myosin cross bridge of actin. Hydrolysis of ATP follows and tension
is developed by conformational changes of cross bridges and relative movements of
actin and myosin. Tension is regulated by the number and rate of turnover of active
cross bridges (Stull & Sanford, 1981). Thus, decreased levels of free cytosolic Ca2+
result in less contraction.
CGMP probably enhances phosphorylation of key proteins involved in
handling Ca2+, perhaps along with direct inhibition of Ca2+ binding to contractile
proteins. CGMP and its dependent protein kinase inhibit:
t
(i) Ca2+ entry into cells through receptor-operated channels (Godfraind, 198ff;
Malta et al., 1986);
(ii) Ca2+ release from sarcoplasmic reticulum (Kobayashi et al., 1985);
(iii) production of inositol triphosphate (IP3) (Rapoport, 1986);
(iv) activation of sarcolemmal Ca2+-ATPase and therefore increase Ca2+
extrusion from cells (Popescu et al., 1985).
1.1.5. Intracellular targets of nitric oxide in other cell types
Macrophages exert their cytotoxic action on tumour cells by release of nitric
oxide which inhibits Fe-S proteins such as NADH (Nathan, 1992). Nitric oxide also
inhibits tumour cell DNA synthesis (Hibbs et al., 1990a). Nitric oxide also reacts
with superoxide anion in a reaction that can either detoxify both molecules, or
generate the powerful oxidants, nitrogen dioxide and hydroxyl radical (Beckman et
al., 1990).
1.2 ACTIONS OF NITRIC OXIDE IN THE VASCULATURE
1.2.1. Role of endothelium in the control of vascular tone
The human body contains a great deal of endothelium - about 1000-1500
grams. The lungs alone account for about a third of this tissue (Warren, 1990b).
The surface area of the body's endothelium would cover an area equal to the size of
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six tennis courts (Henderson, 1991). Yet only since the mid 1960s has endothelium
been considered as little more than an inert lining of blood vessels, and only over the
last 13 years has its fundamental importance in the control of vascular homeostasis
been recognised.
That blood flow could be regulated by generation of locally acting autacoids
within the vasculature became apparent during the 1960's and 70's. Renin-like
activity was detected in vascular walls (Gould et al., 1964; Ryan et al., 1976), and
the pharmacology of prostaglandins and other autacoids developed (Sparks & Belloni,
1978).
In 1980 in their now classic paper Furchgott and Zawadski demonstrated the
obligatory role of the endothelium in the relaxation of vascular smooth muscle by
acetylcholine. This finding explained the paradox of acetylcholine behaviour in
experimental preparations: that it had disparate effects, either vasodilatation or
vasoconstriction in vitro, yet was a vasodilator in vivo. While acetylcholine relaxed
precontracted rabbit aortic rings it had no effect on, or even increased contraction of,
precontracted aortic strips. Furchgott and Zawadski noticed that endothelial damage
was occurring in the preparation of aortic strips, and they postulated that
acetylcholine was acting on an endothelial receptor to release substance(s) which
mediated its vasodilator effect. The humoral nature of this relaxing substance, termed
endothelium-derived relaxing factor (EDRF), was proven in an experiment where
deendothelialised aorta was sandwiched, intima to intima, against aorta with
endothelium intact (Furchgott, 1988).
Many investigators have confirmed and studied this phenomenon further. A
wide range of physiological, chemical and physical agents act in whole or in part by
releasing EDRF from endothelium from large arteries, microvessels and veins. These
are summarised in Table 3.
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Table 3
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These agents can be grouped into neurotransmitters, platelet products and
coagulation factors, local hormones and physicochemical stimuli. Thus intravascular
agents act by diffusion across the cell membrane, while agents released from
autonomic nerve endings on smaller arteries may exert their action after diffusion
from nerve terminal to endothelial cell (Henderson, 1991).
Many of the agents listed have vasoconstrictor properties in the absence of
endothelium. This is particularly important when endothelium is damaged or
removed, for example during percutaneous transluminal coronary angioplasty (PTCA)
(Brady & Warren, 1991).
There is evidence for the existence of at least one other endothelium derived
relaxing factor in addition to nitric oxide and prostacyclin. Taylor and Weston
showed that stimulation of endothelium by acetylcholine caused membrane
hyperpolarisation and this was not inhibited by haemoglobin or methylene blue
(Taylor & Weston, 1988). The physiology of this unidentified factor, termed
endothelium derived hyperpolarising factor, has not been defined.
Not only does endothelium produce factors which affect contraction of smooth
muscle, but vascular smooth muscle itself releases an as yet unidentified factor which
causes sustained release of nitric oxide from endothelium (Warren et al., 1990). This
substance was not characterised in this study with which I was involved, and its role
in vascular physiology is not yet established, although this is being addressed by
current work.
1.2.2. Nitric oxide and blood flow
M-
The most important stimulus to EDRF release may well shear stress on the
A
endothelial luminal surface, secondary to flow of blood. Shear stress exerted on
endothelium varies considerably throughout the vasculature, since the characteristics
of blood flow depend in part on vessel size, shape and deformability. Flow induced
dilatation, long known but unexplained by physiologists, is substantially accounted for
by mechanisms involving release of nitric oxide from endothelium. Rodbard in 1975
suggested that endothelium might sense alterations in flow as changes in shear stress
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(Rodbard, 1975). This was finally shown by experiments where removal of
endothelium markedly attenuated responsiveness of coronary arteries to changes in
flow rate (Holtz et al., 1983; Pohl et al., 1986), and reactive hyperaemia was also
inhibited (Inque et al., 1989). This is supported by the finding that the non-specific
inhibitor of guanylate cyclase, methylene blue, or haemoglobin, which binds nitric
oxide, block flow dependent dilatation in dog femoral (Pohl et al., 1986) and rabbit
ear respectively (Griffith et al., 1984). Griffith et al also found that flow dependent
release of EDRF was greatest in vessels of approximately 150 /xm diameter, where
the resistance and shear force is maximal. Pulsatile flow also enhances release of
EDRF, as well as of PGI2 (Pohl et al., 1985; Rubanyi et al., 1986). Endothelium
may sense shear stress by a K+ channel sensitive to flow (Olesen et al., 1988).
Whether this causes release of nitric oxide is not yet known.
1.2.3. Nitric oxide and hypoxia
Much of the vasodilatation of systemic blood vessels supplying ischaemic
tissue is caused by accumulation of metabolites. But recent studies have shown that
vasoactive substances from endothelium probably contribute to vascular changes
brought about by hypoxia. Nitric oxide, PGI2 and PGEz are all released from
hypoxic cultured endothelial cells (Roberts et al., 1981) (Peach et al., 1985)
suggesting that oxygen sensors are located on endothelium (Bassenge & Busse, 1988).
Park et al have recently shown that nitric oxide, adenosine and vasodilatory
prostaglandins are all involved in hypoxic coronary vasodilatation (Park et al., 1992).
1.2.4. Actions of nitric oxide in vessels of different calibre
The presence of nitric oxide activity has been demonstrated in every blood
vessel studied, from large arteries to the microvasculature and the venous system
(Henderson, 1991). But different vascular beds show marked differences in EDRF
activity, both in response to nitric oxide and to its release (Christie & Lewis, 1988).
Since many stimulants of EDRF release also act directly on smooth muscle, the effect
on vascular tone depends on the relative strengths of the EDRF mediated dilatation
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and the direct effect on vascular smooth muscle (Henderson, 1991).
EDRF activity differs between arteries and veins (DeMey & Vanhoutte, 1982).
Veins release less EDRF for a particular stimulus. There are many differences
between the two tissues, not only in their structure, but probably in their receptors
for stimulants to EDRF release. That organic nitrovasodilators have a more potent
effect on veins than arteries likely reflects greater activity of the enzymes necessary
to generate nitric oxide from these drugs (Kawamoto et al., 1990).
1.2.5. Release of nitric oxide from microvessels
Microvessels from different regions of the body tonically release nitric oxide.
NO has been shown to be a vasodilator in several different microvascular preparations
(Warren et al., 1992; Gardiner et al., 1990; Ekelund & Mellander, 1990; Persson et
al., 1990). Infusion of inhibitory analogues of L-arginine elevate blood pressure
substantially, by inhibiting basal release of EDRF from resistance vessels (Rees et al.,
1989). In the human forearm a similar study caused reduction in arterial flow for the
same reason (Vallance et al., 1989). As mentioned in 1.2.2., there is an important
relationship between flow induced shear stress and EDRF release from resistance
vessels.
The heart is rich in microvascular endothelium (see section 1.4). Yet there
is still no convincing evidence of release of nitric oxide from this tissue. Inhibition
of EDRF reduces coronary blood flow (Amezcua et al., 1989) and it has been
demonstrated recently in isolated, perfused hearts that 5-hydroxytryptamine stimulates
NO release from the coronary microvasculature, measured by coronary sinus nitrite
sampling, and this is accompanied by a reduction in the time to reach peak ventricular
pressure (Shah et al., 1991). These preliminary data suggest that coronary
microvascular endothelium is capable of releasing vasoactive factors, and are further
discussed in section 1.4..
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1.2.6. Release of nitric oxide from nitrovasodilator drugs
Organic nitrates have been used to treat angina pectoris for over a century, but
only recently has their mechanism of action been established (Henderson, 1991).
Nitrovasodilator drugs cause vasodilatation by being metabolised at their site of action
to produce nitric oxide. Different nitrovasodilators are metabolised by different
pathways (Furchgott, 1988). Porcine coronary smooth muscle cells metabolise
glyceryl trinitrate (GTN) to generate nitric oxide by a plasma membrane enzyme
(Chung & Fung, 1990). Sodium nitroprusside undergoes a reduction step requiring
NADPH, NADH or a thiol which takes place in the microsomes (Fung et al., 1991).
Nitrovasodilator drugs are a convenient source of nitric oxide for experimental
purposes. It is generally assumed that they do not have much effect on myocardial
contractility. The effects of nitrovasodilators on cardiovascular haemodynamics are
established in both patients and in experimental models, but the same haemodynamic
changes will obscure any specific action of nitrovasodilators on contractility. The
isolated, functioning cardiac myocyte is thus a suitable model to study contractility
in the absence of haemodynamic changes. Whether cardiac myocytes can metabolise
different nitrovasodilator drugs to generate nitric oxide has not previously been
demonstrated.
1.3 ACTIONS OF NITRIC OXIDE IN MACROPHAGES, NEUTROPHILS,
PLATELETS, BRAIN/NERVOUS SYSTEM AND OTHER CELLS
1.3.1. Action of macrophage derived nitric oxide
s
As mentioned in 1.1.6., macrophage^are toxic to certain tumour cells and
microbes. Nitric oxide released from macrophages activated by cytokines attacks Fe-
S groups of enzymes containing this nonhaem Fe subunit. Such an enzyme is
ribonucleotide reductase, the rate-limiting enzyme in DNA replication (Hibbs et al.,
1988). Why nitric oxide affects DNA replication in only some cells is not known
(Hibbs et al., 1990b).
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The cytotoxic and cytostatic actions of macrophages on large microorganisms
closely involve nitric oxide. Inhibition of nitric oxide production impairs substantially
macrophage-mediated cell killing (Radomski et al., 1987; Granger et al., 1986; Liew
et al., 1990). Likely the free radical properties of nitric oxide account for its
cytotoxicity. Administration of pure nitric oxide also kills microorganisms (Liew et
al, 1990).
1.3.2. Action of neutrophil derived nitric oxide
Although neutrophils contain constitutive nitric oxide synthase, production of
nitric oxide does not seem to contribute much to their cytotoxic ability (Moncada et
al., 1991). Stimulation of neutrophils with formyl-methionyl-leucyl-phenylalanine
(FMLP) or LTB4 increases nitric oxide production (McCall et al., 1989). Nitric
oxide inhibits neutrophil aggregation (McCall et al., 1990) but inhibition of nitric
oxide inhibits neutrophil chemotaxis (Kaplan et al., 1990). The biological role of
constitutive nitric oxide synthase in neutrophils remains to be elucidated.
1.3.3. Role of nitric oxide in platelet function
Nitric oxide elevates cGMP in platelets, inhibiting both adhesion and
aggregation (Ayuma et al., 1986; Furlong et al., 1987; Radomski et al., 1987). PGI2
and adenosine inhibit platelet aggregation by increasing cAMP. These three autacoids
act in synergy (Radomski et al., 1987). The growth factor platelet derived growth
factor (PDGF) is released during platelet adhesion, and nitric oxide thus has a further
important role in the regulation of the mitogenic effects of platelets and PDGF. This
is clear notably during percutaneous transluminal coronary angioplasty (PTCA)
(Brady & Warren, 1991) when subendothelial tissues are exposed.
Endothelium derived nitric oxide has a role modulating platelet function at
sites of vascular injury. Activated platelets release ADP and serotonin, both of which
stimulate nearby intact endothelium to release EDRF, limiting the propagation of
platelet aggregation on to healthy intima, while the absence of nitric oxide at sites of
injury allows platelets to perform their function (Henderson, 1991).
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1.3.4. Action of nitric oxide in the nervous system
Nitric oxide in brain appears to be intimately involved in modulation of amino
acid neurotransmission. Emerging studies are suggesting a role for nitric oxide in
long term synaptic depression and potentiation, processes thought to be central to
learning and memory (Nathan, 1992). Another reaction which may involve nitric
oxide is the toxicity of glutamate during ischaemic cerebral vascular events (Dawson
et al., 1991), which may be mediated in part by nitric oxide acting as a free radical.
This suggests a possible role for inhibitors of nitric oxide or nitric oxide synthase in
treatment of ischaemic stroke (Nowicki et al., 1991).
In the peripheral nervous system, nitric oxide is co-released at non-adrenergic,
non-cholinergic (NANC) nerve terminals, and also appears to be involved in the
mechanism of penile erection (Garthwaite, 1991). Constitutive nitric oxide synthase
activity has been demonstrated in the myenteric plexus of the intestine (Snyder &
Bredt, 1991).
1.3.5. Nitric oxide in other cells
Fibroblasts produce nitric oxide when stimulated with cytokines, as do Kupffer
cells in the liver, and it is likely that this is a property of all reticuloendothelial cells,
and may indeed be found in many other cell types (Nathan, 1992).
1.4 ACTIONS OF NITRIC OXIDE IN THE HEART
1.4.1. Sources of nitric oxide in heart
Nitric oxide activity is found in coronary endothelium and endocardial
endothelium in health. This activity may be induced in coronary vascular smooth
muscle and myocardial interstitial cells in certain conditions. Demonstration of its
presence and function in myocardial contractile cells forms the major part of the work
described in this thesis. The pericardium remains as the only cardiac tissue not yet
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known to produce nitric oxide.
The function of nitric oxide in epicardial and resistance coronary arteries is
probably no different to the other vascular beds described above, i.e. regulation of
vascular tone and maintenance of homeostasis. Evidence from animal studies has
confirmed the importance of nitric oxide in the maintenance of coronary vascular tone
(Kelm & Schrader, 1990). Another study of the coronary circulation in Langendorff-
perfused guinea pig hearts showed that inhibition of nitric oxide synthase abolished
autoregulation of coronary flow (Ueeda et al., 1992).
Alteration in endothelial function may be particularly important in pathological
conditions. Examples include stable atheroma, unstable angina, Syndrome X and
acute myocardial infarction. These are discussed in section 1.5..
1.4.2. Coronary microvascular endothelium
There is much microvascular endothelium within the heart. Figure 3,
(reproduced with permission from the publishers) from the Handbook of Physiology,
demonstrates this. Elastomer injected into the coronary circulation fixed the
vasculature and myocytes and supporting tissue were chemically dissolved, leaving
the dense network of capillary vessels, as shown. These lie in close proximity to
cardiac muscle, so that most myocytes are within 8 /tun of their nearest capillary
(Rose & Goresky, 1984; Randall, 1984). This short diffusing distance means that
myocytes may be influenced by vasoactive factors produced by adjacent endothelium.
The hypothesis that cardiac myocyte contraction is sensitive to endothelium derived
nitric oxide thus became the basis for my first series of experiments.
Important differences exist between the endothelium lining large arteries, and
endothelium within the microvasculature. For example, coronary microvessels are
less sensitive than aorta to the exogenous nitrovasodilator, GTN, but relax equally to
NO solution, albeit at a higher concentration (Sellke et al., 1990). This implies that
metabolism of organic nitrates in the coronary microvasculature is less efficient than
elsewhere in the circulation, perhaps because of a relative deficiency of either the
enzymes required (Chung & Fung, 1990), or available sulfhydryl groups necessary
for generation of NO from GTN. NO has been shown to be a vasodilator in several
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different microvascular preparations (Warren et al., 1992; Gardiner et al., 1990;
Ekelund & Mellander, 1990; Persson et al., 1990).
Nitric oxide release from coronary microvascular endothelium has only been
demonstrated indirectly. Inhibition of EDRF reduces blood flow in the coronary
vascular bed as it does in others (Amezcua et al., 1989). Recent studies in isolated,
perfused hearts using 5-HT to stimulate nitric oxide release showed a reduction in the
time to reach peak ventricular pressure. Nitric oxide release from the coronary
microvasculature was shown by analysis of coronary sinus nitrite (Shah et al., 1991).
The detergent Triton X-100 is used experimentally to denude papillary muscles
of endocardial endothelium. In organ baths this agent can be washed quickly off the
preparation. Careful ultrastructural and functional analysis has shown no damage to
subendothelial structures using this method. Preliminary data have recently been
presented on the effects of infusing Triton X-100 in the coronary circulation (Li et
al., 1992). Contractile parameters were decreased by this action, and although these
data support the hypothesis that coronary microvascular endothelium influences
myocardial contraction, the explanation that the effects of so powerful a toxin in the
coronary circulation are purely on microvascular release of nitric oxide remains
speculative.
Another study using isolated guinea pig hearts showed that intracoronary
methylene blue or the nitric oxide scavenger oxyhaemoglobin both increased coronary
vascular resistance and decreased cGMP production (Kelm & Schrader, 1990).
Bradykinin, which releases nitric oxide from endothelium, dilated coronary resistance
vessels and this was accompanied by elevation of nitrite levels in coronary sinus
blood.
Although there is still no direct evidence from cultured microvascular
endothelium from hearts showing release of nitric oxide more circumstantial evidence
has been reported from Lewis' group, investigating further the effect of bradykinin
on contractile function in intact guinea pig hearts. Perfusion with bradykinin reduced
myocardial contractility, and this effect was abolished by the inhibitor of nitric oxide
synthase, L-NMMA (Fort et al., 1992). Another explanation is that the effect is
secondary to alterations in coronary resistance vessel tone caused by bradykinin, not
to a direct effect of stimulated microvasculature on cardiac myocyte contractility.
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1.4.3. Endocardial endothelium and its role in the modulation of myocardial
contraction
Until recently endocardium was considered, like vascular endothelium, not to
be of much importance other than as a structural element of the heart, but with an
important role in preventing thrombus formation within cardiac chambers. It lines
the trabeculated inner surface of the atria and ventricles. In support of the hypothesis
that important interactions exist between vascular lining cells and the myocardium,
recent studies have now shown that endocardial endothelium influences adjacent
myocardial cells by releasing at least two humoral factors which have opposing effects
on papillary muscle contraction (Smith et al., 1991). This was first described by
Brutsaert and coworkers who showed that damage to the endocardial surface of
isolated papillary muscle by brief exposure to Triton X-100 detergent causes a
reduction of about 20% (at 2.5 mM [Ca2+]0) in maximum isometric tension produced
by the muscle, brought about by an earlier onset of isometric relaxation, but with no
effect on the velocity of contraction (Brutsaert et al., 1988). This effect occurs in
endocardium-intact preparations with administration of lipid-soluble analogues of
cGMP, or with sodium nitroprusside and atrial natriuretic peptide (substances that
increase myocardial cGMP by stimulating soluble and particulate guanylate cyclase
respectively), which reduce papillary muscle contractility similar to endocardial
damage (Smith et al., 1991; Brutsaert et al., 1988; Shah & Henderson, 1992).
From experiments using cultured endocardial cells on beads in a cascade
system, endocardial endothelium appears to release both EDRF and an as yet
unidentified substance, termed endocardin, which both augments contraction and
prolongs relaxation (Smith et al., 1991). This substance does not have the
characteristics of the action of the powerful endothelial vasoconstrictor, endothelin on
papillary muscle, which itself has inotropic effects. Restoration of endocardial
products to endocardium-damaged papillary muscles both increases the force of
isometric contraction and prolongs the relaxation phase after contraction in this
system. The quantitative relationship between this as yet unknown endocardial
product and endocardial EDRF is yet to be fully established, although the unidentified
contraction-prolonging factor appeared to be dominant in these experiments (Shah &
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Henderson, 1992).
The interpretation of the effects of endocardial products on myocardial
contractility is that endocardium may influence both systolic (myocardial contraction)
and diastolic function (myocardial relaxation). The predominant effects of EDRF and
endocardin are on late systolic contraction in vitro, and this is likely to have effects
on events early in diastole, i.e. myocardial relaxation and ventricular filling. These
effects may be particularly important in conditions where myocardial contraction and
relaxation are abnormal, or the heart rate is rapid and tachycardia unduly prolonged
(Henderson, 1991; Shah & Henderson, 1992; Smith et al., 1991; Smith et al., 1992).
Exciting work from this group has just demonstrated that endothelin can be
produced by endocardial endothelium, although its place in the modulation of
myocardial contraction is yet to be established (AJ Shah, personal communication).
Further important work on papillary muscle function in inflammatory
conditions is emerging. This is discussed in chapters 7 and 10.
1.4.4. Nitric oxide release from perivascular nerves in heart
Nitric oxide mediates vasomotor nerve-induced vasodilatation in skeletal
muscle in rabbits (Persson et al., 1990). In heart, substance P nerve fibres form part
of the NANC innervation of the coronary circulation. Substance P affects coronary
blood flow and vascular tone by an endothelium-dependent mechanism (see 1.5.1.),
probably by diffusing from nerve terminals to endothelium to reach its receptors
(Weihe et al., 1981; Crossman et al., 1989). There is no evidence that other NANC
neurotransmitters, for example calcitonin gene-related peptide (CGRP) and
neuropeptide Y, act via an endothelium-dependent mechanism.
Recently, immunohistochemical evidence of nitric oxide synthase has been
found in cardiac nerve fibres and ganglion cells (Klimaschewski et al., 1992). Its
functional significance is not yet clear, but possible sites of nitric oxide activity
include myocytes, conducting tissue and vasculature.
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1.4.5. Nitric oxide activity in myocardium
There is a body of evidence concerning the function of nitric oxide in the
coronary circulation and in endocardial endothelium. Over recent months reports of
a role for nitric oxide within myocardium have begun to accumulate. Such studies
require a reductionist approach, since measurement of contractile function during
application of vasoactive agents to patients or whole animals is complicated by
haemodynamic changes due to the vasoactive agent's vascular effects.
Evidence from studies of endocardium had shown that contractility of papillary
muscle myocardium could be modified by EDRF (see 1.4.3.). Evidence that cardiac
myocyte contraction is affected by nitric oxide forms the main body of the work of
this thesis. At the same time biochemical evidence of nitric oxide synthase activity
in myocardium has become available. This work and discussion of available evidence
is presented in chapters 4-9 and chapter 11.
1.5. NITRIC OXIDE IN PATHOLOGICAL CONDITIONS
1.5.1. Hypertension and atherosclerosis
Infusion of inhibitors of nitric oxide synthase raises blood pressure in animals
by blocking tonic production of nitric oxide in resistance vessels. Disturbances in
endothelial function may contribute to hypertension. Some possible theories are:-
impairment of nitric oxide release from arteriolar endothelium;
abnormalities of nitric oxide agonist receptors;
altered nitric oxide diffusion because of smooth muscle hypertrophy;
alterations in cellular second messengers/cellular breakdown of cAMP and
cGMP.
Endothelial responses are impaired in animal models of hypertension (Lamping &
Dole, 1987; Van de Voorde & Leusen, 1986; Winquist et al., 1984; De Mey &
Gray, 1985; Luscher et al., 1987; Otsuka et al., 1988), and in patients with high
blood pressure (Panza et al., 1990; Linder et al., 1990; Calver et al., 1992). Further
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studies are awaited in this key area of cardiovascular research to place these early
findings in context.
1.5.2. Atherosclerotic vascular disease
Atherosclerosis is characterised by the development of plaques. These lesions
develop within the intima, replacing healthy endothelium with a hyperplastic
collection of lipid-rich material, macrophages, smooth muscle cells and fibrous tissue,
usually covered by endothelium. Small lesions are universal in Western adults.
Problems arise when a plaque grows gradually and becomes flow limiting, or when
it suddenly enlarges following haemorrhage within the plaque or when thrombus
develops on its surface, and then occludes the vessel.
Endothelium overlying stable plaques is abnormal, both in function and in
ultrastructural appearance. In animals made hyperlipidaemic, endothelial responses
to agents which stimulate EDRF release are diminished, while responses to
endothelium-independent (e.g. sodium nitroprusside) vasoactive agents is intact
(Coene et al., 1985; Verbeuren et al., 1986; Freiman et al., 1986; Shimokawa et al.,
1988). Interestingly, in animal models of hyperlipidaemia there is increased
production of oxides of nitrogen (Minor et al., 1990) and this may be due to
induction of inducible nitric oxide synthase in lungs (Lang et al., 1993).
Endothelial dysfunction has been demonstrated in experimental models of
diabetes (Henderson, 1991). Accumulating evidence points to the scavenging effect
of haemoglobin as the mechanism of the cerebral vasoconstriction seen in
subarachnoid haemorrhage. It may be that blood in the subarachnoid space seeps into
the intimal layers of intrathecal arteries, inhibiting EDRF released from endothelium
of those vessels (Henderson, 1991).
1.5.3. Coronary artery disease
In patients with atheromatous coronary artery disease impaired responses to
endothelium dependent vasodilators occur. Acetylcholine causes dilatation of normal
segments but constriction of vessels, not only at areas with severe atherosclerosis on
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angiography but in vessels with "minimal" disease also (Ludmer et al., 1986).
Responses to glyceryl trinitrate (GTN) were unaffected. Of course for atheromatous
lesions to appear on angiography means that significant disease must be present, so
their findings probably represent a spectrum of impaired response, rather than two
different disease processes. The endothelium-dependent vasodilating neuropeptide,
substance P dilates normal coronary arteries (Crossman et al., 1989). This effect is
abolished or much attenuated at sites of atherosclerosis (Mathew et al., 1992),
supporting the hypothesis of endothelial dysfunction in atheromatous arteries.
Loss of tonic EDRF release at sites of atheroma might predispose towards
focal coronary spasm. This is a possible explanation of the type of coronary
hyperreactivity described by Prinzmetal (Prinzmetal et al., 1959). It is tempting to
speculate on the role of nitric oxide in microvascular angina, but to date no evidence
exists to support such conjecture. EDRF activity in the peripheral vasculature is
impaired in models of chronic heart failure, and in the coronary arteries of patients
with dilated cardiomyopathy (Henderson, 1991). Thus, there is much evidence
indicating the importance of nitric oxide in atherosclerotic disease, and much more
is forthcoming.
Recently, the effects of intracoronary administration of L-NMMA in patients
with normal coronary arteries has been examined. Basal distal left anterior
descending (LAD) coronary artery diameter and basal coronary blood flow were
slightly reduced, and acetylcholine-induced distal dilatation was abolished. There was
no effect on the increase in coronary blood flow caused by acetylcholine (LeFroy et
al., 1992). This study provides further information about a tonic role of nitric oxide
in epicardial coronary arteries. The behaviour of the microcirculation was not
addressed in this study.
1.5.4. Restenosis after percutaneous transluminal coronary angioplasty (PTCA)
Endothelium has a key role in the development of restenosis after PTCA.
Most evidence available points to the regulation of smooth muscle cell growth by
endothelial-derived heparin proteoaminoglycans. The necessary loss of endothelium
during PTCA exposes sub endothelial tissue to platelet- and other growth factors.
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Smooth muscle then undergoes the phenotypic and hyperplastic change, accompanied
by remodelling of the extracellular matrix proteins, characteristic of vascular repair
after PTCA. In about a third to a half of cases this remodelling becomes excessive
and leads to restenosis (Brady & Warren, 1991). Interestingly, nitric oxide inhibits
DNA synthesis in vascular smooth muscle in vitro (Nakaki et al., 1990). Thus loss
of endothelium at PTCA removes this additional regulator of smooth muscle
proliferation.
Drug therapy to prevent restenosis has so far not succeeded. Most of the
compounds used affect coagulation or vessel tone, rather than mimicking endothelial
control of cell division. Nitrovasodilators are used to inhibit coronary spasm
immediately following PTCA. Evidence that they inhibit restenosis in patients is
lacking. Whether nitric oxide regulates vascular smooth muscle growth in patients
has yet to be described.
1.5.5. Endotoxic shock
Septicaemia and accompanying septic shock account for a substantial number
of hospital deaths, despite appropriate antibiotic and supportive therapy. In the USA,
an estimated 100,000 patients die from sepsis in hospital each year (Parrillo et al.,
1990). One of the characteristic features of septic shock is profound hypotension
caused by a decrease in peripheral vascular resistance. This hypotension is unusually
resistant to both volume replacement and vasoconstrictor agents. In the earliest stages
of septic shock stroke volume and cardiac output are maintained or even increased;
later, ventricular dilatation develops with a reduction in ejection fraction (MacLean
et al., 1967; Parker et al., 1984; Ellrodt et al., 1985). If patients survive, ventricular
size and function return to normal as the infection is controlled and circulatory
function restored.
Gram-negative bacteria account for about 30% of cases of septic shock (Bone
et al., 1987). Bloodborne infection liberates endotoxin, the lipopolysaccharide
component of the bacterial cell wall, into the circulation. Endotoxin and the
organisms themselves activate host defence and inflammatory systems, including the
complement, kinin and coagulation cascades, the interleukins, tumour necrosis factor
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(TNF) and other endogenous mediators of inflammation, leukocytes and platelets
which together generate the acute inflammatory response to bacteraemia. Although
many inflammatory mediators are themselves vasoactive, recent work has shown that
the hypotension of septic shock is mediated by important changes within the vascular
muscle cells themselves. The key finding of the work in this thesis is the
demonstration that the myocardial depression is caused by similar changes.
1.5.6. Abnormalities of nitric oxide production in endotoxic shock
In endotoxic shock the presence of disseminated foreign antigen, together with
the inflammatory response, causes nitric oxide synthase to be induced in many other
cell types which do not normally express this enzyme, including hepatocytes,
fibroblasts and vascular smooth muscle (Moncada et ah, 1991; Nathan, 1992).
Subsequent production of nitric oxide leads not only to haemodynamic instability, but
also to widespread production of nitric oxide-based free radicals which have the
potential to cause considerable damage to tissues. Evidence from clinical studies
supports this. Patients with endotoxic shock (Ochoa et al., 1991), and cancer patients
receiving interleukin-2 (IL-2) chemotherapy, a cytokine which activates other
endogenous cytokines to induce nitric oxide synthase (Hibbs et al., 1992), excrete
high levels of nitric oxide metabolites.
Vascular smooth muscle is itself not a source of nitric oxide in health. In
endotoxic shock production of nitric oxide occurs within the muscle layer of the
vessel wall, and this causes excessive vasodilatation and hence a reduction in
peripheral vascular resistance. Analogues of the substrate L-arginine have been
developed which act as substrate inhibitors of nitric oxide synthase. These cause
systemic vasoconstriction and a pressor response in healthy animals by inhibiting
constitutive nitric oxide production by the endothelium. Some studies have shown a
fall in cardiac output with these agents as well.(Klabunde & Ritger, 1991; Kilbourn
et al., 1990; Aisaka et ah, 1989) In healthy human volunteers local administration
of these drugs into the brachial artery causes a 50% reduction in forearm blood flow
(Vallance et ah, 1989).
27
In animals with experimental endotoxic shock inhibitors of nitric oxide
synthase reverse hypotension, but also cause a sustained increase in systemic vascular
resistance and at higher doses a decrease in cardiac output. (Klabunde & Ritger, 1991;
Nava et al., 1991; Wright et al., 1992) Whether this fall in cardiac output is
secondary to the rise in vascular resistance, or to an adverse effect of nitric oxide
synthase inhibitors on cardiac contractility, was not established by these studies.
A recent study in dogs points to the activation of ATP-sensitive K+ channels
in vascular smooth muscle by acidosis as a further mechanism of vasodilatation in
experimental endotoxic shock. (Landry & Oliver, 1992) This has not yet been
explored in patients.
1.5.7. Cardiac failure in endotoxic shock
Global deterioration of myocardial contractile function in endotoxic shock has
been well established by clinical and radionuclide studies (MacLean et al., 1967;
Parker et al., 1984; Ellrodt et al., 1985). A study in normal volunteers showed
reversible depression of left ventricular function following administration of purified
endotoxin, in addition to the expected reduction in systemic vascular resistance,
measured both by radionuclide scanning and by echocardiography (Suffredini et al.,
1989). Until recently, the cause of this myocardial depression was considered to be
a direct effect of endotoxin or an inflammatory mediator on myocardial tissue, to
which coronary hypoperfusion might contribute (Parrillo et al., 1990). The existence
of a specific circulating myocardial depressant substance in endotoxic shock has been
postulated, although not proven (Reilly et al., 1989). Although coronary perfusion
abnormalities occur in patients with coexisting cardiac or coronary disease and may
account for segmental abnormalities of left ventricular function, in patients with
global myocardial impairment and endotoxic shock the loss of function cannot be
explained by changes in coronary flow (Parrillo et al., 1990; Ellrodt et al., 1985).
As in the peripheral vasculature, it is likely that multiple factors exist which depress
cardiac function in endotoxic shock. However, there may be a common pathway for
such mediators to impair myocardial contraction.
In the same way that overproduction of nitric oxide in the peripheral
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vasculature accounts for the vasodilatation and loss of vascular control in endotoxic
shock, the notion that overproduction of nitric oxide within cardiac muscle contributes
to impaired function is the key issue addressed in this thesis.
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1.6. MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY
1.6.1. Natural history of injury induced by ischaemia and reperfusion
The presence of inflammatory cells in infarcted myocardium was first
described more than 50 years ago (Mallory et al., 1939). The importance of
inflammatory processes in successful healing after myocardial infarction was revealed
more recently when methylprednisolone given to post infarction patients caused a
substantial increase in both infarct size and deaths from ventricular rupture due to
poor scar formation (Roberts et al., 1976). This indicated that inflammatory
mechanisms are necessary for optimal repair after infarction. However, such
inflammatory processes may also damage nearby healthy or reversibly injured
myocardium.
Following irreversible coronary occlusion the earliest manifestations of
necrosis can be demonstrated in myocyte organelles and contractile elements by
electron microscopy within one hour (Schaper et al., 1992), although gross and
microscopic changes do not become apparent until 6-8 hours after the onset of
ischaemia (Anderson, 1985). The features of coagulative necrosis then appear: after
about 8 hours infiltration by neutrophils occurs, with the development of a zone of
granulation tissue at the margin of the infarct (Levine, 1929; Mallory et al., 1939).
The infarct heals by digestion of necrotic tissue by macrophages with subsequent scar
formation, and the infarct zone is replaced gradually by fibrous tissue. Large
numbers of neutrophils accumulate in the dead myocardium (Go et al., 1988),
although whether they are involved in killing myocytes alive at the time of
reperfusion is uncertain.
After periods of up to three hours of ischaemia (Chatelain et al., 1987)
reperfused myocardium is characterised by the early accumulation of neutrophils,
firstly within the blood vessels and then later within the injured myocardium
(Sommers & Jennings, 1964). There is recovery of some of the injured myocytes and
herein lies the central controversy of recovery after a short period of ischemic injury:
does the process of reperfusion with delivery ofacute inflammatory components cause
irreversible injury ofmyocytes which might have regained normal function, or does
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reperfusion merely hasten the death of cells irretrievably injured? This question
remains unresolved, but in the next sections, evidence is presented that interference
with some of these inflammatory processes reduces ultimate infarct size.
1.6.2. Pathogenesis of inflammatory injury after myocardial ischaemia
Neutrophils are important mediators of injury in ischaemia-reperfusion
damage. Depletion of circulating neutrophils by means of cytotoxic agents (Mullane
et al., 1984) anti-neutrophil antibodies (Romson et al., 1983) or leukocyte filters (Litt
et al., 1989) all reduce myocardial infarct size in experimental models. The
protective action of agents such as ibuprofen and prostacyclin (Romson et al., 1982;
Simpson et al., 1987b) is also associated with a reduction in neutrophil accumulation.
The chemoattractants, complement fragment C5a, and the eicosanoid,
leukotriene B4 (LTB4) both mediate neutrophil damage within the heart. Complement
activation occurs following episodes of myocardial ischaemia (Pinckard et al., 1975;
Langlois & Gawryl, 1988). Complement fragments are found in ischaemic
myocardium (Maroko et al., 1978; Schafer et al., 1986; Rossen et al., 1985).
Cobra venom factor, which depletes circulating complement, reduces infarct
size and neutrophil accumulation (Maclean et al., 1978; Maroko et al., 1978), and
also reduces neutrophil chemoattractant activity of coronary sinus blood following
myocardial ischaemia (Hartmann et al., 1977). Neutrophil chemoattractant activity
in postischaemic cardiac lymph can be neutralised by antibodies to C5a (Entman et
al., 1991). Soluble complement receptor 1 (sCRl), which inhibits complement
activation by binding C3 and C5 convertases, also reduces infarct size and neutrophil
infiltration (Weisman et al., 1990).
LTB4 is produced by activated neutrophils and is detected in infarcted
myocardium (Sasaki et al., 1988). Inhibitors of the 5-lipoxygenase enzyme (which
catalyses synthesis of LTB4) reduce infarct size and neutrophil accumulation (Mullane
et al., 1987; Sasaki et al., 1988). Some of these agents possess other properties such
as free radical scavenging activity. LTB4 receptor antagonists are now available,
although early results are mixed (Karasawa et al., 1991; Hahn et al., 1990).
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Platelet activating factor (PAF) is another mediator of inflammation within the
heart. PAF antagonists reduce myocardial infarct size in experimental models (Stahl
et al., 1988; Montrucchio et al., 1990; Chakrabarty et al., 1992), although
mechanisms other than inhibition of neutrophil accumulation may contribute (Williams
et al., 1990).
Mechanism of tissue damage by neutrophils
Neutrophils cause tissue injury by releasing two main groups of toxic
substances: reactive oxidising chemicals and proteolytic enzymes. Membrane bound
NADPH oxidase enzyme catalyses the production of superoxide anions, hydrogen
peroxide and hydroxyl radicals. These radicals are able to react with a number of
biological substrates themselves, but another product of oxidative metabolism,
hypochlorous acid (HOC1), may be of even greater importance (Harrison & Schultz,
1976; Weiss, 1989). HOC1 and oxygen free radicals cause cellular injury by
oxidising membrane phospholipids, thereby increasing fluidity and permeability of the
membrane and reducing its integrity. They also augment the activity of neutrophil
proteolytic enzymes, which degrade components of the extracellular matrix.
Myocardial damage by oxygen free radicals
Since the 1970s it has been accepted that reoxygenation of ischaemic
myocardium may be associated with immediate and extensive ultrastructural damage,
and the damage is caused, at least in part, by free oxygen radical species derived
from the administered oxygenated medium (Hearse, 1977). Neutrophils also generate
these reactive radicals although to what extent oxygenated blood, neutrophils and the
reperfused tissue itself each contributes to the amount of free radical damage has not
been quantified. The role of oxygen free radicals in myocardial infarction has been
the subject of a large number of studies using agents which can scavenge these radical
species. Of 32 studies of interventions to reduce free radical damage in animal
models of myocardial injury, 16 showed benefit and 16 did not (Reimer et al., 1989).
Although the scavenging agents catalase and superoxide dismutase can neutralise
oxygen free radicals in the extracellular space, they are large molecules and do not
readily enter cardiac myocytes (Downey & Yellon, 1992). Yet within myocytes free
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radicals generated during ischaemia-reperfusion cause damage to contractile proteins
(Shlafer et ah, 1987; Turner et ah, 1991). This may explain the modest protection
afforded by scavenging agents in the published studies.
Recently, monitoring of neutrophil-mediated cardiac myocyte oxidative damage
at the cellular level has become possible using dichlorofluorescein (an intracellular
indicator of oxidation). Neither catalase nor superoxide dismutase had a protective
effect in these studies (Entman et ah, 1992). In contrast, desferoxamine and
dimethylurea, both of which can enter cells, protected myocytes from neutrophil
injury. Some of the protective effect of dimethylthiourea is thought to be due to its
ability to inhibit Na+-Ca2+ exchange (Ziegelstein et al., 1992). There is accumulating
evidence for the importance of this process in reperfusion injury. There is
impairment of Na+-Ca2+ exchange, Na+-K+-ATPase and Na+-H+ exchange in
ischaemia (Tani & Neely, 1989; Kitakaze et ah, 1988) which may facilitate Ca2+
entry into myocytes. Disturbance of intracellular calcium homeostasis may be the
central feature of ischaemic injury (Steenbergen et ah, 1987b; Snyder & Bredt,
1991).
Effects of ischaemia on coronary microvasculature
One of the consequences of ischaemia is injury to the coronary
microvasculature itself. Successful reperfusion of the large coronary arteries may not
always be accompanied by restoration of blood flow within the area of injured
myocardium. This has been termed the "no-reflow" phenomenon (Kloner et ah,
1974), and appears to follow endothelial injury after periods of ischaemia greater than
60-90 minutes. Plugging of the microvessels by neutrophils during reperfusion
contributes to the no-reflow phenomenon, and is likely mediated both by neutrophil
adhesion to damaged endothelium, together with neutrophils wedging in the
microvessels. Such physical trapping occurs because activated neutrophils are less
deformable, and hence their ability to squeeze through capillary lumina is impaired
(Worthen et ah, 1989). I addressed this in an early study using a microvasculature
model of endothelial cells cultured on beads (Brady et ah, 1990) (see section 9.2).
In the clinical situation, the no-reflow phenomenon occurs when restoration
of patency is achieved by thrombolysis or angioplasty, yet reperfusion of myocardium
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in the ischaemic area remains impaired. Such impairment of myocardial perfusion
is associated with a worse outcome, measured in terms of left ventricular ejection
fraction, than patients in whom microvascular and hence myocardial tissue reperfusion
is achieved (Ito et al., 1992).
Ultrastructural studies suggest that endothelium tolerates hypoxia better than
cardiac myocytes, since zones of no-reflow are found only within areas of myocardial
necrosis (Piper et al., 1990; Kloner et al., 1974). However there is accumulating
evidence that important alterations of endothelial function may occur much earlier in
ischaemia, without evidence of morphological damage.
Basal release of nitric oxide is diminished following ischaemia-reperfusion,
and this is associated with neutrophil adherence to coronary endothelium (Ma et al.,
1993). Administration of pharmacological agents which mimic endothelial products,
including nitric oxide (Johnson et al., 1991), Iloprost (a stable analogue of
prostacyclin) (Simpson et al., 1987a) and adenosine (Olafsson et al., 1987) reduce
experimental infarct size, probably both by replenishing protective endogenous
autacoids lost during the ischaemic episode and also by inhibiting neutrophil-
endothelial interactions. Such interventions may become clinically important, since
limiting the no-reflow phenomenon may allow better myocardial perfusion following
epicardial coronary artery occlusion-reperfusion. Unfortunately these agents all have
potent vasoactive effects which may limit their usefulness. In an early study in which
I was involved, Iloprost had beneficial effects on platelet aggregation in patients
undergoing cardiopulmonary bypass, but hypotension precluded widespread
application (Blauth et al., 1987). Other analogues of these agents may be more
useful.
1.6.3. Myocardial response to acute ischaemia - cellular events and intercellular
signalling
Neutrophils have the potential to damage myocardium by their release of toxic
products. Whether such toxins are liberated in a random fashion by activated
neutrophils within an area of injured myocardium, or whether they are targeted
towards injured myocytes in particular has not yet been determined. However,
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emerging evidence suggests that injured cardiac myocytes may signal their own
destruction by activating such mechanisms at their cell surface.
Neutrophil-endothelial adhesion
For neutrophils to reach the interstitium and then the myocytes they have to
adhere to and then traverse the endothelial barrier. At sites of inflammation
neutrophils roll along endothelium by engaging and disengaging to the endothelial
cells by adhesive interactions involving the neutrophil glycoprotein L-selectin
(formerly termed LAM-1, Mel-14, LECAM-1, Leu-8) (Lawrence & Springer, 1991).
Tethering of neutrophils at sites of inflammation occurs via the expression of the
endothelial glycoprotein P-selectin (formerly GMP-140, PADGEM, CD62) which
appears on cell surfaces within minutes of endothelial activation by inflammatory
mediators (Geng et al., 1990). The rapid expression of P-selectin suggests that it
may mediate early neutrophil adhesion to activated or injured endothelium, since it
is expressed from intracellular or cell membrane stores without the need for synthesis
of new proteins (Geng et al., 1990). P-selectin interacts with its carbohydrate ligand
CD 15 on the neutrophil (Larsen et al., 1990). It appears that the neutrophils undergo
an early change in the expression of their adhesion molecule presentation, with L-
selectin exhibiting a rapid increase in affinity followed by down regulation of its
expression and the activation of the CD 18 adhesion glycoprotein complex (Vedder &
Harlan, 1988; Nourshargh et al., 1989).
Migration of neutrophils across the endothelial layer follows adhesion, and
requires contact between the neutrophil integrin CD 18 complex and the endothelial
adhesion molecule, intercellular adhesion molecule-1 (ICAM-1) (Smith et al., 1988).
Activated endothelium synthesises and expresses the adhesion glycoproteins, ICAM-1,
and also E-selectin (formerly endothelial-leucocyte adhesion molecule-1). ICAM-1
is present constitutively on endothelium at low levels but its expression is increased
substantially by inflammatory mediators (Colditz & Movat, 1984). Monoclonal
antibodies to the CD 18 antigen have been shown to be very effective in reducing
neutrophil infiltration into ischaemic-reperfused myocardium (Williams et al., 1990)
and in reducing myocardial infarct size (Seewaldt-Becker et al., 1990). In the latter
study a monoclonal antibody to ICAM-1 was also protective.
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E-selectin only appears on the endothelium after stimulation (Bevilacqua et al.,
1989) and requires de novo protein synthesis. The corresponding ligand for E-
selectin on the neutrophil has been identified recently as another carbohydrate,
sialylated Lewis x tetrasaccharide (Lowe et al., 1990). Both E-selectin and ICAM-1
mediate neutrophil adhesion to and migration through activated endothelium. It may
be envisaged that after early initiation of neutrophil adhesion to ischaemic-reperfused
endothelium by endothelial expression of P-selectin, further neutrophil-endothelial
adhesion to damaged myocardium may be promoted by the ICAM-1/CD 18 and E-
selectin/sialylated Lewis x tetrasaccharide mediated interactions. This hypothesis is
supported by current research. Very recently, increased production of mRNA for
both P- and E-selectin has been demonstrated in the endothelium of blood vessels
from the injured segments of ischaemic-reperfused hearts (DC Anderson, personal
communication).
Neutrophil-cardiac myocyte interactions
Once neutrophils have reached the extravascular space they can directly attack
cardiac myocytes. Whether this damage is directed specifically towards previously
injured myocytes is not known, but current research indicates that activated myocytes
appear to exhibit signals which activate neutrophil wound repair mechanisms. Recent
studies indicate that cardiac myocytes as well as endothelial cells express ICAM-1 in
C.vJ.
response to activation by inflammatory mediators (Smith et al., 1991). Neutrophils
bind to ICAM-1 on activated myocytes by a process involving their adhesion molecule
complex CD 18 (Entman et al., 1990), and this receptor-mediated adhesion appears
to be the main mechanism of neutrophil adherence to cardiac myocytes.
Furthermore, mRNA for ICAM-1 can be induced in both endothelial cells and cardiac
myocytes by post-ischaemic cardiac lymph (Youker et al., 1992), and recent data
suggest that direct neutrophil-mediated injury of cardiac myocytes requires adhesion
by the CD18/ICAM-1 mechanism (Entman et al., 1991). However, expression of
ICAM-1 by myocytes requires de novo protein synthesis (Entman et al., 1990). Since
it has been shown that complement activation products are present on the surface of
myocytes following ischaemia, one mechanism of early neutrophil attachment might
be via a CDllb/CD18 (complement receptor 3) interaction with iC3b. Another
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possible early mechanism is attachment of neutrophils to a PAF-like molecule which
is expressed on the surface of myocytes soon after their injury, without the need for
protein synthesis (CW Smith, personal communication).
It is possible therefore that administration of monoclonal antibodies to CD 18
or ICAM-1 are able to confer protection in models of myocardial ischaemia by
inhibiting direct neutrophil-cardiac myocyte interactions as well as by inhibiting
neutrophil migration through the endothelium (Simpson et al., 1990; Simpson et al.,
1988; Ma et al., 1992), although these experiments have not always shown benefit
(Tanaka et al., 1993). These recently published and ongoing studies provide exciting
new evidence that injured myocardium plays an active role in the inflammatory
response to ischaemic injury.
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1.7. CENTRAL HYPOTHESES OF THIS THESIS
(i) Nitric oxide modifies contractile function of cardiac ventricular myocytes.
Nitric oxide affects cellular function of many different cell types. My
hypothesis is that nitric oxide modifies the major function of cardiac myocytes, i.e.
their contractile function.
(ii) Cardiac myocytes metabolise nitrovasodilators to generate nitric oxide.
Nitrovasodilators act by being metabolised at their site of action to generate
nitric oxide. Glyceryl trinitrate and isosorbide dinitrate require an enzyme but
sodium nitroprusside requires only a reduction step. My hypothesis is that cardiac
myocytes are able to generate nitric oxide from nitrovasodilators and modify their
contractility.
(iii) Nitric oxide from coronary microvascular endothelium modifies contractility
of adjacent cardiac myocytes.
Nitric oxide derived from endothelium modulates tone in adjacent vascular
smooth muscle. Within the myocardium, the coronary microcirculation lies in close
proximity to cardiac muscle. My hypothesis is that within the heart also, nitric oxide
from microvascular endothelium modifies cardiac myocyte contraction.
(iv) Nitric oxide production within cardiac myocytes impairs their contractility
in endotoxic shock.
Profound hypotension is a feature characteristic of endotoxic shock, caused by
induction of nitric oxide synthase within the smooth muscle of the vascular wall.
Cardiac function is also depressed in endotoxic shock. My hypothesis is that, much
like vascular smooth muscle, cardiac myocytes themselves produce nitric oxide in this
situation and depress their own contractility.
(v) Nitric oxide production within cardiac myocytes contributes to the impaired
contractility of postischaemic myocardial stunning.
Myocardial contractility is reversibly depressed following a short period of
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ischaemia. My hypothesis is that activity of constitutive nitric oxide synthase within
cardiac myocytes contributes to this impairment of contraction.
(vi) Nitric oxide modulates cardiac myocyte contractility by reducing peak Ca2+
concentration during contraction.
The results of studies testing hypotheses i-iv showed that nitric oxide attenuates
cardiac myocyte contraction. Attenuated contraction is caused either by a reduction
in [Ca2+]j during the cardiac action potential, or by a change in the sensitivity of the
myocyte contractile apparatus to calcium. My hypothesis is that nitric oxide reduces
the amount of calcium available in the myocyte during contraction, leading to
diminished contractility.
(vii) Neutrophils exert direct action on cardiac myocytes to impair their
contractility.
Neutrophils are important in myocardial ischaemia. Their role in wound
repair after infarction is established. But neutrophils may also cause early damage
during the reperfusion period after ischaemia. Many studies examine alterations in
infarct size as a consequence of interference with neutrophil function during a period
of ischaemia-reperfusion, mainly using in vivo models. But whether neutrophils
damage myocardium because of microvascular obstruction and resulting local
ischaemia, or because of a direct action on myocytes, cannot be determined from
these studies. My hypothesis is that adhesion of activated neutrophils to myocytes
directly impairs contractility, and ultimately leads to myocyte death.
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CHAPTER 2: METHODS
2.1.1. Isolation of guinea-pig cardiac ventricular myocytes
The method of isolation of cardiac myocytes from laboratory animals by
enzymatic digestion of myocardium has been established in the National Heart and
Lung Institute (and previously the Cardiothoracic Institute) for nine years (Harding
Figure 4
et al., 1988; Harding et al., 1990; Vescovo et al., 1989). This method yields healthy
functioning cardiac myocytes, an example of which is shown in Figure 4. I used this
method in all of the experiments using adult guinea-pig myocytes, except those
involving cells from ischaemic-reperfused hearts, where I conceived of and developed
a modified method of isolation (section 3.6).
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To isolate ventricular myocytes from healthy animals, heparin 1000 U i.p. was
injected 15 min before sacrifice. The guinea-pig was killed by cervical dislocation
and the heart quickly removed and placed in 50 ml cold Krebs-Henseleit solution
(containing 119.1 mM NaCl, 1.0 mM CaCl2, 4.7 mM KC1, 0.94 mM MgS04, 1.2
mM KH2P04, 25 mM NaHC03 and 11.5 mM glucose, and previously bubbled with
95%02/5%CO2 at 4°C) with 1000 U heparin added. The heart was dissected free of
excess tissue and mounted by the ascending aorta on a Langendorff perfusion
apparatus. The aorta was perfused retrogradely and coronary flow established.
Coronary perfusion with physiological Krebs-Henseleit solution at 37°C and 20
ml/min continued for 5 min to allow the heart to recover. The perfusate was then
changed to a low calcium solution (containing 120 mM NaCl; 5.4 mM KC1; 15 /xM
CaCl2; 5 mM MgS04; 5 mM pyruvate; 20 tnM taurine; 10 mM HEPES, 5 mM
nitrilotriacetic acid (NTA) and 20 mM glucose) which facilitated breakdown of
intercellular junctions. Asystole usually occurred within 20-30 s. The low calcium
perfusion continued for 4 min 30 s and was followed by 2 min perfusion of enzyme
solution (containing 120 mM NaCl, 5.4 mM KC1, 200 /xM CaCl2, 5 mM MgS04, 5
mM pyruvate, 20 mM taurine, 10 mM HEPES and 20 mM glucose) containing 4 I.U.
protease (type XXIV, bacterial, Sigma). This was followed by collagenase-
hyaluronidase solution (same enzyme solution with 0.6 mg/ml hyaluronidase, type I-
S, bovine, Sigma; and collagenase 0.3 mg/ml, Class II, Worthington, New Jersey,
U.S.A.), recirculated for 10 min.
The heart was then removed from the Langendorff apparatus, the apex and
right ventricle excised and discarded and the left ventricle minced gently with
scissors. This tissue was swirled in two successive digests of collagenase-
hyaluronidase solution, each for 5 min. The supernatant from each was centrifuged
and the myocyte pellet resuspended in the 200 /xM calcium solution for use in
experiments.
A third digest was often performed, swirling the myocardial tissue in a high
K+ solution (containing 20 mM NaCl, 85 mM KC1, 30 mM KH2S04, 5 mM MgS04,
20 mM taurine, 0.5 mM NTA and 20 mM glucose). If the myocyte yields from the
first and second digests were reasonable, they were preferred.
This method of isolation of myocytes yielded reliably functioning cells. The
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first digest often contained cellular debris from the enzymatic digestion, but the
second was comparatively pure. Healthy myocytes are rectangular; terminally
contracted ones are round. The "rod" to "round" ratio of morphologically sound cells
to apparently irreversibly injured cells was established visually. Preparations used
for experiments usually contained at least 60-70% rod shaped cells.
2.1.2. Definition of myocyte viability
Isolated myocytes were defined as healthy and used in experiments if they
fulfilled the following criteria:
(i) Cells were rod shaped.
(ii) Cells were without sarcolemmal blebs (a sign of irreversible injury).
(iii) Cells did not exhibit spontaneous contractions ( except atrial cells).
(iv) Cells that displayed a variable baseline contraction to electrical stimulation
at 2mM Ca2+ were rejected.
(v) Sarcomere length was within the range 1.67-2.05 /xm. Average sarcomere
length was calculated from the number of striations crossing the screen at high
magnification in most of the experiments. Cells were excluded if sarcomere
length was shorter than 1.67 /im, since this is an indication of cell injury.
2.1.3. Purification of cardiac myocyte preparation
To improve the ratio of morphologically functioning myocytes I tried
purification of the pellet by a short centrifuge period in a carbohydrate gradient. This
technique is used widely to isolate leucocytes from whole blood. Such a gradient has
been described in early work on isolation of cardiac myocytes (Maisch, 1981). I
attempted to use the published method to improve myocyte yield for experiments
involving myocyte-neutrophil interactions (chapter 10). This method required lengthy
high-speed centrifugation of Percoll to produce a gradient of continuously variable
density. I simplified this and used just two different densities of Percoll, i.e., a
discontinuous gradient, the interface of which would match the point on the variable
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gradient at which healthy myocytes were found.
In practice, rounded up, terminally contracted myocytes have a density only
fractionally less than healthy cells, according to their respective positions on the
Percoll gradient. In fact, they ought to be more dense, since they lose fluid contents
during the rounding-up process. An explanation of this may be that rod-shaped
myocytes are more streamlined than rounded cells, and so travel through carbohydrate
more easily.
While endothelial cells and other debris could be excluded, differentiation
between healthy and rounded myocytes was not readily reproducible using a Percoll
gradient. Thus, purification of myocytes was not pursued.
I examined the behaviour of myocytes in a fluorescence activated cell sorting
(FACS) flow cytometry cell analyser (Becton-Dickinson). I was interested in the
expression of adhesion molecules on cardiac myocytes, using fluorescent-labelled
antibodies to ICAM-1 as an indicator. Cardiac myocytes have significant intrinsic
autofluorescence and labelling them with either of the fluorescent dyes fluorescein or
rhodamine did not alter the fluorescence of test suspensions of cells by a substantial
degree. Thus differences between labelled and non-labelled cells would not be
determined. Workers at Baylor, Houston, Texas had similarly failed to use FACS
cell sorting to study expression of adhesion molecules on myocytes (ML Entman,
personal communication). Recently however, they have successfully used direct
observation of fluorescence and also fluorometric measurements to detect neutrophil-
mediated myocyte injury (Entman et al., 1992).
2.1.4. Isolation of human ventricular myocytes
Human ventricular myocytes were used in some experiments. A block of
ventricular myocardium was obtained from the recipient heart of a patient receiving
a transplant, usually for dilated cardiomyopathy, sometimes for end stage ischaemic
heart disease. Tissue obtained was transported to the laboratory in cold cardioplegic
solution (containing Na 131 mM; K+ 16 mM; Ca2+ 2 mM; CI" 111 mM; lactate 29
mM; procaine 1 mM) and then minced using an array of razor blades. The tissue
obtained was incubated at 35°C in 25-30 ml low calcium solution (containing 120
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mM NaCl; 5.4 mM KC1; 1-2 juM CaCl2; 5 mM MgS04; 5 mM pyruvate; 20 mM
taurine; 10 mM HEPES, 5 mM NTA and 20 mM glucose) for 3x4 min. Tissue was
then transferred to a similar solution (without NTA) containing 4 U/ml type XXIV
protease (Sigma). Ca2+ was made up to 30 /xM and the solution swirled gently at
35°C for 45 min. This process was repeated twice using the solution of the same
composition, except 400 IU/ml collagenase (Worthington) was added instead of
protease. Dispersed cells were strained and centrifuged in the same way as guinea
pig ventricular myocytes, described in 2.1.1..
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2.2 MEASUREMENT OF CARDIAC MYOCYTE CONTRACTILITY
2.2.1. Design of myocyte cell bath
Adult cardiac ventricular myocytes do not contract spontaneously in vitro,
unlike atrial myocytes and neonatal myocytes. Most of the studies in this thesis
MYOCYTE CELL BATH
Bipolar stimulator





examine modulations of myocyte contractility, thus a method of stimulating the cells
to contract is required.
A 22 mm glass coverslip was fitted under a chamber 10 x 4 x 6 mm in
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dimensions cut into a perspex block (Figure 5). Isolated myocytes were placed in the
chamber and attached spontaneously to the glass. After 4 min to allow attachment,
cells were superfused with Krebs-Henseleit physiological solution at 2 ml/min. The
cell bath was drained by a channel drilled into the end opposite the superfusing
cannula. The position of the channel maintained the volume of solution in the bath
at 200 ia\. The cell bath had a platinum wire along each side to enable stimulation
of myocytes.
2.2.2. Control of temperature of cell bath
The superfusing solution was warmed by a circumferential heater around the
cannula at the entrance to the cell bath. A thermocouple next to the heater was
connected to a feedback control on the heater control unit, and temperature was also
monitored by a second thermocouple within the bath itself. For most of the
experiments when superfusing flow was constantly running, this system could
maintain bath temperature accurately within 32+0.5°C.
For the experiments using coculture of myocytes with endothelium flow was
halted for 5 min to allow accumulation of endothelial-derived factors within the cell
bath. I showed in control experiments that changes in temperature affect markedly
myocyte contractility (see 4.1.4.). Since stopping flow causes bath temperature to
fall, an indwelling thermistor connected directly to a pen recorder was introduced, so
that fluctuations in bath temperature could be determined readily. A moveable 60 W
external heating source was placed near the bath. Altering its positioning accurately
controlled solution temperature in the cell bath, so that paired recordings of baseline
contraction, preceding or following the effects of stimulation of endothelium on
myocyte contractility, could be made at the same temperature.
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2.2.3. Electrical stimulator
Myocytes were stimulated electrically to contract using platinum electrodes
which ran the length of the cell bath (Figure 5). The wires were connected to a
stimulator which delivered a bipolar square wave stimulus. Voltage, pulse-width and
frequency could be modified as desired. The threshold voltage required to cause
contraction of myocytes was measured, and the stimulator set at 1.5x this level. This
usually meant stimulation at approximately 30 V amplitude, 0.5 ms pulse-width.
Frequency was set at 0.5 Hz, since early experiments in the department had shown
cell survival to be optimal at this rate.
2.2.4. Detection of myocyte contraction
The cell bath was placed on the stage of a Zeiss 1M phase-contrast inverted
microscope (Figure 6). Part of the light was diverted to a Newvicon video camera
(Ikegami) side mounted on the microscope. The image was displayed on a high grade
9" monochrome monitor (Ikegami). The magnification factor on the screen was
calibrated using a grid of known size in the cell bath. A myocyte image was
displayed on the screen and the camera rotated until the long axis of the cell was
vertical. The images were stored on conventional VHS video tape and could be
analysed later if desired.
An edge detection device (SP 144, HVS Image Analyzing, Kingston, Surrey)
was connected between the camera and the monitor. This device transforms grey into
black or white, and a variable control allows adjustment of the grey level on the
untransformed image at which the cutoff between black and white occurs. The level
is adjusted until the imaged cell appears as the main white object on the screen. A
rectangular window is placed over the cell. Within this window changes of contrast
between black and white are detected. As the myocyte contracts, the number of
horizontal white lines which make up its image is reduced, and this is detected by the
window. The amplitude and rate of change of amplitude {i.e. velocity of contraction
and relaxation) are thus determined, and the information converted on a digital-










The edge detection system had a time resolution of 20 ms, and a spatial
resolution of 1 in 256, which allowed typically 10 to 15 sampling points within a
single contraction and relaxation. Digital information could also be diverted to a
computer. A program was written for acquiring and handling such data and signal-
averaging of six consecutive contractions was performed to measure time to peak
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Figure 7 Representative computer-averaged trace of contraction and relaxation of a single cardiac
myocyte. Measurement of time to peak contraction, and time from peak contraction to 90% of
diastolic length.
Figure 7 illustrates a representative computer-drawn trace from which time dependent
variables are measured.
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2.2.5. Measurement of myocyte contraction amplitude
The myocyte image was maximised on the monitor using the largest possible
lens that allowed the whole cell to be viewed. This enabled the edge detection device
to operate at its greatest sensitivity and generate the largest displacement of pen on
recording paper. The displacement of the pen reflected the amplitude of contraction,
and this value was converted into a percentage of the diastolic length of the cell
according to the formula:
Contraction amplitude = pen displacement (mm) x 0.459* x 100
(as percentage of resting cell length) resting length of cell on monitor
* 0.459 = conversion factor to match the monitor image with the paper tracing.
Thus, data from each experiment was calculated as percentage changes of
resting (or diastolic) length of the cell. This allowed pooling of data from different
cells and comparison of data.
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2.3 Endothelial cell culture
Culture of bovine aortic endothelium was performed without enzymatic
digestion as described by J.B. Warren (Warren, 1990a), under his supervision. Once
endothelial culture was established the passaging and changing of growth medium was
performed by a technician. I conceived of the idea for endothelium-myocyte primary
Figure 8 Photomicrograph of bovine aortic endothelium cultured on to a 22 mm glass coverslip,
x 200.
coculture and then developed the method of culturing endothelium on to the 22 mm
glass slides used in the inverted microscope, shown in Figure 8.
To culture endothelium, I obtained fresh bovine aortas from the abattoir. A
10 cm length of aorta was rinsed in three consecutive pots of 125 ml sterile phosphate
buffered saline containing calcium and magnesium with penicillin 200,000 IU/1,
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streptomycin 200 mg/1 and gentamicin 100 mg/1. The vessel was cut along its length
and the intimal surface scraped gently with a scalpel, rinsing the accumulating
endothelial cells from the blade into a centrifuge tube containing medium. The cells
were centrifuged and the supernatant discarded. The resuspended pellet was seeded
into a T-25 flask.
Figure 9 Photomicrograph of primary coculture of guinea pig cardiac ventricular myocytes with
bovine aortic endothelium, x 200.
Cells were cultured in a standard medium established in the laboratory. It
consisted of: 500 ml Dulbecco's modified Eagle's medium (Gibco, Paisley, Scotland)
with 4.5 g/1 glucose but without sodium pyruvate; 50 ml fetal calf serum; 1 mg
thymidine; 1/10 vial insulin/transferrin/sodium selenite (ITS) supplement (Sigma);
penicillin 25,000 U; streptomycin 25 mg; and glutamine 250 mg. Contaminating
fibroblasts were eliminated by mechanical passaging. Cells used in the experiments
had undergone no more than 5-6 passages. Once pure cultures of bovine aortic
endothelial cells were obtained, cells were cultured in 30 mm diameter multiwell
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plates into which sterilised 22 mm glass coverslips had been placed. These coverslips
fitted the myocyte cell bath. The endothelium grew to confluence in 2-3 days and the
coverslips were ready for use.
2.4 Endothelium and cardiac myocytes in primary coculture.
Once the endothelial cells were confluent on 22 mm coverslips, they were
ready for use in experiments. A coverslip was mounted in the cell bath and
superfused with 2 mM Ca2+ Krebs-Henseleit solution at 32°C. A droplet of myocyte
solution was placed in the bath and superfusing flow turned off for 5 min to allow the
myocytes to adhere to endothelium. Endothelial cells grew only on the luminal side
of the coverslips, so that viewing of myocytes through the endothelial layer was
possible.
I was concerned about satisfactory adhesion of guinea-pig cardiac myocytes
to bovine aortic endothelium; fortunately, the myocytes adhered to the endothelial
cells, despite the presence of superfusing flow. Whether the myocytes actually were
adherent to the glass via pseudopodia-like extensions between endothelial cells, or
whether they were attached directly to confluent endothelium could not be
determined, although the adhesion itself is an interesting phenomenon. Whatever the
mechanism, the result was a primary coculture of two cell types in apposition, so that
endothelial influences on myocyte contraction could be examined, as shown in
Figure 9.
Baseline characteristics of the contraction of myocytes sited on endothelium
were determined. Basal contractions to electrical stimulation were identical to those
of myocytes adherent to glass (see Chapter 6.1.3.), hence quiescent endothelium has
no effect on myocyte contractility. The effect of pharmacological activation of
endothelium could then be studied.
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2.5 Endotoxic shock model
To study the effects of endotoxaemia on cardiac myocyte function, I developed
a model of endotoxic shock. Guinea-pigs were injected with a large dose of
endotoxin (lipopolysaccharide, E. coli serotype 055:B5; Sigma). 4 mg/kg
lipopolysaccharide was injected intraperitoneally, 4 h before sacrifice. All animals
receiving this treatment were constitutionally upset and moved sluggishly in their
cage, although blood pressure was not measured. Animals were killed and cardiac
myocytes prepared as detailed in 3.1.1.. In every case cardiac myocyte contractility
was substantially decreased.
In some animals, an intravenous injection of dexamethasone 4 mg/kg (David
Bull, Warwick, UK) was given into an ear vein 1 h before injection of endotoxin.
In controls, corticosteroid was administered 5 h before sacrifice, without endotoxin.
2.6 Isolation and preparation of myocytes from ischaemic-reperfused hearts
The cause of myocardial stunning is not known. To address this at the cellular
level I developed modifications of the myocyte preparation protocol. Studies in vivo
have shown that a period of ischaemia of about 20 min reliably induced myocardial
dysfunction lasting approximately 1 h (Heyndrickx et al., 1975). In my first attempt
to recreate stunning I introduced a period of first 15, then 20 min zero coronary flow
during the first stage of the Langendorff preparation, illustrated in Figure 35. I used
Krebs-Henseleit solution with 1.3 mM Ca2+ to maintain buffer ionised calcium at
normal levels during the stabilisation period before zero flow was introduced. During
the ischaemia the heart was kept at 35°C by a water jacket. Hearts continued to beat
under these conditions for <15 min, although arrhythmias were usually evident after
a few minutes of zero coronary flow. After the ischaemic period coronary perfusion
was resumed with low Ca2+ solution and the myocyte preparation followed in the
usual way, described in 2.1.1..
The behaviour of myocytes from early experiments was variable, although
contraction often looked normal and the yield surprisingly good, frequently better than
myocytes produced from hearts with no ischaemic episodes. The notion was
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entertained that a period of ischaemia was actually good for the cells, in that in some
way it preconditioned them against forthcoming chemical insults by enzymes.
It occurred to me that epicardial myocytes might obtain oxygen from room air,
and that I was examining a heterogeneous population of cells. I addressed this in
subsequent experiments by dissecting the interventricular septum and using only this
tissue in the digest stages of the method. This ensured that only truly ischaemic
myocytes were isolated, and epicardial ventricular myocardium was discarded.
Myocytes generated by this method still looked histologically normal and I
introduced another modification to try to achieve stunning of myocytes, with less
variability of contractility. Intracellular [Ca2+] is elevated in ischaemic myocardium.
Reperfusion with low Ca2+ solution protects myocardium after an ischaemic episode
(Kusuoka et al., 1987). Cardiac myocyte hypercontracture following reperfusion
after hypoxia is characterised by a sudden further rise in [Ca2+]j(Josephson et al.,
1991). But intracellular [Ca2+] is only elevated in stunned reperfused myocardium
during the first few minutes following restoration of flow (Bolli, 1992), while
mechanical dysfunction is prolonged. There is impairment of Na+-Ca2+ exchange,
Na+-K+-ATPase and Na+-H+ exchange in ischaemia (Tani & Neely, 1989; Kitakaze
et al., 1988) which may facilitate Ca2+ entry into myocytes. To further approach
conditions of coronary reperfusion I introduced a short period of reperfusion with
oxygenated 1.3 mM Ca2+ Krebs-Henseleit buffer before the low calcium solution.
The results of these experiments are discussed in chapter 8.
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2.7 PREPARATION OF NEUTROPHILS
2.7.1. Isolation of circulating rabbit neutrophils
New Zealand white rabbits of either sex were anaesthetized with
pentobarbitone (1 mg/kg i.v.). Carotid blood was collected into falcon tubes, 9 ml
per tube, each containing 1 ml acid citrate dextrose (160 mM disodium hydrogen
citrate and 0.28 M glucose in sterile water) and 5 ml of 1:10 diluted acid citrate
dextrose (in saline). A further 13 ml blood was collected into trisodium citrate (final
concentration 0.35%) for the preparation of citrated plasma. Neutrophil preparation
was carried out in a laminar flow cabinet using filtered sterile solutions and sterile
pastettes and tubes.
Most of the red blood cells were removed by addition of 15 ml hydroxymethyl
starch (Hespan 3% final concentration) to each tube, followed by facilitated
sedimentation (centrifuging for 15 min at 25 x gravity, 20°C). The resulting
leucocyte-rich plasma was centrifuged at 380 x g for 7 min. The platelet-rich plasma
supernatant was removed and centrifuged twice (1952 x g, followed by 2470 x g,
both at 20°C to produce platelet poor plasma (PPP). The leucocyte pellets were
gently resuspended in a small volume of citrated plasma.
Neutrophils were separated from other leucocytes and remaining red blood
cells using a two layer discontinuous Percoll-plasma gradient. 3 ml of 50% Percoll
in plasma was carefully layered on to 3 ml 68% Percoll-plasma. Leucocyte
suspension was layered on the surface and centrifuged (400 x g; 20 min, 20°C).
Neutrophils were harvested from the interface of the two Percoll-plasma layers and
washed twice in Ca2+ free Hank's solution (containing NaCl 80 g/L, KC1 4 g/L,
KH2P04 0.6 g/L, Na2HP04.7H20 g/L, D-glucose 10 g/L, Phenol red 0.01 g/L).
Cells were counted on a haemocytometer. Final concentrations were made up to 1-
10xl06/ml.
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2.7.2. Isolation of circulating human neutrophils
In some experiments the action of human neutrophils on guinea pig ventricular
myocytes was studied. Human neutrophils were also prepared for studies of
neutrophil adherence to endothelium in cell columns (see section 9.2., Brady et al.,
1990), and some early neutrophil-guinea pig myocyte work. Human neutrophils were
isolated in a manner similar to rabbit circulating neutrophils.
2.7.3. Isolation of guinea pig peritoneal neutrophils
There was a species problem with neutrophil-myocyte studies. Isolation of
guinea pig ventricular myocytes was well established, but guinea pigs are difficult
experimental animals from which to isolate neutrophils reliably from blood. I used
human neutrophils and guinea pig myocytes together in the first experiments, but the
species difference would always make results difficult to explain. For a time I set up
a Langendorff system and made rabbit ventricular myocytes, but there were
difficulties in trying to generate myocytes in one laboratory and neutrophils in
another.
The answer was to use guinea pig elicited neutrophils. Injection of 10 ml
0.2% glycogen into the peritoneal cavity provokes an acute inflammatory reaction.
4h after injection animals were killed with an overdose of anaesthetic and peritoneal
lavage performed. Up to 7-8 ml peritoneal fluid was obtained. This was centrifuged
twice in Hank's buffer without calcium and the pellet resuspended. >90% of cells
obtained were neutrophils on staining. Thus although these were not wholly quiescent
cells they were readily obtainable and species problems avoided.
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2.8. STATISTICAL TESTS
All values are expressed as mean+SEM, except where stated. Statistical
differences between baseline and stimulated endothelium- or nitrovasodilator-
influenced contraction were tested using Student's two-tailed t-test for paired data or
one-way analysis of variance (ANOVA). The dose-dependence of nitrovasodilator
effects was assessed using regression analysis. Statistical differences between
contraction of control myocytes and myocytes from endotoxin-treated animals were
tested using Student's two-tailed t-test for unpaired data. Changes between baseline
contraction and contraction of cells from endotoxin treated animals under different
pharmacological conditions were tested using Student's two-tailed t-test for paired
data.
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CHAPTER 3: VALIDATION OF EXPERIMENTAL DESIGN
3.1.1. Definition of cardiac myocyte contractility
Myocardial contractility, or inotropism, can be defined as the rate or extent
of myocardial shortening. It is useful to regard a change in contractility as "...an
alteration in cardiac performance that is independent of changes resulting from
variations in preload or afterload," (Braunwald et al., 1988). True changes in
contractility are difficult to determine in vivo because of haemodynamic alterations
which precede or follow interventions. Thus the isolated contracting cardiac myocyte
is a good model in which to examine contractility in conditions where shortening may
be modified.
Contractility is dependent on [Ca2+]0 in the superfusing solution used in the
experiment. Physiological ionised [Ca2+]0 is approximately 1.3 mM. Contraction
amplitude of guinea pig cardiac myocytes in vitro at 1 mM [Ca2+]0 is 2.3 + 1.0%
(mean+SD, n = 132. Personal communication, LA Brown, PhD thesis 1992 London
University) of their resting (or diastolic) length. For greater accuracy in measuring
changes in contraction amplitude I used a concentration of 2 mM ionised calcium to
elevate baseline contractility, to 5.3±0.3% (mean+SEM, n=32) of resting length.
This is analogous to the preconstriction of aortic rings using K+ or prostaglandins in
superfusion experiments where vascular tone is being examined. In experiments on
human cells I maintained [Ca2+]0 at 1.3 mM as baseline contraction amplitude was
acceptable.
In most experiments an intervention was performed on a single myocyte, and
changes in contractility were compared to the mean of baseline recordings made
before and after the intervention. This avoided the problem of myocyte fatigue.
When lengthy dose response protocols are followed, basal contractility gradually
declines when cells are stimulated for periods >2 h. None of my studies used
prolonged protocols. Only in the experiments examining methylene blue did I not
compare myocyte responses before and after exposure to the agent. The reasons for
this are discussed in chapters 4 and 7.
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3.1.2. Effects of calcium and isoprenaline on cardiac myocyte contraction
A maximum inotropic response, measured as maximal contraction amplitude
achieved, is obtained by elevating [Ca2+]0 or exposing the myocyte to the 15-
adrenoceptor agonist, isoprenaline. I intended to compare maximum amplitude of
cells from stunned hearts to that of normal cells. This is discussed further in chapter
8. The effects of elevating [Ca2+]0 and isoprenaline on contraction amplitude are
illustrated below. Figure 10 shows a chart recording used to measure contraction
amplitude in response to elevated [Ca2+]0 and isoprenaline.
Figure 11 below shows computer-generated traces used to measure the time
dependent variables, time to peak contraction, and relaxation time. Exposure of this
myocyte to 8 mM calcium from a basal [Ca2+]0 of 1.3 mM increased contraction
amplitude from 4.3% to 9.3% of resting length. Exposure of the same cell to 10"9M
isoprenaline increased amplitude to a level equally as high, although it is usually the
case that isoprenaline has not quite the inotropic effect of maximum tolerated [Ca2+]0
(quoted value is 79.5 + 1.7% of contraction amplitude at Ca2+max, n=46, Wynne et
al., 1993). Interestingly, 15-adrenoceptor agonists frequently cause the characteristic
"dicrotic" notch in the relaxation phase of the contraction, visible as a double twitch
on direct visualisation.
3.1.3. Effect of cell bath temperature on cardiac myocyte contractility
Biochemical processes involving enzymes are temperature dependent. While
this is a truism, different laboratories examine aspects of myocyte function at quite
different temperatures. Experiments in the laboratory to which I was attached were
performed at 32°C. To examine the role of nitric oxide synthase I wished to
maintain bath temperature within tightly controlled limits. This is readily achieved
when continuous superfusion is performed, with a thermocouple-controlled heating
coil around the tubing. For the experiments where myocyte behaviour was examined
in the presence of endothelium it was necessary to halt buffer flow to allow
accumulation of endothelial products. Cell bath temperature falls rapidly when flow
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Figure 11 Increase in contraction amplitude with addition of 8 mM calcium or 10"9M isoprenaline.
Note the characteristic "dicrotic" notch during the relaxation phase of the isoprenaline contraction.
Bath temperature was monitored with a direct reading glass-tipped thermistor inside
the cell bath, calibrated before every experiment, and the 60W heat source adjusted
to maintain bath temperature at 32°C.
I studied the effects of changes in bath temperature over the range 28-36°C
on normal myocytes at 2 mM [Ca2+]0. Amplitude of contraction was higher at lower
temperatures, but velocity of contraction and relaxation was slower. These data are
shown below, in Figures 12-15. A change of +1.0°C from 32°C reduced
contraction amplitude by 5±0.5% (mean+SEM, n = 8), and similarly, a change of -
1°C increased contraction by 5±0.5% (n=7).
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The explanation of this finding possibly relates to the kinetics of cellular
calcium handling. At lower temperatures the rate of opening and closing of calcium
channels will be reduced, perhaps allowing more calcium to enter the cytoplasm.
Effect of cell bath temperature on cardiac myocyte contraction
Figure 12 Effect of temperature of cell bath on myocyte contraction amplitude. Absolute changes
in percentage shortening shown, n = 8.
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Effect of temperature on contraction amplitude, expressed as X of contraction at 32°C
Figure 13 Effect of changes in bath temperature on myocyte contraction, expressed as percentage
change from 32°C baseline, n = 8.
3.1.4. Comparison of myocyte contraction on endothelium compared to glass
Most of the experiments in this thesis were performed on cardiac myocytes
sited on glass coverslips. To establish that baseline contractility was no different
when myocytes were sited on quiescent, unstimulated endothelium I compared basal
contractility on the two surfaces.
Contraction amplitude of myocytes adherent to quiescent endothelium
(5.3+0.6% of resting length, n = 12) was not different to myocytes adherent to glass
coverslips (5.3±0.3%, n=32). There was no difference in time to peak contraction
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Effect of temperature on time to peak contraction of myocytes
0.20 n
Figure 14 Effect of temperature of cell bath on time to peak contraction of myocytes, n = 8.
(0.10+0.02s on endothelium, n = 11; 0.12+0.02s on glass, n=9), nor relaxation time
(0.30±0.04s on endothelium, n = ll; 0.30±0.03s on glass, n=9).
Having established that baseline contraction parameters were not different when
myocytes were situated on confluent endothelium subsequent studies could be
performed.
It was interesting that myocytes adhered without problem to the endothelial
layer. Both cell types express surface glycoproteins, although the majority of these
likely appear when the cells are stimulated by cytokines. An alternative explanation
for adherence is that myocytes were adhering to glass through gaps between
endothelial cells. A further explanation is that the shear force exerted by the buffer
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Figure 15 Effect of temperature on time from peak contraction to reach 90% of diastolic length
(relaxation time), n = 8 cardiac myocytes.
on the surface of the myocyte, transmitted as pressure from the myocyte on the
endothelial surface, was less than that necessary to overcome the resistance to
movement of the static myocyte sited on a non-friction free surface. Experiments to
study this adhesion were not pursued.
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CHAPTER 4: EFFECTS OF NITROVASODILATORS AND
METHYLENE BLUE ON CARDIAC MYOCYTE
CONTRACTILITY
4.1.1. Introduction
Endothelium-derived factors, predominantly nitric oxide, modulate blood flow
within the vasculature (for review see Moncada (Moncada et al., 1991)). Nitric
oxide, synthesised from the amino acid L-arginine by a constitutive nitric oxide
synthase enzyme, is released from endothelium and acts rapidly on adjacent vascular
smooth muscle to cause relaxation and vasodilatation. This mechanism exists in
health to modulate blood flow within tissues. The intracellular pathway involves
stimulation of the soluble guanylate cyclase enzyme system within smooth muscle by
nitric oxide to increase intracellular levels of cyclic 3',5'-guanosine monophosphate
(cGMP), with a subsequent reduction in intracellular calcium. Nitric oxide is capable
of relaxing smooth muscle not only within the vascular system, but smooth muscle
in airways, gut and urinary tract as well (Moncada et al., 1991).
Evidence is accumulating that the endothelium lining the endocardial surface
of the heart can modulate the contraction of myocardial papillary muscle in in vitro
preparations (Brutsaert et al., 1988; Smith et al., 1991). This specialised endothelial
layer produces at least two factors which modify contraction: a substance
indistinguishable from endothelium-derived nitric oxide which reduces contractility;
and another, as yet unidentified substance which augments contraction.
Within the myocardium, the coronary microcirculation lies in close proximity
to cardiac muscle, so that most cardiac myocytes are within 8^m of their nearest
capillary (Rose & Goresky, 1984; Randall, 1984). This short diffusing distance
means that the contractility of cardiac myocytes making up the bulk of the
myocardium might be influenced by vasoactive factors produced by adjacent
endothelium, in the same way that endothelial factors regulate smooth muscle
contraction in blood vessel walls.
The hypothesis tested is that nitric oxide affects cardiac myocyte contractility.
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A secondary aim of the first series of studies was to establish whether cardiac
myocytes can metabolise nitrovasodilators. These drugs cause vasodilatation by being
metabolised to produce nitric oxide, but different nitrovasodilators are metabolised
by different pathways (Furchgott, 1988). Porcine coronary smooth muscle cells
metabolise glyceryl trinitrate (GTN) to generate nitric oxide by a plasma membrane
enzyme (Chung & Fung, 1990). In contrast, sodium nitroprusside requires only a
reduction step requiring NADPF1, NADH or a thiol, a reaction which takes place in
the microsomes (Fung et al., 1991). Although the effects of nitrovasodilators on
cardiovascular haemodynamics are established in both patients and in experimental
models, the same haemodynamic changes will obscure any specific action of
nitrovasodilators on myocardial contractility, that is, the extent and rate of myocardial
shortening. The isolated, functioning cardiac myocyte is thus a suitable model to
study contractility in the absence of haemodynamic changes.
4.1.2. Methods
Measurement of cardiac myocyte contraction
All experiments were performed on single isolated, contracting, ventricular
myocytes. Cells were prepared from isolated, Langendorff perfused guinea-pig hearts
by enzymatic digestion, as described previously in chapter 2. A drop of myocyte
suspension was placed in a 200 /zl perspex chamber on the stage of an inverted
microscope on a 22 mm diameter plain glass coverslip and superfused at 2 ml/min
with 2 mM calcium Krebs Henseleit (KH) buffer (containing 119.1 mM NaCl,
4.7mM KC1, 0.94 mM MgS04, 1.2 mM KH2P04, 25 mM NaHC03 and 11.5 mM
glucose) bubbled with 95%02/5%CO2 at 32+0.5°C. Temperature was monitored by
a thermistor in the cell bath. Cells were allowed to adhere for 4 min without flow
and were then stimulated electrically to contract using a bipolar stimulator delivering
30V/ 0.5 ms pulses at 0.5 Hz.
Contractility of individual myocytes was determined as described in detail in
chapter 2. Briefly, contraction amplitude and velocity of shortening of electrically-
stimulated myocytes were recorded using a videomicroscopy-length detection system
and analysed by computer signal-averaging. This system had a time resolution of
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20 ms and a spatial resolution of 1 in 256, which allowed typically 10 to 15 sampling
points within a single contraction and relaxation. Six consecutive contractions were
signal-averaged to produce data under each particular set of conditions. Myocyte
contraction amplitude was calculated as a percentage of the resting length, and time
to peak contraction, and time from peak contraction to return to 90% of resting length
(relaxation time) were recorded.
Criteria were defined to identify healthy, viable, isolated myocytes, listed in
chapter 2. (i) only rod-shaped cells without sarcolemmal blebs were examined; (ii)
cells which exhibited spontaneous contractions were excluded; and (iii) cells that
displayed a variable baseline contraction to electrical stimulation at 2mM calcium
were rejected.
Sodium nitroprusside solutions were used over the concentration range 10"8-
3xl0"5M and containers wrapped in foil to exclude light. Concentrations of GTN
(Lipha, Middlesex, UK) and ISDN (Schwarz Pharma, Chesham, Bucks., UK) were
used over the dose range 10"6-3xl0"5M. Measurements were made on 6-10 myocytes
at each dose of nitrovasodilator. Effects of each nitrovasodilator were compared
randomly with control measurements recorded before or after myocyte exposure to
nitrovasodilator, at each concentration. Concentrations of nitrovasodilators were
chosen randomly, and cumulative dose-response protocols were avoided. Myocytes
were exposed to each concentration of nitrovasodilator for 10 min and were not
exposed to more than one nitrovasodilator. The time course of the study allowed for
measurements made on individual myocytes within 45 minutes of stabilisation. This
avoided the reduction in myocyte contraction amplitude that can occur in studies of
more than 2 hours' duration.
In further experiments 5x106M methylene blue (David Bull Laboratories,
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Figure 16 Representative signal-averaged trace of the effect of 10"5M sodium nitroprusside on
myocyte contraction.
4.1.3. Results
Effects of nitrovasodilators on guinea pig cardiac myocyte contraction.
Figure 16 shows a representative signal-averaged trace (of six contractions)
of the effect of 10~5M sodium nitroprusside on contraction of a single myocyte. In
this experiment contraction amplitude was reduced from 5.8% to 4.7% of resting































Figure 17 Effect of different nitrovasodilators on myocyte contraction amplitude, differences
expressed as percentage reduction of control contractions; mean + SEM of six-ten experiments.
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peak contraction or relaxation time.
The difference between the fractional shortening in the presence of
nitrovasodilator was expressed as a percentage of the baseline contraction (Figure 17).
GTN and ISDN over the dose range 10"6-3xl0"5M had no effect on contraction
amplitude of contracting myocytes.
Sodium nitroprusside reduced contraction amplitude: the reduction was significant
(p<0.02, ANOVA) at concentrations of 3 x 10"8M or above. Regression analysis
showed that the effect of sodium nitroprusside was concentration dependent
(P<0.001), although it was not possible to determine whether the curve was
monophasic or biphasic.
In further studies 5xlO~6M methylene blue was added to all solutions and
reversed the reduction in myocyte shortening caused by sodium nitroprusside (Figure
18). In control studies, methylene blue itself had no effect on myocyte contractility
over the same time course as these experiments. However, superfusion of methylene
blue for more prolonged periods (> 30-60 min) caused cells to become
hypercontractile and subsequently fibrillate in ten of twelve cardiac myocytes studied.
Compared to control, none of the nitrovasodilators had a significant effect on
time to peak contraction (baseline, 0.14+0.02 s; nitrovasodilator, 0.14+0.02 s,
mean+SD; pooled data from all nitrovasodilator experiments, n = 12 groups of paired
studies). Similarly, relaxation times were not affected by nitrovasodilators (baseline
0.27±0.05 s; nitrovasodilator 0.28+0.04 s, mean+SD, pooled data from the same





Figure 18 SNP, sodium nitroprusside; SNP/MB, sodium nitroprusside + methylene blue. Values




Effects of Glyceryl Trinitrate, Isosorbide Dinitrate and Sodium Nitroprusside on Time
to Peak Contraction and on Relaxation Time of Isolated, Functioning Guinea-pig
Cardiac Myocytes.


































































Values are mean+SEM of six-nine paired experiments at each concentration of
nitrovasodilator (except 3xl0"5M SNP, n=4 experiments). GTN, glyceryl trinitrate;
ISDN, isosorbide dinitrate; SNP, sodium nitroprusside.
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Effect ofsodium nitroprusside on contractility ofhuman cardiac ventricular myocytes.
The opportunity was taken to confirm the effect of the nitric oxide donor,
sodium nitroprusside, on human cardiac ventricular myocytes. Three cells from two
patients with dilated cardiomyopathy were studied. Contractility was reduced in a
manner similar to guinea pig myocytes. The magnitude of reduction was similar to
that seen with guinea pig myocytes, as shown in Figure 25.
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Figure 19 Effect of sodium nitroprusside (SNP)
on time to peak contraction, n = 6-9 myocytes at
each concentration. Open bars=control; hatched
bars= after addition of SNP.
Figure 20 Effect of isosorbide dinitrate
(ISDN) on time to peak contraction, n = 6-9
myocytes at each concentration. Open
bars=control; hatched bars= after addition of
ISDN.
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TIME TO PEAK CONTRACTION
TIME FROM PEAK TO SOX RELAXATION
Figure 21 Effect of glyceryl trinitrate (GTN) on
time to peak contraction, n = 6-9 myocytes at each
concentration. Open bars = control; hatched
bars= after addition of GTN.
Figure 22 Effect of sodium nitroprusside
(SNP) on time from peak contraction to 90%
relaxation, n=6-9 myocytes at each
concentration. Open bars=control; hatched
bars= after addition of SNP.
Figure 23 Effect of isosorbide dinitrate (ISDN)
on time from peak contraction to 90% relaxation,
n=6-9 myocytes at each concentration. Open
bars=control; hatched bars= after addition of
ISDN.
Figure 24 Effect of glyceryl trinitrate (GTN)
on time from peak contraction to 90%
relaxation, n=6-9 myocytes at each
concentration. Open bars = control; hatched
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Figure 25 Effect of sodium nitroprusside on contraction amplitude of human ventricular myocytes,
differences expressed as percentage reduction of baseline contraction; mean + SEM of three studies.
4.1.4. Discussion
Sodium nitroprusside reduced the contraction amplitude of isolated myocytes
in the present study. This effect was reversed by the guanylate cyclase inhibitor,
methylene blue, consistent with it being mediated by generation of nitric oxide from
sodium nitroprusside with subsequent elevation of intracellular cGMP. The effect of
sodium nitroprusside was reversible and repeatable, suggesting that the generation of
cyanide was not a cause of the reduced contraction amplitude.
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The opportunity to confirm these findings in human ventricular myocytes
arose. Sodium nitroprusside reduced contractility in an identical fashion to that seen
in guinea pig cells.
The effect of sodium nitroprusside in papillary muscle (Smith et al., 1991) is
of similar magnitude to the reduction in contraction seen in the present study. In
papillary muscle experiments, small changes in time-dependent variables can be
demonstrated. These changes are within 20 ms (Smith et al., 1991), and while our
studies detected no effects on either times to peak contraction or relaxation times, this
may because the time resolution of our videomicroscopy edge-detection device is
itself of the order of 20 ms.
In the present study methylene blue reversed the effect of sodium nitroprusside
over a short time course. Toxicity was not observed during exposure of myocytes
to methylene blue for periods less than 10 min. However, in the studies on myocytes
isolated from guinea pigs with endotoxaemia exposure of these cells to methylene blue
over 10-15 min resulted in inotropic, then toxic effects (see Chapter 7). In another
recent study methylene blue (10 /xM) administered to both neonatal and adult rat
cardiac myocytes had no effect on basal contractility, but enhanced the inotropic
effects of isoprenaline (Balligand et al., 1993). Toxic effects were not described,
although the time course of exposure of cells to methylene blue was not noted in their
paper. Their interpretation of the effects of methylene blue was that a constitutive
nitric oxide synthase was active during B-adrenergic stimulation and may mediate in
part cholinergic regulatory mechanisms.
It is of interest that sodium nitroprusside, but not the organic, and more
commonly used nitrates, ISDN and GTN, was metabolised to generate nitric oxide
within cardiac myocytes in the present study. Hence cardiac myocytes may not
contain the enzymes necessary to produce nitric oxide from the latter two drugs. This
difference in metabolism may be masked in vivo by the widespread haemodynamic
changes following nitrovasodilator administration. In patients with unstable angina,
sodium nitroprusside showed no difference with respect to haemodynamic changes
when compared to GTN (Breisblatt et al., 1988); it may be that vascular smooth
muscle is more sensitive than cardiac muscle to the actions of sodium nitroprusside,
and thus vasodilator effects are seen before changes in myocardial contractility
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develop. In patients with angina pectoris, the therapeutic concentration range in
plasma of intravenous isosorbide dinitrate is approximately 4xlO"9M - 10~8M
(manufacturer's information, Schwartz Pharma, Chesham, Bucks). Sodium
nitroprusside is used to control blood pressure in anaesthesia over the plasma
concentration range 8xlO~8M - 9xlO"7M (Vesey et al., 1990). Thus vascular smooth
muscle in vivo is about 10-100 fold more sensitive than cardiac tissue in vitro to the
effects of nitrovasodilators.
GTN and ISDN generate nitric oxide in the epicardial coronary circulation.
Yet no effect on myocardial contractility occurs when nitrates are injected down
coronaries. An interesting question is: why is myocardial contractile function not
altered visibly by direct intracoronary injection of nitrate, a procedure frequently
performed at coronary angiography? Presumably, while some GTN or ISDN is
evidently metabolised to release nitric oxide by the endothelium and vascular smooth
muscle, the amount generated locally is limited in its effect to the same vascular
lining cells, without reaching the ventricular myocytes. Alternatively, the same
explanation for the study just mentioned (Breisblatt et al., 1988) may be involved.
Systemic effects may be apparent before cardiac effects are achieved. In animals, the
coronary circulation has been shown to be less sensitive to the effects of GTN than
the peripheral vasculature (Sellke et al., 1990).
The mechanism by which elevation of cGMP may cause a reduction in
myocyte contraction is not well understood. Possible pathways are discussed further
in chapters 5 and 9.
Nitrovasodilators thus differ in their ability to affect cardiac myocyte
contractility. The results of this study led me to proceed to develop a coculture of
endothelium with cardiac myocytes, and to further studies described in the next five
chapters.
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CHAPTER 5: EFFECT OF NITRIC OXIDE AND 8-BROMO-
CYCLIC GMP ON CARDIAC MYOCYTE CONTRACTILITY
5.1.1. Introduction
Nitric oxide synthase is constitutively expressed in many cell types. These
include some neural tissues; circulating neutrophils, mast cells and platelets;
pancreatic islet B cells; and renal macula densa cells, as well as endothelium
(Moncada et al., 1991; Nathan, 1992). Production of nitric oxide appears to be a
fundamental and important mechanism of intercellular signalling in these cell types,
and nitric oxide modulates or mediates cellular function in a variety of tissues.
The experiments in chapter 4 suggested that nitric oxide derived from sodium
nitroprusside attenuated cardiac myocyte contraction. The hypothesis again tested in
the present study is that nitric oxide affects cardiac myocyte contractility. Nitric
oxide directly in aqueous solution superfused over contracting cardiac myocytes is the
ultimate straightforward test of this hypothesis.
Nitric oxide acts in the vasculature by elevating intracellular levels of cGMP.
In the previous study, methylene blue, a nonspecific inhibitor of guanylate cyclase,
reversed the effects of sodium nitroprusside, suggesting the action of the
nitrovasodilator was mediated by elevation of cGMP levels within the myocytes. In
the present study the effects of the stable analogue, 8-bromo-cyclic GMP were
therefore studied. 8-bromo-cyclic GMP is a lipid soluble, stable analogue of cGMP.
It can cross cell membranes and is used experimentally to mimic elevation of cGMP.
5.1.2. Methods
Measurement of cardiac myocyte contraction
All experiments were performed on single isolated, contracting, ventricular
myocytes. Cells were prepared from isolated, Langendorff perfused guinea-pig hearts
by enzymatic digestion, as described previously, in chapter 2.
Contractility of individual myocytes was determined as described in detail in
chapter 2. Criteria were defined to identify healthy, viable, isolated myocytes: (i)
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only rod-shaped cells without sarcolemmal blebs were examined; (ii) cells which
exhibited spontaneous contractions were excluded; and (iii) cells that displayed a
variable baseline contraction to electrical stimulation at 2mM calcium were rejected.
Preparation of aqueous nitric oxide
Experiments were performed to examine the effect of nitric oxide dissolved
in physiological solution on cardiac myocyte contraction. 100 p\ or 1000 p\ aliquots
of nitric oxide gas (99% pure; Merck, Poole, Dorset, UK) were injected using a
Hamilton gas syringe (Reno, Nevada) into 300 ml HEPES buffered 2mM Ca2+
Tyrodes solution (containing 150 Mm NaCl, 5.4 mM KC1, 1.2 mM MgCl2, 5.0 mM
Na-HEPES, 10.0 mM glucose; pH 7.40) which had been bubbled vigorously with
nitrogen gas for 4 h to remove oxygen. This yielded stock solutions of approximately
10"6-10'5M dissolved nitric oxide, respectively, and the stock solutions were kept
anoxic. Aliquots were withdrawn and superfused into the cell bath for 7 min. The
concentration of the 10~6M nitric oxide solutions was confirmed using a Sievers Nitric
Oxide Chemiluminescence Analyzer (Denver, Colorado) to be within the range 1-
3x10 6M on multiple samplings of different 100 /A solutions. The 1000 p\ solutions
were assumed to contain tenfold more nitric oxide. Control experiments were
performed using the same Tyrodes solution, bubbled with 100% nitrogen.
5.1.3. Results
Figure 26 shows a representative trace of six signal-averaged contractions of
the effect of 10"5M nitric oxide solution on contraction amplitude of a single cardiac
myocyte. Figure 27 shows the effect of direct superfusion with 10"6M and 10"5M
nitric oxide solution on myocyte contraction amplitude, compared to control, of five
experiments. Nitrogen gassed control solution had no effect on myocyte contraction
(n = 13 myocytes) so the effect of the nitric oxide solution was not due to hypoxia.
Administration of 10"5M nitric oxide did not have a greater effect than 10"6M nitric
oxide. The reduction in contractility seen with the nitric oxide solutions was similar
to that caused by 3xlO"5M sodium nitroprusside.
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Figure 26 Representative signal averaged trace of the effect of 10"5M nitric oxide on cardiac
myocyte contraction.
slight reduction in relaxation time at one of the doses of nitric oxide solution. This
effect on relaxation time was not seen with sodium nitroprusside, nor with stimulated
endothelium. Its significance is uncertain. This reduction was not seen with 8-
bromo-cyclic GMP either, although this drug reduced time to peak contraction slightly
at 10"5M, but not at other doses (Figure 30).
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Figure 27 Effect of 10'6M and 10"5M NO solution, and N2 solution on myocyte contraction.
Mean + SEM of five (NO) and 13 (N2) experiments.
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The stable cGMP analogue, 8-bromo-cyclic GMP, caused a concentration-
related reduction in myocyte contraction amplitude, similar in magnitude to the effect
of sodium nitroprusside shown in chapter 4 (Figure 17). Effects of 8-bromo-cyclic
GMP on time to peak contraction and relaxation time are shown in Figure 29. I
tested 8-bromo-cyclic GMP on two human ventricular myocytes. Administration of
10"7M and 10"6M solutions decreased contraction amplitude by approximately 25% in
each case.
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Effect of 10"6M and 10"5M nitric oxide on time to peak contraction















10~6M NO 0.11 +0.02s; p=NS 0.37+0.06s; p<0.01
10 5M NO 0.12+0.02s; p=NS 0.45+0.03; p=NS
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Figure 29 Effect of 10"6M-3xl0"5M 8-bromo-cyclic GMP on myocyte contraction amplitude, as a
percentage of baseline contraction. Mean±SEM of five-seven experiments; p<0.025 at each dose.
86
Effect of 8-bromo-cyclic GMP on time to peak contraction
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10~6M 8-bromo-cGMP 0.12+0.02s; p=NS 0.34+0.02s; p=NS
10"5M 8-bromo-cGMP 0.11+0.02s; p<0.05 0.27+0.05s; p=NS
87
5.1.4. Discussion
The experiments show that nitric oxide in aqueous solution directly causes a
reduction in cardiac myocyte contraction amplitude. This was not caused by anoxia
because the control solution containing only N2 was without effect. The open design
of the cell bath allowed adequate oxygenation from the atmosphere. Although the
amount of nitric oxide converted to nitrite on exposure to air within the cell bath is
unknown, because the nitric oxide solution was protected from exposure to air until
it reached the cell under study, sufficient nitric oxide from a solution of
approximately 10"6M could reach the myocytes unchanged with an effect similar to
3xlO"5M sodium nitroprusside. It appears that 10"6M nitric oxide in aqueous solution
had a maximum effect, since 10~5M solution did not significantly reduce further the
contraction amplitude.
Nitric oxide acts within cells by stimulating soluble guanylate cyclase to
increase levels of cGMP, and in vascular smooth muscle this can be inhibited
predictably by methylene blue. Haemoglobin is used in vascular preparations to bind
free nitric oxide, and this ability was recognised early in the development of nitric
oxide biology. Proteins froth due to bubble formation at the electrodes in the cell
bath, so haemoglobin was not used.
Exposure of myocytes to the stable analogue of cGMP, 8-bromo-cyclic GMP,
had an effect similar to nitric oxide either administered in aqueous solution or derived
from sodium nitroprusside. A relatively high concentration of 8-bromo-cyclic GMP
was needed, consistent with the natural amplification of a biological signal, whereby
receptor-mediated events, for example stimulation by nitric oxide, are amplified by
the second messenger systems. Alteratively, this may reflect the difficulty of entry
of 8-bromo-cyclic GMP into myocytes. The same analogue has been tested in
endothelium-intact papillary muscles (Shah & Henderson, 1992). A negative
inotropic effect similar to that seen in the present study was observed. KP^M 8-
bromo-cyclic GMP was required in their study to produce the negative inotropic
effect on papillary muscle contraction.
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The mechanism by which elevation of cGMP may cause a reduction in cardiac
myocyte contraction is not well understood. In frog cardiac myocytes, cGMP inhibits
the L-type inward calcium channel current (ICa) by stimulation of cyclic 3'5'-
adenosine monophosphate (cAMP) phosphodiesterase, but in rat ventricular myocytes
cGMP predominantly inhibits this calcium current by a mechanism involving cGMP-
dependent protein kinase, independent of any effect on cAMP levels (Walter, 1989;
Lohmann et al., 1991). Furthermore, cGMP has both stimulatory and inhibitory
actions on different phosphodiesterases in rat cardiac myocytes and under certain
experimental conditions has a stimulatory effect on 1^ (Lohmann et al., 1991). I
studied the effect of nitric oxide on calcium transients recorded during contraction,
and these results, together with further discussion of the mechanism of cGMP action
within myocytes, are presented in Chapter 9.
In the present study a maximal effect occurred with the lowest dose of nitric
oxide solution, i.e. 10"6M. When I designed the study the available data from my
nitrovasodilator experiments suggested that a reliable reduction in myocyte
contractility was obtained with administration of 1CT6-10 5M solutions. This accounts
for the concentrations of nitric oxide chosen for the present study. Stoichiometrically,
one nitroprusside molecule releases one nitric oxide molecule. Generation of nitric
oxide from nitroprusside requires a reduction step which takes place in the
microsomes. Nitric oxide was at least 10 fold more potent than nitroprusside in my
experiments, and this may reflect incomplete metabolism of nitroprusside by
myocytes. In both the sodium nitroprusside and nitric oxide studies the reduction in
contractility was reversible, which makes this effect unlikely to be due to toxicity.
I would have liked to have examined the effects of lower concentrations of
nitric oxide to establish a dose-response curve. Threshold changes in contractility
are smaller and greater numbers would be required for accuracy. Only one dose of
nitric oxide solution could be studied each day, because preparation of solutions was
lengthy and only one concentration could be performed each day. Moreover, nitric
oxide is expensive. A clear effect was demonstrated at 10"6M, so studies at lower
concentrations were not pursued.
Superfusion with anoxic 2 mM Tyrode's solution had no effect compared to
baseline. While this result was an important control, supportive of the data from
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nitric oxide solution experiments, it meant that to study hypoxia-reperfusion at
cellular level, simply using hypoxic buffer would have no effect. The open nature
of the cell bath allowed adequate oxygenation from room air. The ways I addressed
hypoxia to study myocardial stunning at a cellular level are discussed in chapter 8.
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CHAPTER 6: CARDIAC MYOCYTE CONTRACTILITY IN
PRIMARY COCULTURE WITH ENDOTHELIUM
6.1.1. Introduction
Endothelium-derived factors modulate blood flow within the vasculature.
Nitric oxide, synthesised from the amino acid L-arginine by a constitutive nitric oxide
synthase enzyme, is released from endothelium and acts rapidly on adjacent vascular
smooth muscle to cause relaxation and vasodilatation. This mechanism modulates
blood flow within tissues. The intracellular pathway involves stimulation of the
soluble guanylate cyclase enzyme system within smooth muscle by nitric oxide to
increase intracellular levels of cyclic 3',5'-guanosine monophosphate (cGMP), with
a subsequent reduction in intracellular calcium.
Within the myocardium, the coronary microcirculation lies in close proximity
to cardiac muscle, so that most cardiac myocytes are within 8 yum of their nearest
capillary, as illustrated in chapter 1.4.2.. This short diffusing distance means that the
contractility of cardiac myocytes making up the bulk of the myocardium might be
influenced by vasoactive factors produced by adjacent endothelium, in the same way
that endothelial factors regulate smooth muscle contraction in blood vessel walls.
The hypothesis tested is that nitric oxide affects cardiac myocyte contractility.
For this series of experiments I developed a coculture of myocytes together with
endothelial cells to examine if there was a direct effect of endothelial factors on
myocyte contraction.
Since endothelial cells can release prostacyclin and other prostaglandins I
performed some experiments in the presence of indomethacin. Prostaglandins have
inotropic effects on myocardium, but only at high pharmacological concentrations
(Alloatti et al., 1991; Otani & Das, 1988). The effect of Iloprost, a stable analogue
of prostacyclin, was examined in control myocytes without endothelium.
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6.1.2. Methods
Endothelium-cardiac myocyte coculture model
Bovine aortic endothelial cells were isolated and passaged by non-enzymatic
methods, as described in chapter 2. The cells had normal cobblestone morphology,
Factor VIII immunoreactivity and high levels of angiotensin-converting enzyme
activity. They were used between passages 10-18 and grown in Dulbecco's modified
Eagle's medium with 10% fetal-calf serum (Gibco, Paisley, Scotland), penicillin
200,000 IU/1, streptomycin 200 mg/1 and glutamine 480 mg/1. Cells were passage
on to sterile glass coverslips contained in multiwell plates and used 2-3 days later
when confluent.
In the endothelium-myocyte coculture experiments 10~7M bradykinin was used
to stimulate release of endothelial-derived factors. The ability of the endothelium to
generate nitric oxide when stimulated with bradykinin was confirmed in separate
studies by chemiluminescence using the nitric oxide chemiluminescence analyzer
(Warren JB, Wilson AJ, work in preparation), and also by bioassay using endothelial
cells grown on microcarrier beads in a superfusion cascade system (O'Shaughnessy
etal., 1992).
To allow accumulation of endothelial-derived factors, superfusing buffer flow
was halted 5 minutes before recordings were made. An indwelling thermocouple and
heating element were used to maintain bath temperature and 95%02/5%C02 gas was
superfused over the cell bath to maintain oxygenation and pH. The temperature of
the system was controlled so that paired recordings were made at matched
temperatures. Control studies showed that a change of + 1.0°C from 32°C reduced
contraction amplitude by 5+0.5% (mean+SEM, n = 8), and similarly, a change of -
1°C increased contraction by 5+0.5% (n=7). The complete data from the studies
of superfusing buffer temperature are presented in chapter 3. For the recordings
made during coculture experiments, bath temperature was maintained at 32.6+0.2°C.
Some endothelium-myocyte studies were performed in the presence of lO^M NG-
nitro-L-arginine methyl ester (L-NAME) to inhibit production of nitric oxide, or in
the presence of 10"5M indomethacin to block prostaglandin synthesis.
Iloprost was a generous gift from Schering AG, Berlin, Germany.
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6.1.3. Results
To examine the effect of endothelium-derived nitric oxide on myocyte
contractility, myocytes were studied in primary coculture with confluent endothelium.
To determine whether unstimulated endothelium affected baseline characteristics of
contraction, the contractility of myocytes on endothelium was compared to that on
glass. Contraction amplitude of myocytes adherent to quiescent endothelium
(5.3+0.6% of resting length, n = 12) was not different to myocytes adherent to glass
coverslips (5.3+0.3%, n=32). There was no difference in time to peak contraction
(0.10+0.02 s on endothelium, n = 11; 0.12+0.02 s on glass, n=9), nor relaxation





























Figure 31 Endothelium-myocytecoculture; mean + SEM of 12 (control±BK), 11 (L-NAME + BK)
and 6 (indomethacin + BK) experiments. BK, bradykinin; indo, indomethacin.
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Myocyte contractility in coculture with endothelium.
In coculture experiments 10"7M bradykinin was used to release nitric oxide
from the endothelium. Myocyte contraction was reduced by 11+3.5% (p<0.03).
This effect was abolished by the presence of lCfM L-NAME, and was not reduced
by 10"5M indomethacin (Figure 31). Although the bradykinin-induced reduction in
contraction was greater in the presence of indomethacin, this further reduction was
not significantly larger than that of bradykinin alone. Bradykinin-stimulated nitric
oxide release had no effect on either time to peak contraction or relaxation time (see
Table 5).
In control experiments without endothelium, bradykinin had no effect on
contraction amplitude of isolated myocytes (Table 6). Bradykinin-stimulated nitric
oxide release had no effect on either time to peak contraction (TTP), or time from
peak contraction to 90% relaxation (PTR):
TTP:-0.13+0.01 s at baseline v 0.12+0.01 s BK; n=6
PTR:- 0.39+0.02 s at baseline v 0.38+0.04 s BK; n=6
Even more importantly, L-NAME had no significant effect (+1.0+3.6%
increase, n=9; p=NS, see Table 6 below) on contraction amplitude of normal
ventricular myocytes without endothelium. This suggests that in their normal state,
cardiac ventricular myocytes do not have appreciable nitric oxide synthase activity.
L-NAME had no effect on time dependent variables either, as shown below:
TTP:-0.11 ±0.01 s at baseline v 0.11 ±0.01 s L-NAME; n =9
PTR:- 0.29±0,02 s at baseline v 0.27±0.02 s L-NAME; n=9
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Table 5 Effect of bradykinin, L-NAME and indomethacin on time to peak contraction and





10 5M indo indo + BK
Time to peak
contraction (s)
0.10+0.02 0.10+0.02 0.10+0.02 0.10±0.02 0.11+0.02 0.11+0.02
relaxation
time (s)
0.30+0.04 0.28±0.03 0.30+0.02 0.28±0.03 0.38+0.03 0.34±0.03
Table 6 Effect of bradykinin, L-NAME and indomethacin on contraction amplitude of normal
ventricular myocytes without endothelium. Mean±SEM of fractional shortening of contracting













bradykinin 10 7M; n=12 4.4+0.4% 4.3+0.4% -0.1+0.3 +2.2 + 8.0% NS
L-NAME 10 4M; n=9 4.5+0.6% 4.7 + 0.79% +0.2 + 0.2 + 1.0+3.6% NS
indomethacin 10'5M; n=10 6.7+0.7% 6.4±0.7% -0.3+0.2% -5.0+3.7% NS
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Indomethacin had no effect on contraction amplitude in control experiments
without endothelium (Table 6 above). In other controls without endothelium,
Iloprost, the stable analogue of prostacyclin, had no effect on contractility over the
dose range 10~7 -10~5M, as shown.
Table 7 Effect of Iloprost l(f7-10"5M on contraction amplitude of control cardiac myocytes











Iloprost 107M 5.2±0.7% 5.2±0.7% + 1.6+2.7% NS
Iloprost 10 ,:M 4.5 + 0.2% 4.7+0.5% +4.8±7.3% NS
Iloprost 10 5M 5.2 + 0.9% 5.5 + 1.1% +3.0± 12.2% NS
6.1.4. Discussion
The contraction of cardiac myocytes was attenuated by nitric oxide released
by endothelium. The contraction amplitude of myocytes was reduced by 11 % when
they were in close proximity to cultured endothelial cells which had been stimulated
with bradykinin, a substance known to release nitric oxide from cultured bovine aortic
endothelial cells. In control experiments bradykinin alone or non-stimulated
endothelial cells had no effect on contractility. It is likely that the bradykinin-
stimulated effect was mediated by the release of nitric oxide, or a similar
intermediate, from the endothelial cells as it was blocked by the substrate inhibitor
of nitric oxide synthase, L-NAME. The bradykinin-stimulated effect was independent
of cyclooxygenase inhibition, excluding endothelial-derived prostaglandins as a cause
of the attenuation. Neither indomethacin, the inhibitor of cyclooxygenase, not
Iloprost, the stable analogue of prostacyclin, affected myocyte contractility in control
experiments.
Stimulated endothelium had a lesser effect on contraction amplitude than did
sodium nitroprusside or solution of nitric oxide, probably because the local
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concentration of nitric oxide generated within the myocyte from the nitroprusside or
directly administered was higher than that made available by exogenous stimulation
of endothelium.
L-NAME had no effect on contractility of isolated cardiac myocytes in the
absence of endothelium. This was an important control study because it shows that
ventricular myocytes from healthy guinea-pigs do not possess intrinsic nitric oxide
synthase activity under normal circumstances. It also shows that L-NAME has no
other effects on contractile apparatus. Another specific nitric oxide synthase
inhibitor, L-NMMA was shown to have no effect on contractility of normal rat
cardiac myocytes (Amrani et al., 1992). Constitutive nitric oxide synthase has now
been shown to be present in normal, healthy cardiac myocytes (Schultz et al., 1992;
Balligand et al., 1993) but does not appear to generate appreciable nitric oxide.
Inhibitors and substrates of nitric oxide synthase had no effect on contractile function
of cells in their basal state, either in my experiments (this chapter, and Chapter 7) or
theirs (Amrani et al., 1992; Schultz et al., 1992; Balligand et al., 1993).
My hypothesis that important interactions exist between endothelium and
myocardium is supported by studies that have shown influence of endocardial
endothelium over adjacent myocardial cells in papillary muscle experiments in vitro.
This was first described by Brutsaert and coworkers who showed that damage to the
endocardial surface of papillary muscle causes a reduction of about 20% (at 2.5 mM
external Ca2+ concentration) in maximum isometric tension produced by the muscle,
brought about by an earlier onset of isometric relaxation, but with no effect on the
velocity of contraction (Brutsaert et al., 1988). This effect occurs in endocardium-
intact preparations with administration of lipid-soluble analogues of cGMP, or with
sodium nitroprusside and atrial natriuretic peptide (substances that increase myocardial
cGMP by stimulating soluble and particulate guanylate cyclase respectively), which
reduce papillary muscle contractility similar to endocardial damage(Smith et al.,
1991; Brutsaert et al., 1988; Shah & Henderson, 1992). From experiments using
cultured endocardial cells on beads in a cascade system, endocardial endothelium
releases a substance indistinguishable from endothelium-derived nitric oxide with
negative inotropic effects, and an as yet unidentified opposing substance which both
augments contraction and prolongs relaxation (Smith et al., 1991). Restoration of
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endocardial products to endocardium-damaged papillary muscles both increases the
force of isometric contraction and prolongs the relaxation phase after contraction in
this system. The quantitative relationship between this inotropic endocardial product
and endocardial nitric oxide is yet to be fully established, although the unidentified
contraction-prolonging factor appeared to be dominant in these experiments (Shah &
Henderson, 1992).
Another group examined histochemical evidence of contractile activity in
blocks of myocardium or in papillary muscles (McClellan et al., 1992). They found
an unequal distribution of myosin ATPase activity in myocardium, with activity
highest in those cells nearest blood vessels. Their explanation was that factor(s)
released from blood vessels modified myosin ATPase activity, although they could
not determine what these factors were.
Implicit in the hypothesis for the present study is that coronary microvascular
endothelium releases nitric oxide, but there is yet no direct evidence that this occurs.
I used non-enzymatically cultured bovine aortic endothelium for the cardiac myocyte-
endothelium coculture experiments since it is both readily obtained and is a known
source of nitric oxide. But important differences exist between the endothelium lining
large arteries, and endothelium within the microvasculature. For example, coronary
microvessels are less sensitive than aorta to the exogenous nitrovasodilator, GTN, but
relax equally to nitric oxide solution, albeit at a higher concentration (Sellke et al.,
1990). This implies that metabolism of organic nitrates in the coronary
microvasculature is less efficient than elsewhere in the circulation, perhaps because
of a relative deficiency of either the enzymes required (Chung & Fung, 1990), or
available sulfhydryl groups necessary for generation of nitric oxide from GTN.
Nitric oxide has been shown to be a vasodilator in several different microvascular
preparations (Warren et al., 1992; Gardiner et al., 1990; Ekelund & Mellander,
1990; Persson et al., 1990).
It has been demonstrated recently in isolated, perfused hearts that 5-
hydroxytryptamine stimulates nitric oxide release from the coronary microvasculature,
measured by coronary sinus nitrite sampling, and this is accompanied by a reduction
in the time to reach peak ventricular pressure (Shah et al., 1991). These preliminary
data suggest that coronary microvascular endothelium, as well as the endocardial
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endothelium covering papillary muscles, is capable of releasing factors which
modulate myocardial contraction.
Support for a functional relationship between nitric oxide and the myocardium
comes from three recent reports. Finkel et al (Finkel et al., 1992) have shown that
the negative inotropic effects of inflammatory cytokines on papillary muscle are
mediated rapidly by generation of nitric oxide within the muscle itself. Such effects
in other tissues require de novo protein synthesis and the rapid time course of their
results has been questioned. Moncada's group have demonstrated the presence of
both the constitutive and inducible forms of the nitric oxide synthase enzyme in rat
cardiac myocytes (Schulz et al., 1992), and I have shown recently that in
experimental endotoxemia cardiac myocyte contractility is markedly impaired by a
mechanism involving nitric oxide production within the myocytes themselves (Brady
et al., 1992). Thus cardiac myocytes contain the biochemical apparatus necessary to
both generate and handle nitric oxide. My evidence that healthy cardiac myocytes are
sensitive to exogenous nitric oxide in three different delivery systems supports the
hypothesis that microvascular endothelium influences cardiac myocyte contraction by
activation of nitric oxide-sensitive guanylate cyclase, although nitric oxide production
by microvascular endothelium within the heart has yet to be demonstrated.
The mechanism by which nitric oxide may cause a reduction in myocyte
contraction is not understood. In chapter 5 I discussed possible mechanisms of cGMP
action within myocardium. An alternative, although less likely explanation of the
effect of nitric oxide on cardiac myocytes is that the elasticity of proteins forming the
cytoskeleton, rather than the actin-myosin myofibrils, is modified by nitric oxide.
Important changes in cytoskeletal proteins occur in ischaemia (Steenbergen et al.,
1987a) and in cardiomyopathy (Schaper et al., 1991), but these changes probably
evolve over a long time course. Whether nitric oxide can cause transient changes in
cellular ultrastructure has not been described.
Recently, L-NAME has been shown in rabbit coronary artery to have actions
of a muscarinic antagonist (Buxton et al., 1993) as well as its inhibitory effect on
nitric oxide synthase. L-NMMA does not have this property. This study has
important bearing on many reports, but since the only action of L-NAME in this
chapter and the next was a specific inhibition of nitric oxide synthesis, the
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interpretation of my results is not affected by these implications.
That nitric oxide affects cardiac myocyte contractility may have important
consequences. It may be that in normal hearts, capillary endothelium produces EDRF
which has a tonic effect on contraction of nearby myocytes. With the development
of cardiac hypertrophy or dilatation in disease states, the normal architecture and
relationship between microvasculature and myocytes becomes disturbed with increased
diffusion distance and impairment of function. Implications of this research are
discussed further in chapter 11.
Further new evidence of a role of nitric oxide modulating cardiac myocyte
contraction has recently been published by Michel's group in Boston (Balligand et al.,
1993). Studies were performed in both neonatal and adult ventricular myocytes.
Constitutive nitric oxide production by healthy cells of both types was demonstrated,
although neither the provision of substrate, L-arginine, nor the presence of the
inhibitor, LNMMA, had an effect on basal contractility. Nitric oxide activity was
demonstrated as a modulating influence on B-adrenergic stimulated inotropy in adult
cells, and nitric oxide appeared to mediate the effect of the muscarinic agonist,
carbachol, on myocytes. LNMMA augmented isoprenaline-induced contraction, and
LNMMA blocked the attenuating effect of carbachol on myocyte contraction.
8-bromo-cyclic GMP had the same effect as nitric oxide in their studies, and
methylene blue and oxyhaemoglobin reversed the moderating influence of nitric
oxide. Interestingly, sodium nitroprusside did not restore the negative inotropic effect
of LNMMA on carbachol-treated myocytes. Sodium nitroprusside did not attenuate
contractility in their experiments, although they did not formally examine the effects
of sodium nitroprusside directly (n=3 in their controls). A possible explanation may
be that signal transduction mechanisms mediating the effect of carbachol involve more
than production of free nitric oxide within cells.
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CHAPTER 7: EFFECTS OF ENDOTOXIN TREATMENT ON
CARDIAC MYOCYTE CONTRACTILITY
7.1.1. Introduction
While endothelial control of vascular tone is central to normal cardiovascular
function, disturbances of nitric oxide physiology have recently been shown to occur
in disease states. One such example is endotoxic shock. Septicaemia and
accompanying septic shock account for a substantial number of hospital deaths,
despite appropriate antibiotic and supportive therapy. In the earliest stages of septic
shock stroke volume and cardiac output are maintained or even increased; later,
ventricular dilatation develops with a reduction in ejection fraction (MacLean et al.,
1967; Parker et al., 1984; Ellrodt et al., 1985). If patients survive, ventricular size
and function return to normal as the infection is controlled and circulatory function
restored.
In endotoxic shock the presence of disseminated foreign antigen, together with
the inflammatory response, causes an inducible nitric oxide synthase to be generated
in many cell types which do not normally express this enzyme, including hepatocytes,
fibroblasts and vascular smooth muscle (Moncada et al., 1991; Nathan, 1992).
Subsequent production of large quantities of nitric oxide leads not only to
haemodynamic instability, but also to widespread production of nitric oxide-based free
radicals which have the potential to cause considerable damage to tissues.
Vascular smooth muscle is itself not a source of nitric oxide in health. In
endotoxic shock the production of nitric oxide occurs within the muscle layer of the
vessel wall causes excessive vasodilatation and hence a reduction in peripheral
vascular resistance (Moncada et al., 1991). Substrate inhibitors of nitric oxide
synthase cause systemic vasoconstriction and a pressor response in healthy animals
by inhibiting constitutive nitric oxide production by the endothelium. In animals with
experimental endotoxic shock inhibitors of nitric oxide synthase reverse hypotension,
but also cause a sustained increase in systemic vascular resistance and at higher doses
a decrease in cardiac output (Klabunde & Ritger, 1991; Nava et al., 1991; Wright et
al., 1992). A reduction in cardiac output has also been seen with these agents in
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normal animals (Klabunde & Ritger, 1991; Kilbourn et al., 1990; Aisaka et al.,
1989). Whether this fall in cardiac output is secondary to the rise in vascular
resistance, or to a direct effect of nitric oxide synthase inhibitors on cardiac
contractility, was not addressed by these studies.
Global deterioration of myocardial contractile function in patients with
endotoxic shock has been established by clinical and radionuclide studies (MacLean
et al., 1967; Parker et al., 1984; Ellrodt et al., 1985). In normal volunteers
administration of purified endotoxin causes reversible depression of left ventricular
function, in addition to the expected reduction in systemic vascular resistance
(Suffredini et al., 1989). Until recently, the cause of myocardial depression in
endotoxaemia was considered to be a direct effect of endotoxin or an inflammatory
mediator on myocardial tissue. The existence of a specific circulating myocardial
depressant substance in endotoxic shock has been postulated, but not proven (Ellrodt
et al., 1985). While coronary perfusion abnormalities in patients with coexisting
cardiac or coronary disease and endotoxic shock may account for segmental
abnormalities of left ventricular function, in patients with global myocardial
impairment and endotoxic shock the loss of function cannot be wholly explained by
changes in coronary flow (Ellrodt et al., 1985). As in the peripheral vasculature,
multiple factors exist which depress cardiac function in endotoxic shock. However,
there may be a common pathway for such mediators to impair myocardial contraction.
My hypothesis tested in these experiments is that, similar to the behaviour of
vascular smooth muscle in endotoxic shock, production of nitric oxide occurs within
cardiac myocytes in this condition and contributes to the reduced cardiac contractility
seen in endotoxaemia. This study was designed to examine whether contractility of
cardiac myocytes was reduced by endotoxin treatment of animals, and if so, whether





Animals treated with endotoxin (lipopolysaccharide, E. coli serotype 055:B5;
Sigma, Poole, Dorset, UK) were administered 4 mg/kg intraperitoneally, 4 h before
sacrifice. In some cases, an intravenous injection of dexamethasone 4mg/kg (David
Bull, Warwick, UK) was given 1 h before injection of endotoxin. Cardiac ventricular
myocytes were isolated by enzymatic digestion, as before.
Once stable contraction had been achieved, myocytes were exposed for 10 min
to nitric oxide synthase inhibitors and substrates, and values obtained were compared
to the mean of control contractions measured both before and after exposure to each
drug. All recordings were made within 45 min of stabilisation to avoid the decline
in myocyte contraction amplitude which is seen in experiments lasting longer than 2
hours. Some experiments were performed in the presence of the guanylate cyclase
inhibitor, methylene blue (David Bull Laboratories). In these experiments, recordings
were made after 15 min exposure, and compared to baseline before administration.
The nitric oxide synthase inhibitors N°-nitro-L-arginine methyl ester (L-NAME) and




Effect of endotoxin treatment on contraction amplitude of cardiac myocytes.
L-NAME had no effect on contractility of myocytes from normal animals (see
chapter 6). This suggests that there is no nitric oxide synthase activity in cardiac
ventricular myocytes in health. The second series of studies examined the contraction
of myocytes from guinea pigs with experimental endotoxaemia. Figure 32 shows the
effect of endotoxin (lipopolysaccharide) treatment on myocyte shortening. This study
generated the most important finding of the entire thesis: contraction amplitude of
myocytes isolated from endotoxin treated animals was reduced by 46% (p <0.001)
when compared to cells from control animals. The reduced contractility ofmyocytes
from endotoxin treated animals was substantially reversed by the nitric oxide synthase
inhibitor L-NAME, whereas L-NAME had no effect on control cells. Pre-treatment
with dexamethasone, known to block induction of inducible nitric oxide synthase,
abolished the effects ofendotoxin. Addition of L-NAME to cells from animals treated
with both dexamethasone and endotoxin had no further effect (fractional shortening
5.0±0.9%; n=7, p=NS, compared to normal cells).
Effect ofsubstrates and inhibitors ofnitric oxide on contraction amplitude ofmyocytes
from endotoxin treated animals.
Figure 33 shows the effects of different substrates and inhibitors on contraction
of myocytes from endotoxin-treated guinea-pigs. Addition of 10^M L-NAME to
myocytes from endotoxin-treated animals increased contraction amplitude by
40+6.6% (p< 0.001, n = 17). Contractility returned to baseline within a 10 min
washout period. N°-methyl-L-arginine (L-NMMA) gave similar results. The effect
of L-NAME was reversed by coadministration of 10"3M L-arginine, but not
D-arginine. Neither amino acid had a significant effect on control myocytes
(Table 10). L-NAME 10"4M had no effect on contraction of normal myocytes





































Figure 32 Effect of endotoxin (lipopolysaccharide, LPS) treatment on fractional shortening. Dex,
































Figure 33 Effect of substrates and inhibitors of NO synthase on contractility of myocytes from
endotoxin-treated animals. n=17 (L-NAME), 8 (L-arg + L-NAME), 6 (D-arg +L-NAME) and 5 (L-
NMMA) experiments.
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Table 8 Endotoxin treatment had no effect on either time to peak contraction (TTP)





animals; n = 17
p value
Time to peak contraction
(TTP)
0.12+0.02s 0.10+0.02s NS
Relaxation time (PTR) 0.30+0.03s 0.32+0.02s NS
Table 9 Addition of L-NAME to myocytes from endotoxin treated guinea pigs
increased contraction amplitude substantially but had no effect on TTP/PTR:
Myocytes from endotoxin-
treated animals; n = 17
baseline + L-NAME p value
Time to peak contraction
(TTP)
0.10+0.02s 0.10+0.01s NS
Relaxation time (PTR) 0.32+0.02s 0.35+0.02s NS
Dexamethasone pretreatment of healthy guinea pigs had no effect on myocyte
contraction in control studies (see Table 10).
Effect of methylene blue on contraction amplitude of myocytes from normal and
endotoxin-treated animals.
Exposure of cells from endotoxin-treated animals to methylene blue 5x10 6M
for 15 min increased contraction amplitude substantially, by 157+27% (fractional
shortening increased from 2.3+0.4% of cell length to 6.1 ± 1.4% of cell length; n=7,
p<0.005), as shown in Figure 34. Exposure of normal control myocytes to
methylene blue also increased contraction amplitude at 15 min (by 54+11%, n = 8,
p<0.01). Interestingly, the maximum contraction of cells from both normal and
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endotoxin-treated animals in the presence of methylene blue was similar. In
experiments with myocytes from both normal and endotoxin treated animals, some
cells showed signs characteristic of calcium overload, with hypercontractility and
fibrillation, after 20 min superfusion with methylene blue. Four of seven myocytes
from endotoxin treated animals, and four of eight normal myocytes, failed to return
to baseline contraction after exposure to methylene blue.
Table 10 Effect of substrates and inhibitors of nitric oxide synthase on contraction amplitude of
normal ventricular myocytes. Mean±SEM of fractional shortening of contracting myocytes, expressed













L-NAME 10"M; n=9 4.5 + 0.6% 4.7±0.79% + 0.2+0.2 + 1.0+3.6% NS
L-arginine 103M; n=5 3.2+0.4% 3.3±0.5% +0.1+0.2 + 3.9+4.7% NS










































Figure 34 Effect of 10"5M methylene blue (MB) on myocyte contraction. LPS, myocytes isolated
from endotoxin-treated animals; normal, myocytes from healthy animals.
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7.1.4. Discussion
Endogenous production of nitric oxide within cardiac myocytes contributes to their
reduced contractility in endotoxaemia.
I have shown that endotoxin treatment of guinea-pigs causes a substantial
reduction in the contractility of isolated cardiac myocytes. About half of this
reduction can be reversed by specific nitric oxide synthase inhibitors, and their effect
can be overcome by an excess of L-arginine, the L-isomer amino acid from which
nitric oxide is generated, but not by the inactive D-isomer. These results suggest that
nitric oxide is being produced within the myocytes themselves, and that this nitric
oxide has an attenuating effect on myocyte contraction.
As I was completing these experiments, biochemical evidence became
available of the presence of nitric oxide synthase enzymes in myocardium (Schulz et
al., 1992). In that study, endotoxin caused an elevation in cGMP, and pretreatment
with dexamethasone prevented the induction of inducible nitric oxide synthase within
cardiac myocytes. In the present study prior administration of dexamethasone
prevented the reduction in contractility caused by endotoxin, and subsequent addition
of L-NAME had no effect. This is further evidence for inducible nitric oxide
synthase activity within the heart contributing substantially to the reduction in
contractility occurring in endotoxic shock. Normal cardiac myocytes contain
detectable amounts of constitutive nitric oxide synthase (Schulz et al., 1992), although
this does not appear to generate effective levels of nitric oxide, since in the present
study, and in the first series of experiments nitric oxide synthase inhibitors had no
effect on contractility of cardiac myocytes isolated from healthy animals.
Nitric oxide synthase inhibitors did not completely reverse the effect of
endotoxin. This suggests that factors other than nitric oxide might contribute,
although it is possible that nitric oxide production was not blocked completely by the
nitric oxide synthase inhibitors. While endotoxin may itself be cytotoxic to myocytes
many other inflammatory mediators are released in endotoxic shock. Recent attention
has focused on the use of anti-tumour necrosis factor (TNF) antibodies in septic
shock, which appears to improve left ventricular function in such patients (Vincent
et al., 1992). In the present study the effect of endotoxin was abolished by pre-
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treatment with dexamethasone. Steroids not only prevent the induction of nitric oxide
synthase by endotoxin but also prevent the generation of many inflammatory cytokines
which might impair myocyte contractility. Such cytokines may themselves act by
induction of nitric oxide synthesis within the heart: in a recent study the cytokines
TNFa, interleukin-2 and interleukin-6 inhibited myocardial papillary muscle
contraction by a nitric oxide dependent mechanism (Finkel et al., 1992), although the
rapid time course of this study suggests activation of an existing constitutive nitric
oxide synthase enzyme, rather than induction of new protein. Neonatal cardiac
myocytes cultured in a mixture of IL-1 and TNFa show depressed responses to B-
adrenergic stimulation (Gulick et al., 1989), although in this study the role of nitric
oxide was not considered.
Inhibition of inducible nitric oxide synthase may have therapeutic potential in
patients with endotoxic shock. In animal models of endotoxic shock, recent studies
have shown that nitric oxide-synthase inhibitors were without significant
haemodynamic benefit given in small doses whereas larger doses caused intense
peripheral vasoconstriction and cardiovascular collapse (Nava et al., 1991; Wright et
al., 1992; Klabunde & Ritger, 1991). It appears that at high doses inhibition of both
the normal, constitutive nitric oxide synthase and the inducible nitric oxide synthase
occurs, and complete inhibition of endogenous nitric oxide synthesis then allows
unopposed peripheral vasoconstriction, deleterious in endotoxic shock. Either
coadministration of a nitric oxide donor with a nitric oxide synthase inhibitor, or
selective inhibition of the inducible form of nitric oxide synthase might be of benefit
in this condition (Wright et al., 1992).
Action ofmethylene blue on contractility ofmyocytesfrom endotoxin treated animals.
Over the short time course of the experiments on healthy cardiac myocytes
described in chapter 4, methylene blue reversed the negative inotropic effects of nitric
oxide from sodium nitroprusside. However, superfusion with methylene blue for
prolonged periods >30-60 min caused these cells to contract much more strongly,
before fibrillating. Exposure of myocytes to methylene blue in the present study
caused a large increase in contraction amplitude of cells from endotoxin-treated
animals. Contraction of normal myocytes was also increased, although the time
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course of these studies was longer than the early experiments with sodium
nitroprusside. In both series of studies administration of methylene blue caused some
of the myocytes to become hypercontractile, with contractions characteristic of
calcium overload. It may be that exposure to methylene blue causes progressive
injury to cardiac myocytes, perhaps by increasing the permeability of the cells to
extracellular calcium. The explanation why contractility of some of the cells did not
return to baseline when methylene blue superfusion was discontinued is not clear.
Whether the effect of methylene blue is limited to changes in cGMP concentration,
or whether methylene blue has a direct toxic effect, is not explained by either study.
The present study is the first to show direct loss of contractility of cardiac
myocytes in endotoxic shock, associated with the induction of nitric oxide synthase
and production of nitric oxide within the myocytes. Contractility was restored
partially by nitric oxide synthase inhibitors, in keeping with two recent clinical case
reports. In two patients with septic shock, administration of L-arginine analogues
caused short-term increases in blood pressure. Cardiac output was increased in one
patient and decreased in the other (Petros et al., 1991). A further intriguing report
described short-lived improvement in a patient with hepatic failure following
administration of methylene blue (Midgley et al., 1991). Methylene blue inhibits
guanylate cyclase, but does not inhibit the cytotoxic effects of nitric oxide. In the
present study I found methylene blue to be toxic to myocytes after prolonged
administration, although the reasons for this effect are not yet clear, as described
above. The loss of contractility after endotoxin exposure can be prevented by
pretreatment of animals with dexamethasone, but it is generally accepted that steroid
therapy is of no benefit to patients with endotoxic shock (Bone et al., 1987; Sprung
et al., 1984; The Veterans Administration Systemic Sepsis Cooperative Study Group,
1987). Until a specific inhibitor of inducible nitric oxide synthase is available,
careful titration of a nitric oxide synthase inhibitor, perhaps combined with a nitric
oxide donor, may be a possible treatment in endotoxic shock, not only by reducing
the profound peripheral vasodilatation (Wright et al., 1992), but also by augmenting
myocardial contraction. This is discussed further in the General Discussion in
Chapter 11.
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CHAPTER 8: CARDIAC MYOCYTE CONTRACTILITY AFTER
ISCIIAEMIA AND REPERFUSION
8.1.1. Introduction
Short periods of myocardial ischaemia are accompanied by a transient
reduction in contractile function. This was first described in 1975 by Heyndrickx
(Heyndrickx et al., 1975) and is now popularly termed myocardial "stunning"
(Braunwald & Kloner, 1985). Central to the definition of stunning is that despite
restoration of coronary flow after a transient occlusion, mechanical dysfunction
persists, but this dysfunction ultimately recovers (Bolli, 1992). This means that there
is mechanical dysfunction without irreversible injury. The time course of recovery
from myocardial stunning is related to the duration of ischaemia. After 1 min of
coronary occlusion active shortening in the affected area returns within 20 s, and is
complete by 30 min (Braunwald & Kloner, 1985). Following a single 15 min episode
of myocardial ischaemia in dogs slight return of function is seen 5 min into the
reperfusion period, although even after 1 h of reperfusion contractility has reached
only 50% of baseline. Function has not quite recovered by 24 h but reaches normal
by 48 h (Bolli et al., 1988).
Even after prolonged ischaemia, some return of myocardial function in the
affected area may be seen as late as 1-2 weeks after the event (Braunwald & Kloner,
1985). Ischaemic myocardial necrosis must not be confused with stunning, since
stunning is fully reversible whereas infarction is not. For laboratory studies of
reperfusion injury, periods of ischaemia of 30-90 min are usually employed so that
a moderate degree of myocardial injury is achieved, whereas to induce reversible
stunning of myocardium coronary occlusion of up to 20 min is performed
(Heyndrickx et al., 1975).
8.1.2. Proposed mechanisms of myocardial stunning
There have been different hypotheses to try to explain the myocardial
dysfunction of stunning. Stunned myocardium can maintain ATP synthesis in the face
114
of increased demand, therefore inadequacy of energy production is not the explanation
(Ellis et al., 1984). Abnormalities of coronary vascular function occur in stunning.
While prolonged ischaemia, severe enough to cause myocyte necrosis, is associated
with endothelial cell swelling and injury (Kloner et al., 1974; Piper et al., 1990)
there is accumulating evidence that important alterations of endothelial function occur
much earlier in ischaemia, before evidence of morphological damage appears. Brief
periods of ischaemia cause loss of endothelium-dependent vasodilatation and enhanced
coronary vasoconstrictor responses (Kim et al., 1992), together with increased
permeability of the coronary endothelium (Dauber et al., 1990). These functional
changes occur without evidence of structural injury. There is evidence of injury
caused by oxygen radicals in ischaemic-reperfusion injury (see sections 1.6.5) and
oxygen radical scavengers attenuate the endothelial dysfunction in stunned
myocardium (Bolli, 1992). As well as being a target for free radical-mediated
damage, endothelium itself generates these species in reperfusion injury (Zweier et
al., 1988; Schinetti et al., 1989). The commonly used agents catalase and superoxide
dismutase, and "spin trap" agents (drugs which bind and inactivate free radicals) are
large molecules which do not readily cross cell membranes (Downey & Yellon,
1992). One explanation of their beneficial action in the recovery from myocardial
stunning is that they bind endothelial-derived free radicals and thus reduce exposure
of myocytes to these injurious species (Mullane & Young, 1992). Another possibility
is that free radicals produced within myocytes will pass through the cell membrane
down a concentration gradient. Continuously "mopping up" these radicals outside the
cell by scavengers may aid myocyte recovery.
Bolli has listed four likely explanations of myocardial stunning (lecture to
National Heart and Lung Institute, London, 19th October 1992; also reference- (Bolli,
1992). These are:
(i) Reduced sensitivity of myofilaments to calcium
(ii) Transient calcium overload within myocytes
(iii) Excitation-contraction uncoupling due to sarcoplasmic reticulum
dysfunction
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(iv) Generation of oxygen free radicals
These are not mutually exclusive, but are discussed individually.
Reduced sensitivity of myofilaments to calcium
Stunned isolated hearts are less sensitive to increased levels of extracellular
calcium (Kusuoka et al., 1987). Cytosolic free calcium is not reduced (Kusuoka et
al., 1990) and one suggestion is that the myofilaments become less sensitive to
calcium. But stunned myocardium in vivo responds normally to inotropic agents, as
mentioned above, and this means that myofilament handling of calcium is not
impaired under these conditions. Furthermore, in single cells myofilament relaxation
is impaired following hypoxia (Silverman et al., 1991). The time course of this
disturbance is not matched by alterations in [Ca2+];. The mechanism of altered
relaxation is thus not readily explained by changes in [Ca2+];. Silverman (Silverman
et al., 1991) suggested that abnormalities of phosphorylation of myofilaments might
explain their results.
Excitation-contraction uncoupling due to sarcoplasmic reticulum dysfunction
Injury to the sarcoplasmic reticulum with impaired release of calcium to the
contractile proteins has been suggested (Krause et al., 1989) and by itself might
contribute to the reduced contractility of stunned myocardium. Other workers have
shown no reduction in [Ca2+]; following ischaemia (Kusuoka et al., 1990), although
these conflicting ideas could be reconciled by alterations in compartmentalisation of
Ca2+ within the cell.
Transient calcium overload within myocytes
Intracellular [Ca2+] is elevated in ischaemic myocardium [Steenbergen #3*1].
Reperfusion with low Ca2+ solution protects myocardium after an ischaemic episode
(Kusuoka et al., 1987). Cardiac myocyte hypercontracture following reperfusion
after hypoxia is characterised by a sudden further rise in [Ca2+]| (Josephson et al.,
1991). But intracellular [Ca2+] is only elevated in stunned reperfused myocardium
during the first few minutes following restoration of flow (Bolli, 1992), while
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mechanical dysfunction is prolonged. The mechanism of this elevation of [Ca2+]j is
under intensive study. There is impairment of Na+-Ca2+ exchange, Na+-K+-ATPase
and Na+-H+ exchange in ischaemia (Tani & Neely, 1989; Kitakaze et al., 1988)
which may facilitate Ca2+ entry into myocytes. Studies using cardiac myocytes
loaded with Na+- and Ca2+-sensitive dyes have shown that [Na+k rises as well as
[Ca2+]j during hypoxia (Haigney et al., 1992). Removing extracellular Na+ markedly
reduced the rise in [Ca2+];, suggesting that the Na+-Ca2+ exchange mechanism is of
importance in the development of elevated cytosolic Ca2+. Some of the protective
effect of the antioxidant, dimethylthiourea, in ischaemic myocyte injury is thought to
be due to its ability to inhibit Na+-Ca2+ exchange, rather than its action against free
radicals (Ziegelstein et al., 1992). The relative importance of disturbances in
extracellular, sarcolemmal and mitochondrial calcium (Miyata et al., 1992) causing
myocyte damage is not yet fully established.
As I was developing methods of isolating ventricular myocytes from
ischaemic-reperfused hearts I found that to achieve stunning, Langendorff hearts had
to be exposed to physiological Ca2+0 immediately after the ischaemic episode (see
sections 8.2).
Mechanism of myocardial stunning caused by oxygen free radicals
(see also 1.6.2.)
All cells within the heart, including myocytes (Turner et al., 1991) are
potential sources of free radicals, since all cells generate these as part of normal
metabolism. Impaired ATP production in ischaemia reduces a cell's ability to handle
its own radicals. Abnormalities of mitochondrial oxidative phosphorylation generate
extra radicals, which cannot be cleared by the cell's usual mechanisms. Xanthine
oxidase catalyses free radical production in some species, although its contribution
in man is disputed. In animal models, xanthine oxidase inhibitors reduce stunning in
some studies (Bolli, 1992). There is evidence from clinical studies of free radical
activity during myocardial ischaemia (Bell et al., 1990; Oldroyd et al., 1990;
McMurray et al., 1992; Davies et al., 1990).
It is likely that neutrophils contribute substantially to free radical production
in stunned myocardium. These cells are a potent source of oxygen free radicals,
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which together with hypochlorous acid and proteolytic enzymes, act in concert at sites
of inflammation in the acute inflammatory response.
The exact mechanism by which oxygen free radicals modify myocardial
contractility is not known. Oxygen radicals cause damage by denaturing cellular
proteins and enzymes (Davies, 1987). They also oxidise polyunsaturated fatty acids
(Thompson & Hess, 1986) and alter membrane permeability. Lipid peroxidation is
an attractive theory but experimental evidence is presently lacking. Another
possibility is damage to the sarcoplasmic reticulum (SR). Calcium uptake by
myocardium is impaired in myocardial stunning (Thompson & Hess, 1986). In
isolated SR preparations, exposure to oxygen free radicals depresses calcium uptake,
and this can be reversed by free radical scavengers (Bolli, 1992). The sarcolemma
may also be a target for free radical injury. As mentioned above, there is impairment
of Na+-Ca2+ exchange, Na+-K+-ATPase and Na+-H+ exchange in ischaemia (Tani
& Neely, 1989) (Kitakaze et al., 1988) which may facilitate Ca2+ entry into
myocytes.
Original hypothesis: stunning is caused by nitric oxide production within cardiac
myocytes
There is much experimental data, yet the mechanism of myocardial stunning
is not known. Even the phenomenon itself is disputed by some. Having access to
isolated myocytes I wished to address one hypothesis to explain stunning: constitutive
nitric oxide synthase exists in ventricular myocytes, yet its function is not understood.
My studies with L-NAME in normal myocytes showed no effect of this inhibitor on
contractility, and this is confirmed by unpublished observations of Shah and Lewis.
I wanted to examine the effect of substrates and inhibitors of nitric oxide synthase on
myocytes from ischaemic-reperfused hearts, to determine whether constitutive nitric
oxide synthase is activated in this situation.
118
8.1.3. Methods
The experimental models I tried are described in section 2.6.. The protocol
for the present study is shown in Figure 35. The important modification was to
introduce a period of reperfusion with Ca2+-containing buffer before beginning the



























Figure 35 Protocol for production of ischaemia-reperfused cardiac ventricular myocytes from
interventricular septal tissue. The heart was maintained at 35°C in a water jacket.
during reperfusion, although atrial fibrillation sometimes occurred. To ensure that
only ischaemic cells were obtained epicardial tissue was discarded and the
interventricular septum dissected out and used as the source of myocytes, which were
then isolated in the usual way. Cells from the first digest were used to keep the time
from ischaemic injury as brief as possible. It was intended to then study the effects
of drugs affecting nitric oxide synthase on myocyte contractility over the following
60 min.
The protocol meant that a minimum of 25 min elapsed from the end of the
ischaemic period until the first digest of cells was ready for study. In vivo studies
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suggest that 20 min ischaemia impairs myocardial contractility for at least 1 h
afterwards. Studies of the effects of 10 min hypoxia on single myocytes showed
abnormalities of time to peak contraction and relaxation time which persisted for up
to 50 min (Silverman et al., 1991). Thus, this ought to leave a time window of about
half an hour after the cells were ready in which to study their recovery from
ischaemia.
Only one myocyte from each preparation could be studied by a single
observer, so on some days a technician performed a concurrent study on another
videomicroscopy apparatus.
The yield of myocytes was surprisingly good, often better than the yield from
non ischaemic hearts. All the control and hypoxia studies used the same Langendorff
apparatus.
8.1.4. Results
The behaviour of myocytes from ischaemic-reperfused interventricular septa
followed over 60 min without pharmacological intervention is variable. The data is
shown in Table 11: there are some cells where contractility is reduced at the start and
subsequently improves; and there are cells where contractility never improves but
fades rapidly over the time course of the experiment. The results are shown
graphically in Figure 36. The solid line in Figure 36 indicates control data of
mean+SEM contraction amplitude of six normal myocytes without pharmacological
intervention, also followed over 60 min.
The myocytes in the table show a variable pattern of contraction. It is
impossible to select at the start of the experiment which cell is stunned and recovering
and which is not going to recover. Thus pharmacological studies with these cells are
not helpful. This was disappointing since the myocytes appeared histologically
normal.
Some early experiments with L-arginine and L-NAME superfused over cells
prepared in this way were tried before analysis of all the control cells was performed.
The findings with L-arginine and L-NAME were not consistent and this was
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Figure 36 Contractility of cardiac myocytes following ischaemia-reperfusion. Dashed lines indicate
contraction of ischaemic-reperfused cells; solid line indicates mean + SEM of six normal myocytes.
explained subsequently by the studies of the natural behaviour of ischaemic-reperfused
cells.
8.1.5. Discussion
A study yielding definitive information at a cellular level on mechanisms
involved in post-ischaemic myocardial stunning would be worthy indeed.
Unfortunately the model in the present study did not generate cells with reliable
characteristics, so the hypothesis that nitric oxide production accounted for impaired
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Contraction of isolated interventricular septal myocytes prepared after 20 min ischaemia
during the Langendorff retroperfusion period.
0 15 30 45 60
cell 1 4.1 4.1 5.7 5.7 7.0
cell 2 0.9 1.8 2.3 3.0 3.0
cell 3 1.9 2.1 2.6 2.6 2.6
cell 4 2.1 2.1 2.5 3.4 3.4
cell 5 2.0 2.0 5.0 5.8 6.7
cell 6 1.4 1.4 1.4 5.6 8.3
cell 7 2.4 2.4 2.4 2.1 1.7
cell 8 3.0 3.0 2.7 1.5 1.1
cell 9 4.5 3.7 2.5 2.0 1.6
cell 10 4.2 1.7 1.3 1.3 0.9
cell 11 7.8 5.6 5.0 3.9 3.3
Table 11 Fractional shortening of individual cardiac myocytes, expressed as a percentage of
resting length.
contractility could not be tested. However, the results obtained examining the natural
history of myocytes from ischaemic-reperfused hearts merit some explanation.
Cells were obtained from the interventricular septa of hearts subjected to zero
flow for 20 min. During the period of zero flow hearts continued to beat for about
12-15 min. They were not paced, but clearly had been subjected to a substantial
insult. On reperfusion a regular rhythm usually developed, although on inspection
atrial arrhythmias were sometimes present. Oxygenation during zero flow from room
air was excluded because only septal cells were used.
It is interesting that two types of injured cells were generated by the
ischaemia-reperfusion protocol: cells which were terminally injured and cells which
were recovering. In a small control study myocytes from normal hearts showed a
gradual reduction in contraction amplitude over 1 h (solid line in Figure 36). A
possible explanation of the behaviour of myocytes from ischaemic hearts might be
that there is heterogeneity in the ability of myocytes to withstand ischaemic injury.
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Alternatively, production of toxic free radicals may vary depending on the local
architecture and proportion of myocytes to interstitial cells. Production of protective
substances like adenosine may similarly be variable at a local level. With myocytes
from normal hearts the investigator chooses the best cell available, with a stable
contractile pattern within defined limits (see Chapter 2). It was not possible to
impose the same limits in the present study since many of the cells behaved
abnormally to start with. A better method would be to study a population of cells,
similar to the method described for the neutrophil-myocyte studies in Chapter 10, and
examine recovery measured simply as diastolic length. The disadvantage is that
measurements of contractile function cannot be performed.
Another interesting, and unexplained, point was the high yield of myocytes
despite the ischaemic episode. Perhaps the hypoxia selects out survivor cells and
many injured cells die during the enzymatic digests. Without the hypoxic period
these cells might have survived until the digests were ready.
Probably the main problem with the method was the time lost performing the
necessary enzymatic digests. This immediate phase following onset of reperfusion
is likely the key time when most of the reversible abnormalities due to ischaemia take
place, but this time was unavoidably spent preparing the cells. It is during this early
phase that abnormalities of sodium and calcium exchange occur (Tani & Neely, 1989;
Kitakaze et ah, 1988), free radical production within myocyte mitochondria is likely
at its peak and the sarcoplasmic reticulum is functioning least well. Altering calcium
flux during the first few minutes of reperfusion after ischaemia reduces myocardial
stunning (du Toit & Opie, 1992). In isolated, blood perfused rat hearts after 20 min
ischaemia, reperfusion with plasma and neutrophils generates free radicals for 10 min
into the reperfusion period (Shandelya et ah, 1993). Reperfusion with either
component or plain buffer generated a short burst of free radical activity lasting 1-2
min only. This is further indication that the important events in reperfusion occur
very early and these events were lost in the preparation of isolated cells in my
system. I intend to address this in the future by developing a model where healthy
cells from normal hearts are subjected to hypoxia while under videomicroscopic
scrutiny. This is a substantial task since achieving adequately low levels of 02 in the
cell bath will involve design of new equipment. Silverman's group in Baltimore
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achieve this by superfusion with argon gas (Silverman et al., 1991) but few others
have achieved reliable systems to study cell function under hypoxic conditions.
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CHAPTER 9: NITRIC OXIDE AND CARDIAC MYOCYTE
CALCIUM TRANSIENTS
9.1.1. Introduction
The experiments described in chapters 4-7 show that nitric oxide - from a
variety of sources including: sodium nitroprusside; endothelium; a direct solution of
nitric oxide itself; and, in endotoxic shock, myocytes themselves - attenuates cardiac
myocyte contraction amplitude. This mechanism appears to be mediated by
production of cGMP within the myocytes. The mechanism by which cGMP reduces
contractility in cardiac myocytes is not yet defined, but two possibilities might explain
this finding:
(i) The peak free calcium concentration (Ca2+ transient) within the cell during
contraction is reduced by mechanisms involving either release of calcium from
sarcoplasmic reticulum stores or entry of calcium from the exterior.
(ii) The sensitivity of myocyte contractile myofilaments to calcium is reduced,
possibly by changes in intracellular pH, or protein phosphorylation regulated by
cyclic nucleotide concentration.
9.1.2. Excitation-contraction (EC) coupling and cardiac myocyte contraction
This large area of research is presented in outline only, for the purposes of
discussion in this chapter.
During the cardiac action potential Ca2+ enters myocytes via sarcolemmal Ca2+
channels and there may also be entry via Na+/Ca2+ exchange across the cytoplasmic
membrane. This Ca2+ which enters the myocyte may directly bind to myofilaments.
Ca2+ entry from outside the cell may also be involved in the release of Ca2+ from the
sarcoplasmic reticulum (SR), termed Ca2+-induced Ca2+ release. Calcium ions from
both the intracellular SR store and from the exterior activate myofilaments to bring
about cell contraction (Bers, 1991a).
During contraction peak intracellular free calcium concentration ([Ca2+],)
reaches approximately 1 ^M. At rest [Ca2+] within the cytoplasm is approximately
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100 nM. Restoration of Ca2+ to resting levels is achieved by active extrusion of Ca2+
out of the cytoplasm either into the intracellular calcium store, the SR, or out of the
cell either by the sarcolemmal Ca2+ pump or by Na+/Ca2+ exchange (Bers, 1991a).
9.1.3. Mechanism of B-adrenergic inotropic effect
Force of contraction, or inotropy, is influenced by multiple complex reactions
within myocytes, and by other factors including temperature, sarcomere (and cell)
length, hypoxia and pH. In general, contractility is modified either by factors which
influence the amount of calcium present in the cytoplasm during the action potential,
or factors which change the sensitivity of the myofilaments to Ca2+. As an
illustration B-adrenergic agonists exert multiple effects on contractility (Bers, 1991b).
They increase Ca2+ current (ICa) through the sarcolemma; they enhance SR uptake of
Ca2+; and they decrease myofilament sensitivity to Ca2+. These mechanisms are
mediated in part by production of cAMP within myocytes. Cyclic AMP-dependent
protein kinases are activated and these cause phosphorylation of a number of cellular
proteins: sarcolemmal Ca2+ channels; phospholamban; and troponin I.
Phosphorylation of sarcolemmal Ca2+ channels increases Ca2+ entry into myocytes.
B-adrenergic agonists can also increase ICa directly by opening sarcolemmal Ca2+
channels by a different mechanism independent of cAMP, which involves direct
binding of the B-receptor to a G protein. Phosphorylation of phospholamban
stimulates the SR Ca2+ ATPase, the enzyme which pumps Ca2+ into the SR. This
promotes quicker restoration of resting [Ca2+];, as well as increasing the amount of
calcium stored in the SR. Conversely, phosphorylation of troponin I decreases the
sensitivity of myofilaments to Ca2+. The net result is that the stimulated Iq, and
uptake of Ca2+ by the SR results in a larger and faster Ca2+ transient.
Other agents can elevate cAMP levels in cardiac myocytes (Bers 199lb).
Histamine activates adenylate cyclase in myocytes and exerts a positive inotropic
effect. Phosphodiesterase inhibitors, which inhibit metabolism of cAMP, also
augment contractility by elevation of cAMP.
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9.1.4. Effect of acetylcholine on cAMP in cardiac myocytes
Acetylcholine acting via muscarinic receptors inhibits adenylate cyclase,
probably acting via an inhibitory G protein (Fischmeister & Hartzell, 1986).
Acetylcholine also stimulates guanylate cyclase, elevating cGMP in guinea pig
(Watanabe & Besch, 1975) and frog myocardium (Flitney & Singh, 1981). Cyclic
GMP may stimulate cyclic nucleotide phosphodiesterase to metabolise cAMP, a
second mechanism whereby acetylcholine reduces contractility. The relevance of this
mechanism to the action of nitric oxide is discussed later in this chapter. Atrial
natriuretic peptide (ANP) also inhibits adenylate cyclase by a G protein mechanism,
and stimulates particulate guanylate cyclase, both of which stimulate cAMP
breakdown in frog cardiac tissue (Gisbert & Fischmeister, 1988). This effect is seen
mainly when ICa has been elevated by isoprenaline, and is less evident at basal Iq,.
9.1.5. Calcium sensitivity of the myofilaments
Reducing sensitivity of the myofilaments to calcium reduces contractile force
for the same amount of activating calcium. 15-adrenergic agonists reduce myofilament
sensitivity to calcium, although their net effect is one of increasing the calcium
transient. Cooling reduces myofilament sensitivity to calcium in guinea pig, rat and
frog ventricle (Harrison & Bers, 1990). Shortening of sarcomere length also reduces
Ca2+ sensitivity, as does acidosis (Fabiato & Fabiato, 1978). This may be important
in ischaemia when intracellular pH falls. Increasing [Mg2+]j also decreases Ca2+
myofilament sensitivity. Some inotropic agents, for example isomazole and
pimobendan, act by increasing myofilament sensitivity to Ca2+ (Bers 1991a).
Caffeine and theophylline also have this capability.
Phosphorylation of myosin light chains occurs in cardiac muscle as well as
smooth muscle cells. This phosphorylation appears to have dual effects on Ca2+
sensitivity in different models, and the physiology of this reaction is not determined
(Bers, 1991a). Other myofilament sites can be phosphorylated, with alteration in the
sensitivity of myofilaments to Ca2+. Furthermore, there are other intricate regulatory
mechanisms controlling the Ca2+-mediated Ca2+ release from SR, which affect the
magnitude of the Ca2+ transient (Bers, 1991b). The control of myofilaments by Ca2+
is thus complex indeed, and the subject of intensive study.
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9.1.6. Hypothesis
My hypothesis for this series of experiments was that nitric oxide modulates
cardiac myocyte contractility by reducing peak Ca2+ concentration during contraction.
To study this I examined the effect of nitric oxide on free [Ca2+], recorded during the
contraction of single cells, using the fluorescent Ca2+ indicator, Indo-1.
9.2.1. Methods
I performed these experiments under the supervision of KT MacLeod, in his
laboratory at the National Heart and Lung Institute.
Isolated adult guinea pig cardiac ventricular myocytes were prepared as
described in Chapter 2. Cells from the third digest were used frequently, as they
appeared to have greater stability in Indo-1 labelling experiments. Briefly, 2 ml of
myocyte suspension in low calcium solution (see Methods, Chapter 2) was incubated
with the acetoxymethyl ester of Indo-1 (Indo-1 AM, Molecular Probes, Eugene,
Oregon, USA; final concentration 5-10 fxM). Myocytes were incubated for 30 min
at room temperature.
Indo-1 AM, the lipid soluble ester form of Indo-1, readily enters myocytes and
diffuses throughout the cytoplasm. Cytoplasmic esterases cleave the lipid soluble
esters leaving the free Indo-1 acid which is membrane impermeable (Grynkiewicz,
et al, 1985). Compartmentalisation of this indicator is known to occur but
experiments in the host laboratory showed that accumulation of Indo-1 in intracellular
compartments is negligible. When cells loaded with Indo-1 are "skinned," that is, the
sarcolemmal membrane is removed, the fluorescence signal declines smoothly to zero
(background levels) over a short time course (7 min). If Indo-1 was concentrated in
compartments its decline would not follow a simple exponential function, nor would
it decline to background fluorescent values.
Indo-1 loaded cells were placed in a cell bath and superfused with 2 mM
Tyrode's solution at 32°C, as before. Cells were stimulated to contract at 0.5 Hz
using field stimulation. Light from a 150 W xenon arc was used for epifluorescence.
An interference filter was used to select the wavelength 360 nm (+10 nm bandwidth)
to excite the Indo-1. After excitation, the fluorescent emitted light was split using a
128
dichroic mirror and the emissions at 405 and 485 nm were recorded. As [Ca2+]j rises
during the cardiac action potential fluorescence at 405 nm increases, and fluorescence
at 485 nm decreases. The change in fluorescence at both wavelengths is expressed
as a ratio, measured in arbitrary units. When measuring the effect of nitric oxide on
the Ca2+ transient 8-10 Ca2+ transients from each cell were averaged.
Basal recordings of the Ca2+ transient were made during superfusion with
control solution, and then myocytes were superfused with 10"6M nitric oxide solution,
as described in Chapters 2 and 5. Briefly, 2 mM Tyrode's solution was bubbled with
N2 for 4 h to exclude 02. Nitric oxide gas was injected using a Hamilton gas syringe
to make a 10"6M solution. The concentration was checked with chemiluminescence.
Nitric oxide solution was kept anoxic until it reached the cell bath. Myocytes were
exposed for 4 min to nitric oxide or control solution, at which time recordings of
Ca2+ transients were performed. Whether the Ca2+ transient returned to its previous
control level was also noted.
9.3.1. Results
The experiments described in Chapter 5 showed that administration of 10~6M
nitric oxide solution attenuated cardiac myocyte contraction amplitude. In the present
study nitric oxide solution reduced the calcium transient of ventricular myocytes.
Figure 37 shows a representative Ca2+ transient of a single cell. The larger
transient shows the changes in [Ca2+]; during a single cardiac action potential while
the cell is being superfused with control solution. In the presence of 106M nitric
oxide the Ca2+ transient is reduced by approximately 30% in this cell (producing the
smaller change in [Ca2+]j).
Nine myocytes were studied. 8-10 Ca2+ transients were signal averaged for
each cell under control conditions, then during superfusion with nitric oxide solution.
The mean data from this study are inset into Figure 37. Exposure of myocytes to
nitric oxide caused a reduction in peak calcium transient of 24+7% (n=9, p<0.01).
On returning to control solution the Ca2+ transients did not always make a
complete recovery to control levels. Ca2+ transients did not return to their control
diastolic level in six of the nine myocytes studied.
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NITRIC OXIDE AND CARDIAC MYOCYTE CALCIUM TRANSIENTS
Figure 37
MEAN DATA
1(f M Nitric oxide





Nitric oxide at 10"6M attenuates cardiac myocyte contraction amplitude by
approximately 25%, as shown by the results of the experiments in Chapter 5. In the
present study nitric oxide reduced cardiac myocyte Ca2+ transients by a similar
amount. This suggests that in this model nitric oxide, acting on guanylate cyclase
within myocytes to elevate cGMP, causes a reduction in the amount of free Ca2+ in
the cytoplasm during the cardiac action potential. There is less calcium available for
excitation-contraction coupling and contractility is decreased. These results do not
rule out an additional effect on Ca2+ sensitivity of myofilaments, but the reduction in
[Ca2+]j during contraction may be adequate to account for the reduced contractility
seen in contraction amplitude experiments. It is interesting, although probably
coincidental, that the reduction in contraction amplitude, and the reduction in Ca2+
transient, are of similar magnitude. The relationship between [Ca2+]j and contractile
force is sigmoidal, not linear (Bers, 1991b). The relationship between [Ca2+]; and
cell shortening is not established.
How nitric oxide causes the reduction in Ca2+ transient is not explained by this
study. The likely possibilities are either that Ca2+ entry from the exterior, or Ca2+
release from SR stores, is reduced by some means. A clue to a likely site of action
can be drawn from the results of experiments studying ANP.
ANP acts on particulate guanylate cyclase to elevate intracellular cGMP.
Cyclic GMP stimulates cyclic nucleotide phosphodiesterase which metabolises cAMP.
In frog cardiac cells, using whole-cell patch-clamp techniques, ANP has been shown
to reduce ICa (Gisbert & Fischmeister, 1986). ANP also activates a G protein which
inhibits adenylate cyclase, and thus there are two mechanisms to reduce cAMP, which
may explain the action of ANP on myocyte I<-a.
As mentioned in 9.1.4., acetylcholine reduces cAMP in myocytes, both by
inhibiting adenylate cyclase via a G protein, and by stimulating production of cGMP.
Thus, neurohumoral pathways exist for cGMP regulation of myocyte contraction.
That nitric oxide may act by a similar mechanism, elevation of cGMP, to reduce
contractility, is logical.
Shah and colleagues have recently presented preliminary data on a similar
131
study, the influence of cGMP on Ca2+ transients in rat ventricular myocytes (Shah et
al, 1993). The stable analogue of cGMP, 8-bromo-cyclic GMP (8-br-cGMP) reduced
contractility but had no effect on the Ca2+ transient. Their conclusion was that cGMP
was modifying the sensitivity of myofilaments to calcium. Their findings are thus the
converse of my results. However, there are two important differences between the
two experimental models. Firstly, elevation of [Ca2+]; during the cardiac action
potential in rat cardiac myocytes results mainly from Ca2+ release from SR stores.
In guinea pig (and human) ventricular myocytes a greater proportion of the rise in
[Ca2+]; is due to calcium entry via sarcolemmal channels. Calcium handling during
excitation-contraction coupling is therefore different in the two species tested.
Mechanisms involving cGMP may therefore also be different.
Secondly, I performed my experiments with cells superfused with 2 mM Ca2+
Tyrode's solution. Shah's study was performed with 1 mM Ca2+ solution. If nitric
oxide is modifying calcium entry via sarcolemmal channels, the effect of blocking
these may be greater when external Ca2+ is higher.
In the present study myocyte Ca2+ transients did not reach baseline levels after
exposure to nitric oxide solution in six of the nine myocytes studied. Recovery of
contraction amplitude also appeared to be impaired, although this was not formally
measured in this study. The failure of Ca2+ transients to return to basal values may
be due to the exposure of cells to a high concentration of nitric oxide, which may be
toxic. In the experiments in Chapter 5 cells were exposed to nitric oxide for 7 min.
Contraction amplitude was reduced but returned to approximately 90% of normal
once the control solution was reinstated. In the present study the design of the cell
bath and nitric oxide delivery apparatus was different, and it is possible that the local
concentration of nitric oxide was higher in these studies.
Alternatively, this may be a pharmacological, rather than a toxic, effect. Shah
also found that recovery of contractility in rat myocytes was impaired after exposure
to high levels of 8-br-cGMP (AM Shah, personal communication). It may be that
high intracellular concentrations of cGMP have a prolonged effect on the contractile
apparatus. In my early experiments using sodium nitroprusside, and myocytes in
coculture with endothelium, myocyte contraction amplitude returned to baseline in
most cases after exposure to the nitric oxide source. This suggests that the
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conversion of sodium nitroprusside to nitric oxide within myocytes may be limited.
It is also likely that the amount of nitric oxide released from endothelium in coculture
which reaches myocytes causes less elevation of cGMP than administration of high
doses of 8-br-cGMP.
In conclusion, administration of nitric oxide solution to cardiac myocytes
reduces Ca2+ transient by approximately 25%. This may explain the reduction in
myocyte contraction amplitude caused by nitric oxide from the sources described in
earlier chapters. The results from the present study suggest that the effect of nitric
oxide may be either to modulate Ca2+ entry into the myocytes, or modulate Ca2+
release from SR stores, at least in this model. Work in progress by others suggests
that, in rat cardiac myocytes, nitric oxide acts on the myofilaments to modify their
sensitivity to calcium. In the future, I plan to perform studies to examine the effect
of 8-br-cGMP and sodium nitroprusside on guinea pig myocyte Ca2+ transients to
resolve these differences.
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CHAPTER 10: EFFECT OF NEUTROPHILS ON CARDIAC
MYOCYTE CONTRACTION
Preface
When I wrote the Fellowship application for this research period there was
nothing published on cellular interactions between neutrophils and cardiac myocytes.
Many studies had shown the importance of neutrophils in myocardial ischaemia, and
historically their role in wound repair after infarction was established. Most of the
recent studies examined alterations in infarct size as a consequence of interference
with neutrophil function before, during or after a period of ischaemia-reperfusion,
mainly using in vivo dog models. But by their nature none of these studies addressed
the mechanism of neutrophil-mediated myocardial injury. Whether neutrophils
damage myocardium because of microvascular obstruction and resulting local
ischaemia could not be excluded. Studies at a cellular level to define whether direct
neutrophil-mediated myocyte injury occurred were required. These I planned to carry
out.
My hypothesis was that adhesion of neutrophils to myocytes injured by
ischaemia would modify contractility, and ultimately lead to myocyte death.
Difficulties were identified with the different models tried. These methods, together
with some promising results, are presented below.
I had some early experience of working with neutrophils, while at the
Hammersmith Hospital. I examined the relative contributions of flow (shear stress)
versus activation in the adherence of neutrophils to endothelial cells in a novel
dynamic model. This work is included in this chapter for completeness.
INTRODUCTION
Neutrophils have the potential to damage myocardium by their release of toxic
products. Whether such toxins are liberated in a random fashion by activated
neutrophils within an area of injured myocardium, or whether they are targeted
towards injured myocytes in particular has not yet been determined. However,
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emerging evidence suggests that injured cardiac myocytes may signal their own
destruction by activating such mechanisms at their cell surface. This is reviewed in
depth in chapter 1, and summarised here.
10.1.1. Neutrophil-endothelial adhesion
At sites of inflammation neutrophils roll along endothelium by engaging and
disengaging to the endothelial cells by adhesive interactions involving the neutrophil
glycoprotein L-selectin (Lawrence & Springer, 1991). Tethering of neutrophils at
sites of inflammation occurs via the expression of the endothelial glycoprotein P-
selectin which appears on cell surfaces within minutes of endothelial activation by
inflammatory mediators (Geng et al., 1990). P-selectin probably mediates early
neutrophil adhesion to activated or injured endothelium, since it is expressed from
intracellular or cell membrane stores without the need for synthesis of new proteins
(Geng et al., 1990). P-selectin interacts with its carbohydrate ligand CD15 on the
neutrophil (Larsen et al., 1990). Neutrophils undergo an early change in their
adhesion molecule presentation, with L-selectin appearing briefly first, followed by
the CD18 adhesion glycoprotein complex (Vedder & Harlan, 1988; Nourshargh et
al., 1989).
Migration of neutrophils across the endothelial layer follows adhesion, and
requires contact between the neutrophil integrin CD 18 complex and the endothelial
adhesion molecule, intercellular adhesion molecule-1 (ICAM-1) (Smith et al., 1988).
Activated endothelium synthesises and expresses the adhesion glycoproteins, ICAM-1,
and also E-selectin (formerly ELAM-1). ICAM-1 is present constitutively on
endothelium at low levels but its expression is increased substantially by inflammatory
mediators (Colditz & Movat, 1984). Monoclonal antibodies to CD 18 reduce
neutrophil infiltration into ischaemic-reperfused myocardium (Williams et al., 1990)
and have been shown to reduce infarct size (Seewaldt-Becker et al., 1990). In the
latter study a monoclonal antibody against ICAM-1 was also protective, but not all
authors have found that the anti-CD 18 antibody reduces infarct size, although
neutrophil infiltration is decreased (Tanaka et al., 1993).
E-selectin on endothelium requires de novo protein synthesis (Bevilacqua et
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al., 1989). It binds to a carbohydrate on the neutrophils surface, sialylated Lewis x
tetrasaccharide (Lowe et al., 1990). Both E-selectin and ICAM-1 mediate neutrophil
adhesion to and migration through activated endothelium.
10.1.2. Neutrophil-cardiac myocyte interactions
Once neutrophils have reached the extravascular space they can directly attack
cardiac myocytes. Whether this damage is directed specifically towards previously
injured myocytes is not known, and this was one of the main aims of my planned
studies. Cardiac myocytes as well as endothelial cells are now known to express
C.vJ.
ICAM-1 in response to activation by inflammatory mediators (Smith et al., 1991),
and bind to neutrophil CD18 glycoprotein (Entman et al., 1990). MRNA for ICAM-
1 can be induced in both endothelial cells and cardiac myocytes by post-ischaemic
cardiac lymph (Youker et al., 1992), and recent data suggest that direct neutrophil-
mediated injury of cardiac myocytes requires adhesion by the CD18/ICAM-1
mechanism (Entman et al., 1991). However, expression of ICAM-1 by myocytes
requires de novo protein synthesis (Entman et al., 1990). Since it has been shown
that complement activation products are present on the surface of myocytes following
ischaemia, a possible mechanism of early neutrophil attachment is via a CD 1 lb/CD 18
(complement receptor 3) interaction with iC3b.
Hypotheses
I wished to study the direct interaction between activated neutrophils and
cardiac myocytes. Planned early studies were:
(i) To determine whether activated neutrophils would attack healthy cardiac
myocytes, myocytes primed with cytokines, or whether they would adhere
specifically to injured cells.
(ii) Whether adhesion of neutrophils was required for toxicity, or whether by
releasing toxic products into the medium, nearby healthy myocytes would be
damaged.
(iii) Whether contractility of myocytes was affected by adhesion or presence
of neutrophils.
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(iv) More elaborate plans included injuring a population of isolated myocytes
with hypoxia, colour labelling them and then mixing them with healthy
myocytes, adding neutrophils and watching which myocytes were attacked.
Adherence with mIn-labelled neutrophils to quantify adhesion was also
considered.
10.1.3. Methods
Figure 38 High power view of guinea pig ventricular myocyte with adherent neutrophils. Note
irregular outline of neutrophils indicating their activated state, x400.
I had ready access to isolated guinea pig ventricular myocytes. The problem
to avoid species heterogeneity was to obtain guinea pig neutrophils. A method of
preparing neutrophils from guinea pig whole blood had never been well defined in the
literature and exploratory trials were not fruitful. For a short while I used rabbit
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blood neutrophils, since the purification method was established in the department,
and prepared rabbit ventricular myocytes in the same manner as for guinea pig hearts.
There were difficulties in doing both myocyte and neutrophil preparations in different
laboratories concurrently so I returned to guinea pig ventricular myocytes.
Different early models of cellular interaction were explored. In the first
experiments I used multiwell plates with different proportions of neutrophils and
myocytes, and added recombinant human IL-1 to activate myocytes and/or the
neutrophil activating oligopeptide, FMLP to activate neutrophils, in different
combinations. Myocyte function could not be studied, and there were technical
difficulties focusing on the multiwell plate, so I changed to using the cell bath
employed in regular experiments on isolated cardiac myocytes (see chapter 2).
I performed a series of exploratory experiments using neutrophils isolated
from rabbit blood together with guinea pig myocytes. Although different species
were used, encouraging results were obtained.
Viewed under high power magnification addition of neutrophils activated with
FMLP after 30 min exposure to IL-1 2U/ml had a marked effect on contractility of
a healthy myocyte. Neutrophils adhered in large numbers to the myocyte, as
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illustrated in Figure >?". That the neutrophils were not merely proximal but were
adherent to the myocyte was shown by their adhesion in the presence of flow. With
adhesion of neutrophils contraction became sluggish and the myocyte fibrillated before
finally rounding up in irreversible contracture. Such experiments were carried out
at room temperature in the absence of flow, except when flow was turned on to test
adherence. In control studies without neutrophils myocytes continued to contract for
> 1 h under these conditions, so the effects of neutrophils were not a result of stasis,
nor of changes in temperature.
I modified this model so that under lower magnification between five and nine
myocytes were viewed simultaneously. Instead of measuring fractional shortening
only diastolic length was measured, since shortening cannot be determined accurately
at low power.j Control studies showed that healthy myocytes only gradually reduced
their diastolic length over 1 h. I therefore examined the effects of addition of
neutrophils, with the addition of FMLP in some cases to a field of healthy myocytes.
Cells which rounded because of irreversible injury were readily visible and could be
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recorded as terminally injured cells. 0.5xl06 neutrophils were added to a field of
about 100 myocytes already adherent to the coverslip in the 200 pd cell bath and were
allowed to settle for 5 min. Flow was then turned on for a few minutes to wash away






































Figure 39 Effect of neutrophils on myocyte survival over 1 h. N = 5-9 myocytes in each group.
+ PMN, neutrophils added; FMLP, formylated Met-Leu-Phe peptide.
10.1.4. Results
Figure 39 shows the effect on myocyte contractility, shown as survival of
isolated myocytes after addition of neutrophils. In the absence of neutrophils myocyte
survival was nearly 100% over 1 h. Addition of neutrophils activated fully with
FMLP rapidly injured previously healthy myocytes in one set of myocytes, although
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in another set only a proportion of myocytes were injured. In another set addition
of neutrophils without FMLP also directly injured some of the myocytes.
10.1.5. Discussion
This exploratory study showed that addition of neutrophils directly damages
cardiac myocytes. Activation with FMLP tended to increase the cytotoxicity but even
the trace amounts of endotoxin present in the system seemed to be enough to prime
the neutrophils to an oxidant state. Activation of the myocytes by cytokines was not
required for adhesion in this model. Although the study was performed without flow,
observational experiments showed that once neutrophils were adherent to myocytes,
they were not dislodged at even high flow rates. This is persuasive evidence for a
direct adhesion between myocyte and neutrophil.
These studies provide data which addressed in part my hypotheses. Activated
neutrophils did appear to adhere to apparently healthy myocytes, as well as to
rounded cells. Myocyte priming with cytokines was not required. This is in contrast
c.w.
to the results from Smith's group in Houston (Smith et al., 1991; Youker et al.,
1992; Entman et al., 1990). In their studies incubation of cardiac myocytes with IL-
1, TNFo: or IL-6 was necessary to induce ICAM-1 expression, which was a
prerequisite for neutrophil-myocyte adhesion. They also found that adhesion was
dependent on neutrophil activation with inflammatory mediators. Antibodies to either
CD 18 or ICAM-1 substantially inhibited neutrophil-myocyte adhesion.
However, their studies do not explain fully what happens in vivo. Neutrophils
accumulate in the heart following ischaemic damage shortly after reperfusion begins
(see section 1.6.1.). Yet in their in vitro experiments 4 h are required to induce new
protein in myocytes for neutrophil adhesion. There must be another, earlier signal
for neutrophil attraction and adhesion to damaged myocardium. Very recently, a
surface adhesion molecule with properties similar to PAF has been found to be
expressed early in post-ischaemic cardiac myocytes (CW Smith, personal
communication). Its structure and physiological significance have not been defined
but it is tempting to suggest a role for this molecule in early ischaemia-reperfusion
injury, since PAF antagonists appear to moderate post-ischaemic myocardial injury
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(see section 1.6.4.).
The present study shows that contractility of myocytes is markedly modified
by addition of neutrophils, measured as loss of diastolic length. Although it was
evident that fractional shortening was profoundly altered before irreversible cell
injury, the edge detection system usually used to measure contractility could not be
used because of the presence of large numbers of neutrophils which made definition
of myocyte extremities difficult. A way round this would be to use only a few
neutrophils, and this could then be extended to investigate what ratio of neutrophils
to myocytes was required for cell killing. Anderson and Entman have found that
adhesion of two or three neutrophils is enough to cause myocyte oxidant injury (DC
Anderson, personal communication, and (Entman et al., 1992)). Whether this is the
same for modification of contractility is not known. In my studies I wished to
establish first of all whether neutrophils directly injured myocytes. Future
experiments could then address specific issues to dissect this mechanism.
While these early studies provided interesting information on neutrophil-
myocyte interactions, to perform a satisfactory programme of experiments would
require a restructuring of laboratory practice to work in an endotoxin free
environment. It is likely that trace amounts of endotoxin activates myocytes, much
as it activates other immunocompetent cell types (CW Smith, personal
communication). Studies of cardiac myocyte immunological behaviour need
comparisons between activated and unactivated states, otherwise parameters cannot
be defined.
10.1.6. Conclusions and future perspectives
In conclusion, laboratory evidence is accumulating that myocardial injury
during reperfusion after ischaemia is a real phenomenon. Neutrophils exert potent
effects on myocyte contractility and survival, and inhibition of neutrophil function or
adhesion to myocytes improves recovery from ischaemia in animal models. Studies
in patients have yet to confirm these findings. In the large trials of thrombolysis, an
excess of deaths on the first day following reperfusion could be due to injury caused
by reperfusion. But these trials were not designed to address this phenomenon so
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overinterpretation of data is dangerous (Fox, 1992). Proper randomised trials of
agents to block neutrophil function are required.
While some possible therapeutic agents, such as monoclonal antibodies to
neutrophil adhesion molecules, are available, the size and cost of a carefully
conducted, randomised trial would be substantial. Thrombolysis in myocardial
infarction is so successful, and the mortality in the large trials so low (10-11%,
ISIS-3 collaborative group, 1992) that additional benefit over current strategies would
require the study of many thousands of patients to test the ultimate efficacy and safety
of such a therapy. When the cost of producing such agents in large quantities
becomes economic, such studies may be performed.
Encouragingly however, new low molecular weight carbohydrate agents which
bind to the oligosaccharide moieties of adhesion receptors are becoming available.
These block neutrophil-cardiac myocyte adhesion and are cheaper to produce, easier
to manufacture and are potentially more readily administered to patients. Such agents
are nearing clinical trials (K Mullane, personal communication). Another potential
agent to reduce inflammation in myocardial injury is the soluble CR1 receptor,
already shown to be of benefit in animal studies (Weisman et al., 1990). Prostacyclin
analogues which switch off neutrophil function is another area of therapeutic interest
(Simpson et al., 1987a), although hypotension is a problem in patients (Blauth et al.,
1987). In the near future results of trials using drugs which act either as analogues
of adenosine or stimulants of its release are expected, and these and other early
modulations of the inflammatory response may offer important gains in the
management of myocardial ischaemia.
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10.2. NEUTROPHIL ENDOTHELIAL INTERACTIONS
10.2.1. Introduction
The mechanism of neutrophil adhesion to endothelium has been described in
chapter 1 sections 1.6.8.-1.6.9., and in the introduction to this chapter. Since
adherence of a moving neutrophil to stationary endothelium involves loss of motion
in a continuously flowing medium I set out to examine the relative contributions of
flow of perfusing solution and level of neutrophil activation to adhesion to endothelial
cells. My hypothesis was that adhesion of neutrophils to endothelium might be
directly related to the rate at which perfusing solution was flowing.
10.2.2. Methods
Bovine pulmonary artery endothelial cells were prepared without enzymatic
digestion, in the same manner as bovine aortic endothelium, described in chapter 2.
The cells were cultured on to 150 jum diameter Cytodex beads and 0.5 ml placed in
a cell column made from the barrel of a 2 ml syringe, as shown in Figure 40. The
system was maintained at 37°C with a water jacket round the cell column.
Circulating human neutrophils were prepared from volunteer donor blood
under the direction of Dr CH Haslett, using sedimentation through a discontinuous
carbohydrate gradient, similar to the preparation of rabbit neutrophils described in
chapter 2. Isolated neutrophils were labelled with 11'Indium in tropolonate, and
washed three times in Hank's buffered salt solution (Ca2+ 1 mM). Since partial
activation of neutrophils is difficult to achieve, cells were either used in unactivated
form, or were fully stimulated with 10 min incubation in lipopolysaccharide 100
ng/ml, followed by 3 min exposure to FMLP 10~6M. The level of neutrophil
activation was determined by shape change assay. Quiescent neutrophils are round;
activated cells have an irregular outline, readily distinguishable as irreversible
activation.
70-80x106 neutrophils in a final volume of 3 ml were gently loaded into











Figure 40 Bovine pulmonary artery endothelial cells cultured on to Cytodex beads, perfused with
human neutrophils.
was maintained at 0.5 ml/min for 16 min, then increased to 1 ml/min for 16 min,
then to 2 ml/min for 16 min. 1 minute collections were made and counted for mIn
activity using a gamma counter. Counts at each flow rate were totalled and residual
inIn activity on the endothelial column, i.e. the proportion of neutrophils retained,
was counted. Neutrophils adherent to the filter were counted but were a small
proportion of the total.
Pressure in the system was measured on one occasion through a side arm
using a Grass pressure transducer. The recordings are shown below:
0.5 ml/min : 10 mm Hg
1 ml/min : 32 mm Hg


































Figure 41 Retention of neutrophils on endothelial cell column at different flow rates, expressed are
the percentage of total injected neutrophils. PMN, polymorphonuclear leukocytes (neutrophils).
10.2.3. Results
Figure 41 shows the adhesion of neutrophils to the endothelial column at
different flow rates. It is clear that adhesion, measured as retention of neutrophils
on the endothelial column, is related to the level of activation, and not to the rate of
perfusing flow.
N=5 experiments with activated neutrophils; activation recorded as >90%




My hypothesis was that adhesion of neutrophils to endothelium was related to
the rate at which perfusing solution flowed past the adherent neutrophils. In fact
neutrophil activation had a greater influence on adhesion than did a fourfold increase
in flow. A possible explanation of this is that the strength of neutrophil binding to
endothelium is enough to resist the increased shear force generated by the perfusing
fluid. Endothelium is now known to rapidly express the adhesion glycoprotein P-
selectin within minutes of endothelial activation by inflammatory mediators (Geng et
al., 1990). P-selectin may mediate early neutrophil adhesion to activated or injured
endothelium, since it is expressed from intracellular or cell membrane stores without
the need for synthesis of new proteins. P-selectin interacts with its carbohydrate
ligand CD 15 on the neutrophil (Larsen et al., 1990). The way to prove this would
have been to examine the effect of blocking antibodies to either the endothelial or
neutrophil adhesion molecule, but this was not possible.
An alternative explanation is that neutrophils aggregate in the spaces between
endothelial cell beads and some of the apparent adhesion to the column is in fact due
to neutrophil-neutrophil adhesion. I tried to address this by making sections of
glutaraldehyde-fixed columns and having transmission electron microscopy performed.
Unfortunately the cytodex beads fragmented on the apparatus used to cut sections,
both at room temperature and after freezing with liquid nitrogen, so this was not
pursued. Thus this study does not answer fully the question it was designed to test,
but it does provide interesting data on a dynamic model of neutrophil-endothelial
adhesion, an area under study by other research groups.
One implication of this study is that at sites of inflammation, recruitment of
neutrophils from nearby patent vessels can occur down chemotactic gradients while
blood continues to flow. This is important because neutrophils need to adhere to
endothelium with a bond strong enough to resist the shear force of flowing blood.
That they do so in the present system where the pressure within the microcirculation
is as high as 63 mm Hg and flow 2 ml/min suggests that the adhesion is strong
indeed. Estimation of the haemodynamics in my experimental model is difficult
because there will be convectional accelerations round the curved surfaces of the
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beads. Nevertheless, assumptions can be made to estimate the size of the lumen of
the cell column.
The approximate size of the channels between beads in an assumed cross
section of the system is shown below:
area of endothelial cell column
area of a cell bead
area of a square of side equal
to the diameter of a bead
= xr2
= x x 0.52 = 0.79 cm2
= 2xl0"5 cm2
= 2.5xl0~5 cm2
areasquare - areabead = area of perfusing channel = 5xl0"6 cm2
No. of squares covering area of
column
therefore, effective area of perfusing channel
= areacolunm/areasquare = 31600
= 31600 x 5xl0"6 cm2 = 0.158
cm2
At 1 ml/min flow in the experimental model is roughly equivalent to laminar flow in
a vessel 0.158 cm2 in cross section, or 0.44 cm in diameter, with an intraluminal
pressure of 32 mm Hg. These measurements are within physiological limits.
Thus it can be suggested from the present study that the level of activation is
more important than the rate at which blood flows through vessels in determining
neutrophil adhesion to endothelium. It can be suggested that neutrophils can move
to extravascular sites of inflammation from nearby vessels without the need for
sluggish blood flow. Flow in these vessels will be increased because of vasodilatation
due to the effects of inflammatory mediators and rather than being washed away,
neutrophils will stick to endothelium and migrate towards the source of chemotactic
factors. When flow is reduced, the adhesive properties of neutrophils, combined with
increased stiffness (Worthen et al., 1989), will encourage retention and this may
contribute to the no reflow phenomenon sometimes observed during reperfusion after
coronary occlusion.
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CHAPTER 11: GENERAL DISCUSSION
Cardiac myocytes metabolise sodium nitroprusside, but not organic nitrates, to
generate nitric oxide
The importance of nitric oxide in the function of many different cell types has
been recognised only recently. The main thrust of most of the work in this thesis was
to establish whether nitric oxide has a role in modulation of myocardial contraction.
Its influence on healthy cells was demonstrated first by the effects of sodium
nitroprusside on cardiac myocyte contraction.
Nitrovasodilators act by being metabolised locally to release nitric oxide.
Contractility of cardiac myocytes was not affected by the organic nitrates, glyceryl
trinitrate and isosorbide dinitrate, but administration of sodium nitroprusside reduced
myocyte contraction. This suggests that cardiac ventricular myocytes do not contain
the enzyme(s) necessary to generate nitric oxide from organic nitrates. The effect of
sodium nitroprusside was blocked by the inhibitor of soluble guanylate cyclase,
methylene blue. This suggests that nitric oxide is acting by stimulating production
of cGMP within the myocytes.
Nitric oxide attenuates cardiac myocyte contraction
Administration of nitric oxide solution provided direct evidence for an
attenuating effect of nitric oxide on contractility. That this effect is mediated by
production of cGMP within the myocytes is further supported by the experiments
using 8-bromo-cGMP. This stable analogue of cGMP had an effect similar to sodium
nitroprusside, reducing myocyte contraction.
The effect of elevating cGMP within myocytes appears to be to limit the rise
in [Ca2+]j during the cardiac action potential, as shown by the experiments described
in Chapter 9. This means that either the entry of calcium from outside the cell is
decreased, or the release of stored calcium from intracellular stores is reduced. How
nitric oxide modifies these mechanisms occur is not known.
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Nitric oxide from stimulated endothelium attenuates cardiac myocyte contraction
The work was extended into a physiological coculture model of myocytes with
endothelium. Again, nitric oxide from stimulated endothelium attenuated contractility
of myocytes. Inhibition of endothelial nitric oxide production with L-NAME blocked
this effect. The attenuation was small, in the range 10-25%, when nitric oxide in
solution, or when derived from nitrovasodilator drugs or the endothelium acted on
healthy myocytes.
Cardiac myocytes from healthy animals do not demonstrate appreciable nitric
oxide synthase activity in their basal state
Administration of either inhibitors of nitric oxide synthase, or its substrate L-
arginine, had no effect on contraction of normal myocytes in my study. This has
since been confirmed by others (Amrani et al., 1992), (Shah and Lewis, personal
communication). These important control studies show that quiescent myocytes do
not express nitric oxide synthase in an active form. Constitutive nitric oxide synthase
has now been shown to be present in normal, healthy cardiac myocytes (Schultz et
al., 1992; Balligand et al., 1993) but does not appear to generate appreciable nitric
oxide. Inhibitors and substrates of nitric oxide synthase had no effect on contractile
function of cells in their basal state, either in the experiments of this thesis, or the
experiments of others (Amrani et al., 1992; Schultz et al., 1992; Balligand et al.,
1993).
It has now been shown by others that nitric oxide produced endogenously
within myocytes may modify the inotropic response to B-adrenergic stimulation in
cardiac myocytes (Balligand et al., 1993). This phenomenon only occurred following
exposure of myocytes to isoprenaline. The same paper also provided evidence that
nitric oxide mediates the inhibitory effect of carbachol on myocytes.
The report by Finkel which showed nitric oxide-dependent depression of
papillary muscle contraction after a few minutes' exposure to cytokines (Finkel et al.,
1992) does not fit with the data on isolated myocytes. Possibly a cytokine-dependent
nitric oxide synthase enzyme is induced very rapidly in hamster papillary myocytes.
Alternatively, the cytokines are acting on another cell type within the papillary muscle
which quickly generates nitric oxide.
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A role for nitric oxide in myocardial contraction?
There are important implications of this work. The coronary microcirculation
is in close proximity to cardiac myocytes and endothelium-derived nitric oxide may
have a tonic effect on myocardial contractility, analogous to the release of EDRF
from endothelium in the vasculature. Within the circulation, local blood flow is
probably regulated by tonic modulations in neurohumoral mechanisms which affect
nitric oxide release, and its subsequent effect on vascular smooth muscle. Whether
some form of regulation of myocyte contraction by nearby endothelium occurs within
the heart is not known. Importantly, others have now shown that nitric oxide
production within myocytes may be involved in the regulation of inotropic responses
of myocytes to B-agonists, and nitric oxide may mediate the effects of negatively
inotropic cholinergic pathways within myocytes (Balligand et ai, 1993).
The circumstantial evidence from the work of this thesis, together with studies
of endocardial endothelium, which shows that ventricular myocytes are sensitive to
exogenous nitric oxide in physiological amounts, argues that a relationship between
endothelium and cardiac myocytes may exist. This relationship may be particularly
important when cardiac architecture is disturbed in myocardial disorders.
In ventricular hypertrophy and in cardiomyopathic conditions, there is
accumulation of interstitial cells and fibrous tissue. The distance from vasculature to
myocyte is increased, and myocyte contractility may thus be affected by altered
diffusion of nitric oxide. In the whole organ this may result in abnormalities of
contraction and relaxation. Although the effects of nitric oxide in my studies are
mainly on contraction amplitude, papillary muscle work suggests that there are
important effects on the rate of contraction and relaxation as well. Thus alterations
of nitric oxide diffusion into myocytes may be important in both systolic and diastolic
dysfunction.
150
Does nitric oxide contribute to post ischaemic myocardial stunning?
Coronary endothelial dysfunction occurs early in ischaemia-reperfusion injury
and impaired production of nitric oxide may be important in this condition. It is
tempting to suggest that an abnormality of nitric oxide production affects myocyte
contraction as well. I was keen to test whether loss of contractility of myocytes
following ischaemia was the result of activation of constitutive nitric oxide synthase.
There is biochemical evidence of the presence of this enzyme in human myocardium
(De Belder et al., 1993) and in animal ventricular myocytes (Schulz et al., 1992).
As shown by the work of this thesis the function of this enzyme in health is not
known (Brady et al., 1992). As mentioned above, cytokines can activate nitric oxide
synthase activity in hamster papillary muscle with a time course too short for
induction of new protein (Finkel et al., 1992). The experimental model designed in
my studies to address the effects of reversible ischaemia did not function satisfactorily
so the hypothesis that activity of constitutive nitric oxide synthase contributes to
postischaemic myocardial stunning remains untested.
Production of nitric oxide within cardiac myocytes contributes to their impaired
contractility in endotoxic shock
Probably the most important finding of the work of this thesis, readily
applicable to the clinical situation, was the study of behaviour of cardiac myocytes
from animals with endotoxic shock. Myocytes from healthy animals do not have
appreciable nitric oxide synthase activity. In endotoxaemia, the contractility of
cardiac myocytes is markedly reduced. A substantial proportion of this reduction is
due to the induction of nitric oxide synthase and subsequent production of nitric oxide
within the myocytes themselves. Again, similar to the situation in many other tissues
overproduction of nitric oxide accounts for important functional abnormality.
Endotoxic shock is associated with myocardial depression, exacerbating the profound
haemodynamic changes which occur in this condition. Nitric oxide production within
cardiac myocytes may contribute to the contractile impairment in endotoxic heart
failure.
A randomised trial of the effect of L-arginine analogues in patients with
endotoxic shock is nearing completion (P Vallance, personal communication). This
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study examines haemodynamic profiles but does not measure myocardial contractility
directly. Vallance and I plan to carry out a second clinical study with
echocardiography as well as haemodynamic measurements, to address this question.
Recently, inducible nitric oxide synthase activity in biopsies of human
myocardium from patients with dilated cardiomyopathy has been demonstrated (De
Belder et al., 1993). The key question from that study is: does production of nitric
oxide within myocytes in dilated cardiomyopathy account for impaired contractility?
Endomyocardial biopsy yields many cell types, including endocardial endothelium,
vascular endothelium, vascular smooth muscle and fibroblasts, all of which show
inducible nitric oxide synthase activity in inflammatory conditions (Brady, 1993).
Thus their methodology cannot answer the central question, but the implication is that
a common mechanism, overproduction of nitric oxide within myocardium, may cause
myocardial depression in both acute and chronic inflammatory conditions.
The evidence that nitric oxide production from inducible nitric oxide synthase
activity may impair myocardial contractility suggests exciting possibilities for specific
therapy in cardiomyopathy conditions in the future.
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—Cardiac muscle fibers have microvessels in close proximity,
the distance from the nearest capillary being no greater than 8
lim. We performed experiments on isolated, electrically stimu¬
lated, contracting guinea pig cardiac myocytes to test whether
NO from endothelium or nitrovasodilators or directly super-
fused in solution might affect myocyte contractility. In endot¬
helium-myocyte coculture experiments, 10~7 M bradykinin re¬
duced myocyte shortening by 11 ± 3.5%. This effect was
abolished in the presence of lVG-nitro-L-arginine methyl ester
and was unaffected by indomethacin. Sodium nitroprusside, but
not organic nitrovasodilators, reduced myocyte contraction am¬
plitude by 23% at 3 x 10-5 M. This effect was reversed by
methylene blue. Superfusion with NO solution had an effect
similar to sodium nitroprusside, as did exposure to 8-bromogua-
nosine 3',5'-cyclic monophosphate. Thus the present study
shows that cardiac myocyte contraction is attenuated by NO,
which appears to act via production of guanosine 3',5'-cyclic
monophosphate within the myocytes. Because cardiac myocytes
in vivo are in such close proximity to endothelium, the effects of
endothelial products on cardiac myocyte contractility may be
important in myocardial function.
endothelium; nitrovasodilator; guanosine 3',5'-cyclic mono¬
phosphate
THE CORONARY MICROCIRCULATION lies in close prox¬
imity to cardiac muscle, so that most myocytes are
within 8 pm of their nearest capillary (16, 17). This
short diffusing distance means that myocytes may be
influenced by vasoactive factors produced by adjacent
endothelium. Endothelium-derived relaxing factor
(EDRF), considered now to be NO or a closely related,
short-lived compound, is capable of relaxing smooth
muscle of the vascular system, airways, gut, and urinary
tract (14). The intracellular mechanism involves the
stimulation of soluble guanylate cyclase to increase
intracellular levels of guanosine 3',5'-cyclic monophos¬
phate (cGMP) with a subsequent reduction in intracell¬
ular calcium.
It is not known whether vasodilator factors from
endothelium affect contraction of cardiac myocytes.
However, we have shown recently that the contractility
of isolated cardiac myocytes can be attenuated by gen¬
eration of NO within the myocytes themselves (2). My¬
ocardial contractility is markedly impaired in the later
stages of endotoxic shock. We found that the contrac¬
tility of cardiac myocytes from endotoxin-treated ani¬
mals was substantially reduced and this could be re¬
versed by inhibition of either NO synthase or guanylate
cyclase, indicating NO synthase activity within the my¬
ocytes themselves. This phenomenon was not present in
cardiac myocytes from normal animals.
The primary aim of the present study was to examine
whether isolated, functioning cardiac myocytes from
healthy animals are sensitive to exogenous NO. The
sources of NO used were 1) stimulated endothelium in a
primary coculture model, 2) nitrovasodilator com¬
pounds, and 3) NO gas dissolved in solution. Because
NO acts by elevating intracellular levels of cGMP, the
effects of the stable analogue, 8-bromoguanosine 3',5'-
cyclic monophosphate (8-BrcGMP), were also studied,
as well as the effects of the inhibitor of guanylate cy¬
clase, methylene blue.
The secondary aim of this study was to establish
whether cardiac myocytes can metabolize nitrovasodila¬
tors other than sodium nitroprusside to generate NO.
Although nitrovasodilators act by being metabolized to
produce NO, different nitrovasodilators are metabolized
by different pathways (9). It has been shown recently
that porcine coronary smooth muscle cells metabolize
glyceryl trinitrate (GTN) to generate NO by a plasma
membrane enzyme (5). In contrast, sodium nitroprus¬
side requires only a reduction step to generate NO,
which requires NADPH, NADH, or a thiol and takes
place in the microsomes (8). Although the effects of
nitrovasodilators on cardiovascular hemodynamics are
established in both patients and experimental models,
the changes induced in coronary flow, peripheral resis¬
tance, venous filling pressure, and pulmonary capillary
wedge pressure will obscure any specific action of nitro¬
vasodilators on myocardial contractility, i.e., the extent
and rate of myocardial shortening. The isolated, func¬
tioning cardiac myocyte is a suitable model to study
contractility in the absence of hemodynamic changes.
MATERIALS AND METHODS
Guinea pig cardiac myocytes were isolated by enzymatic di¬
gestion, as described previously (12). A drop of myocyte suspen¬
sion was placed in a 200-/il Perspex chamber on the stage of an
inverted microscope, either on a 22-mm-diam plain glass cover
slip or on a cover slip with confluent bovine aortic endothelium,
and superfused at 2 ml/min with 2 mM calcium Krebs-
Henseleit buffer [containing (in mM) 119.1 NaCl, 4.7 KC1, 0.94
MgS04, 1.2 KH2P04, 25 NaHC03, and 11.5 glucose] bubbled
with 95% 02-5% C02 at 32 ± 0.5°C. Temperature was moni¬
tored by a thermistor in the cell bath. Cells were allowed to
adhere for 4 min without flow and were then stimulated elec¬
trically to contract using a bipolar stimulator delivering pulses
of 30 V/4 ms at 0.5 Hz.
Contractility of individual myocytes was determined as de¬
scribed in detail elsewhere (11). Briefly, contraction amplitude
and velocity of shortening of electrically stimulated myocytes
were recorded using a videomicroscopy length-detection system
and analyzed by computer-signal averaging. This system had a
time resolution of 20 ms and a spatial resolution of 1 in 256,
which allowed typically 10-15 sampling points within a single
contraction and relaxation. Six consecutive contractions were
signal averaged to produce data under each particular set of
conditions. Myocyte contraction amplitude was calculated as a
percentage of the resting length, and time to peak contraction
H176 0363-6135/93 $2.00 Copyright © 1993 the American Physiological Society
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and time from peak contraction to return to 90% of resting
length (relaxation time) were recorded. The following criteria
were defined to identify healthy, viable, isolated myocytes (12):
1) only rod-shaped cells without sarcolemmal blebs were exam¬
ined; 2) cells that exhibited spontaneous contractions were ex¬
cluded; and 3) cells that displayed a variable baseline contrac¬
tion to electrical stimulation at 2 mM calcium were rejected.
Bovine aortic endothelial cells were isolated and passaged by
nonenzymatic methods (26). The cells had normal cobblestone
morphology, factor VIII immunoreactivity, and high levels of
angiotensin-converting enzyme activity. They were used be¬
tween passages 10 and 18 and grown in Dulbecco's modified
Eagle's medium with 10% fetal calf serum (GIBCO, Paisley,
UK), 200,000 IU/1 penicillin, 200 mg/1 streptomycin, and 480
mg/1 glutamine. Cells were passaged onto sterile glass cover slips
contained in multiwell plates and used 2-3 days later when
confluent.
In the endothelium-myocyte coculture experiments 10-7 M
bradykinin was used to stimulate release of EDRF. The ability
of the endothelium to generate NO when stimulated with brady¬
kinin was confirmed in separate studies by chemiluminescence
using a Sievers Nitric Oxide Chemiluminescence Analyzer
(Denver, CO) and also by bioassay using endothelial cells grown
on microcarrier beads in a superfusion cascade system (data not
shown).
To allow accumulation of endothelium-derived factors, super-
fusing buffer flow was halted 5 min before recordings were made.
An indwelling thermocouple and heating element were used to
maintain bath temperature, and 95% 02-5% C02 gas was su¬
pervised over the cell bath to maintain oxygenation and pH.
The temperature of the system was controlled so that paired
recordings were made at matched temperatures. Control studies
showed that a change of +1.0°C from 32°C reduced contraction
amplitude by 5 ± 0.5% (SE; n = 8), and similarly, a change of
—1°C increased contraction by 5 ± 0.5% {n = 7). For the re¬
cordings made during coculture experiments, bath temperature
was maintained at 32.6 ± 0.2°C. Some endothelium-myocyte
studies were performed in the presence of 10~4 M IVG-nitro-l-
arginine methyl ester (l-NAME) to inhibit production of NO or
in the presence of 10-5 M indomethacin to block prostaglandin
synthesis.
In the experiments examining the effect of nitrovasodilators
on isolated myocyte contractility, sodium nitroprusside solu¬
tions were used over the concentration range 10 ~8 to 3 x 10~5
M, and containers were wrapped in foil to exclude light. Con¬
centrations of GTN (Lipha, Middlesex, UK) and isosorbide
dinitrate (ISDN; Schwarz Pharma, Chesham, Buckingham¬
shire, UK) were used over the dose range 10~6 to 3 x 10~5 M.
Measurements were made on 6-10 myocytes at each dose of
nitrovasodilator. Effects of each nitrovasodilator were com¬
pared randomly with control measurements recorded before or
after myocyte exposure to nitrovasodilator at each concentra¬
tion. Concentrations of nitrovasodilators were chosen ran¬
domly, and cumulative dose-response protocols were avoided.
Myocytes were exposed to each concentration of nitrovasodila¬
tor for 10 min and were not exposed to more than one nitrova¬
sodilator. The time course of the study allowed for measure¬
ments made on individual myocytes within 45 min of
stabilization. This avoided the reduction in myocyte contrac¬
tion amplitude that can occur in studies of >2 h in duration.
In further experiments 5 X 10~6 M methylene blue (David
Bull Laboratories, Warwick, UK) was added as an inhibitor of
guanylate cyclase. In another series of experiments the effect of
the stable analogue of cGMP, 8-BrcGMP (Boehringer Mann¬
heim, Lewes, East Sussex, UK), was examined using cumulative
doses, over the range 10~6 to 3 x 10~6 M. All other drugs and
chemicals were from Sigma (Poole, Dorset, UK) except where
stated.
Some experiments were performed to examine the effect of
NO dissolved in physiological solution on cardiac myocyte con¬
traction. Aliquots (100 or 1,000 pi) of NO gas (99% pure; Merck,
Poole, Dorset, UK) were injected using a Hamilton gas syringe
(Reno, NV) into 300 ml of Ar-2-hydroxyethylpiperazine-V-2-
ethanesulfonic acid (HEPES)-buffered 2 mM Ca2+-Tyrode so¬
lution [containing (in mM) 150 NaCl, 5.4 KC1, 1.2 MgCl2, 5.0
Na-HEPES, and 10.0 glucose; pH 7.40] that had been bubbled
vigorously with nitrogen gas for 4 h to remove oxygen. This
yielded stock solutions of ~10~6 to 10~5 M dissolved NO (for
100 and 1,000 pi, respectively), and the stock solutions were
kept anoxic. Aliquots were withdrawn and superfused into the
cell bath for 7 min. NO solution was protected from exposure to
air until it reached the cell under study. The NO concentration
of the 10~6 M NO solutions was confirmed using the NO chemi¬
luminescence analyzer to be within the range 1-3 X 10-6 M NO
on multiple samplings of different 100-pl NO solutions. The
1,000-pl NO solutions were assumed to contain 10-fold more
NO. Control experiments were performed using the same Ty-
rode solution, bubbled with 100% nitrogen.
Values are expressed as means ± SE except where stated.
Statistical differences between baseline and stimulated endot¬
helium- or nitrovasodilator-influenced contraction were tested
using Student's two-tailed t test for paired data or one-way
analysis of variance (ANOVA). The dose dependence of nitro¬
vasodilator effects was assessed using regression analysis.
RESULTS
Figure 1 shows a representative signal-averaged trace
(of 6 contractions) of the effect of 10~5 M sodium nitro¬
prusside on contraction of a single cardiac myocyte. In
this experiment contraction amplitude was reduced from
5.8 to 4.7% of resting length, a reduction in myocyte
contraction of 19%, with no effect on either time to peak
contraction or relaxation time. The difference between
the fractional shortening in the presence of nitrovasodi¬
lator was expressed as a percentage of the baseline con¬
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Fig. 1. Representative signal-averaged trace of 10~5 M sodium nitro¬
prusside (SNP) effect on myocyte contraction. Solid line, baseline con¬
traction; dotted line, effect of SNP.










Fig. 2. Effect of different nitrovasodilators on myocyte contraction am¬
plitude (differences expressed as % reduction of control contractions).
ISDN, isosorbide dinitrate; GTN, glyceryl trinitrate. Values are means
± SE of 6-10 experiments. SNP significantly reduced contraction am¬
plitude at concentrations >3 x 10~8 M. P < 0.02 by analysis of variance.
SNP+MB
more prolonged periods (>30-60 min) caused cells to be¬
come hypercontractile and, subsequently, to fibrillate in
10 of 12 cardiac myocytes studied.
Compared with control, none of the nitrovasodilators
had a significant effect on time to peak contraction
(baseline, 0.14 ± 0.01 s; nitrovasodilator, 0.14 ± 0.01 s;
pooled data from all nitrovasodilator experiments, n =
12 groups of paired studies). Similarly, relaxation times
were not affected by nitrovasodilators (baseline 0.27 ±
0.01 s; nitrovasodilator 0.28 ± 0.01 s; pooled data from
same experiments).
To examine the effect of endothelium-derived NO on
myocyte contractility, myocytes were studied in primary
coculture with confluent endothelium. To determine
whether unstimulated endothelium affected baseline
characteristics of contraction, the contractility of myo¬
cytes on endothelium was compared with that of myo¬
cytes on glass. Contraction amplitude of myocytes adher¬
ent to quiescent endothelium (5.3 ± 0.6% of resting
length; n = 12) was not different from that of myocytes
adherent to glass cover slips (5.3 ± 0.3%; n = 32). There
was no difference in time to peak contraction (0.10 ± 0.02
s on endothelium, n = 11; 0.12 ± 0.02 s on glass, n = 9) or
relaxation time (0.30 ± 0.04 s on endothelium, n = 11;
0.30 ± 0.03 s on glass, n = 9).
In coculture experiments 10~7 M bradykinin was used
to release NO from the endothelium. Myocyte contrac¬
tion amplitude was reduced by 11 ± 3.5% (P < 0.03). This
effect was abolished by the presence of 10~4 M L-NAME
and was not reduced by 10-5 M indomethacin (Fig. 4).
Although the bradykinin-induced reduction in contrac¬
tion was greater in the presence of indomethacin, this
further reduction was not significantly larger than that of
bradykinin alone. Bradykinin-stimulated NO release had
no effect on either time to peak contraction or relaxation
time (Table 1).
Fig. 3. Effect of 10_s M SNP on myocyte contraction ± 5 x 10~6 M
methylene blue (MB). Differences are expressed as %reduction of con¬
trol contractions. Values are means ± SE of 6 experiments. ** P < 0.01,
both SNP vs. control and SNP vs. SNP + MB.
10"6 to 3 X 10~5 M had no effect on contraction ampli¬
tude of contracting myocytes. Sodium nitroprusside re¬
duced contraction amplitude: the reduction was signifi¬
cant (P < 0.02, ANOVA) at concentrations of 3 x 10~8 M
or above. Regression analysis showed that the effect of
sodium nitroprusside was concentration dependent (P <
0.001), although it was not possible to determine whether
the curve was monophasic or biphasic. The effect of so¬
dium nitroprusside was reversible and repeatable, sug¬
gesting that the generation of cyanide was not a cause of
the reduced contraction amplitude.
In further studies 5 X 10~6 M methylene blue was
added to all solutions and reversed the reduction in my¬
ocyte shortening caused by sodium nitroprusside (Fig. 3).
In control studies, methylene blue itself had no effect on
myocyte contractility over the same time course as these
experiments. However, superfusion of methylene blue for
-10
□ BK BK + L-NAME BK + Indo
Fig. 4. Cardiac myocytes in coculture with endothelium. Change in con¬
traction amplitude after addition of 10"7 M bradykinin (BK), ± 10~4 M
AN'-nitro-L-arginine methyl ester (l-NAME), and ± 10~5 M in¬
domethacin (Indo). Differences are expressed as %reduction of control
contractions. Values are means ± SE of 12 (control ± BK), 11 (BK ±
l-NAME), and 6 (BK ± Indo) experiments. * P < 0.03. ** P < 0.01.
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Table 1. Isolated guinea pig cardiac myocytes with cultured endothelium: effect of 10 7 M bradykinin-stimulated
























Values are means ± SE of 12 [control ± bradykinin (BK)], 11 [!VG-nitro-l-arginine methyl ester (l-NAME) ± BK], and 6 (indomethacin :
experiments.
BK)
In control experiments without endothelium, bradyki¬
nin had no effect on contraction amplitude (fractional
shortening: control 3.7 ± 0.4% vs. 3.8 ± 0.4% in the
presence of bradykinin, n = 8) and did not affect either
time to peak contraction or relaxation time (data not
shown). In further control studies on isolated myocytes
l-NAME had no significant effect (+1.0 ± 3.6% increase)
on contraction amplitude (n = 9, P = not significant).
Figure 5 shows the effect of direct superfusion with
10"6 M and 10-5 M NO solution on myocyte contrac¬
tion amplitude compared with control. Nitrogen-gassed
control solution had no effect on myocyte contraction;
thus the effect of the NO solution was not due to hy¬
poxia. The reduction in contractility seen with the NO
solutions was similar to that caused by 3 x 10~5 M so¬
dium nitroprusside.
The stable cGMP analogue, 8-BrcGMP, caused a con¬
centration-related reduction in myocyte contractility,
similar in magnitude to the effect of sodium nitroprusside
(Fig. 6).
discussion
In the present study we have shown that the contrac¬
tion of cardiac myocytes is attenuated by NO from endo¬
thelium, NO from sodium nitroprusside, or NO in aque¬
ous solution. The effect of stimulated endothelium on
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itor of NO synthase, l-NAME. Importantly, l-NAME
had no effect on isolated myocyte contraction in control
studies. In a previous study, we showed that another spe¬
cific NO synthase inhibitor, A^'-monomethyl-l-arginine,
did not affect contractility of healthy cardiac myocytes
(1). Therefore, as in our study of myocyte behavior in
endotoxic heart failure (2), it appears that cardiac myo¬
cytes themselves do not synthesize appreciable NO in
their normal state and also that l-NAME has no other
effects on the contractile apparatus.
Direct superfusion with a solution of dissolved NO had
an effect similar to sodium nitroprusside, causing a sub¬
stantial reduction in myocyte contractility. Although the
amount of NO converted to nitrite on exposure to air
within the cell bath is unknown, because the NO solution
was protected from exposure to air until it reached the
cell under study, sufficient NO from a solution of ~10~6
M could reach the myocytes unchanged with an effect
similar to 3 X 10-5 M sodium nitroprusside. A maximal
effect was seen at 10~6 M NO, thus cardiac myocytes are
more sensitive to NO than to either sodium nitroprusside
or the stable analogue of the second messenger of NO,
8-BrcGMP. A relatively high concentration of 8-Brc-
GMP was needed, consistent with the natural amplifica¬
tion of a biological signal, whereas receptor-mediated
events, e.g., stimulation by NO, are amplified by the sec¬
ond messenger systems. Alteratively, this may reflect the




















Fig. 5. Effect of 10~6 and 10-6 M NO solutions and N2 solution on
myocyte contraction amplitude. NO, NO-Tyrode solution; N2, N2-bub-
bled Tyrode. Differences are expressed as %reduction of control con¬
tractions. Values are means ± SE of 5 (10~6 M NO), 5 (10~5 M NO), and
13 (N2) experiments. * P < 0.05. ** P < 0.01.
6 5
Fig. 6. Effect of 10-6 to 3 x 10-5 M 8-bromoguanosine 3',5'-cyclic mono-
phophate (8-BrcGMP) on myocyte contraction amplitude. Differences
are expressed as %reduction of control contractions. Values are means
± SE of 5-7 experiments. P < 0.025 at each concentration of 8-BrcGMP
compared with baseline contraction.
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The lack of response of myocytes to either GTN or
ISDN suggests that these cells, unlike vascular smooth
muscle cells (5), do not possess the plasma membrane
enzyme necessary for the liberation of NO from those
compounds. NO solution and sodium nitroprusside had a
greater effect on contraction amplitude than did stimu¬
lated endothelium, probably because the local concentra¬
tion of NO generated within the myocyte from the nitro¬
prusside, or administered directly, was higher than that
made available by exogenous stimulation of endothelium.
In support of the hypothesis that important interac¬
tions exist between vascular lining cells and the myocar¬
dium, previous studies have shown that endocardial
endothelium influences adjacent myocardial cells by re¬
leasing at least two humoral factors that have opposing
effects on papillary muscle contraction (23). This was
first described by Brutsaert and co-workers (4), who
showed that damage to the endocardial surface of the
papillary muscle causes a reduction of ~20% (at 2.5 mM
Ca2+) in maximum isometric tension produced by the
muscle, brought about by an earlier onset of isometric
relaxation but with no effect on the velocity of contrac¬
tion. This effect occurs in endocardium-intact prepara¬
tions with administration of lipid-soluble analogues of
cGMP or with sodium nitroprusside and atrial natriuretic
peptide (substances that increase myocardial cGMP by
stimulating soluble and particulate guanylate cyclase, re¬
spectively), which reduce papillary muscle contractility in
a manner similar to endocardial damage (4, 22, 23). From
experiments using cultured endocardial cells on beads in
a cascade system, endocardial endothelium appears to
release both EDRF and an as-yet-unidentified substance
that both augments contraction and prolongs relaxation
(23). Restoration of endocardial products to endocardi¬
um-damaged papillary muscles both increases the force of
isometric contraction and prolongs the relaxation phase
after contraction in this system. The quantitative rela¬
tionship between this as-yet-unknown endocardial prod¬
uct and endocardial EDRF is yet to be fully established,
although the unidentified contraction-prolonging factor
appeared to be dominant in these experiments (22).
The effect of sodium nitroprusside in papillary muscles
(23) is of similar magnitude to the reduction in contrac¬
tion seen in the present study. In papillary muscle exper¬
iments, small changes in time-dependent variables can be
demonstrated. These changes are within 20 ms (23), and
whereas our studies detected no effects on either times to
peak contraction or relaxation times, this may because
the time resolution of our videomicroscopy edge-detec¬
tion device is itself of the order of 20 ms.
Implicit in the hypothesis for the present study is that
coronary microvascular endothelium releases NO, but
there is yet no direct evidence that this occurs. We used
nonenzymatically cultured bovine aortic endothelium for
the cardiac myocyte-endothelium coculture experiments,
since it is both readily obtained and a known source of
NO. But important differences exist between the endo¬
thelium lining large arteries and endothelium within the
microvasculature. For example, coronary microvessels are
less sensitive than the aorta to the exogenous nitrova-
sodilator, GTN, but relax equally to NO solution, albeit at
a higher concentration (20). This implies that metabo¬
lism of organic nitrates in the coronary microvasculature
is less efficient than elsewhere in the circulation, perhaps
because of a relative deficiency of the enzymes required
(5) or a deficiency of available sulfhydryl groups neces¬
sary for generation of NO from GTN. Importantly, NO
has been shown to be a vasodilator in microvascular prep¬
arations from diverse parts of the peripheral circulation
(6, 10, 15, 27). It has been demonstrated recently in iso¬
lated, perfused hearts that 5-hydroxytryptamine stimu¬
lates NO release from the coronary microvasculature,
measured by coronary sinus nitrite sampling, and this is
accompanied by a reduction in the time to reach peak
ventricular pressure (21). These preliminary data suggest
that coronary microvascular endothelium, like microvas¬
cular endothelium elsewhere, is capable of releasing fac¬
tors that modulate nearby muscle contraction.
Support for a functional relationship between NO and
the myocardium comes from three recent reports. Finkel
et al. (7) showed that the negative inotropic effects of
inflammatory cytokines on papillary muscle are mediated
by generation of NO within the muscle itself. Schulz and
colleagues (19) demonstrated the presence of both the
constitutive and inducible forms of the NO synthase en¬
zyme in rat cardiac myocytes, and we have shown that in
experimental endotoxemia cardiac myocyte contractility
is markedly impaired by a mechanism involving NO pro¬
duction within the myocytes themselves (2). Thus cardiac
myocytes contain the biochemical apparatus necessary to
both generate and handle NO. Our evidence from the
present study that healthy cardiac myocytes are sensitive
to exogenous NO in three different delivery systems sup¬
ports the hypothesis that microvascular endothelium in¬
fluences cardiac myocyte contraction by activation of
NO-sensitive guanylate cyclase, although NO production
by microvascular endothelium within the heart remains
to be demonstrated.
The mechanism by which elevation of cGMP may
cause a reduction in myocyte contraction is not well un¬
derstood. In frog cardiac myocytes, cGMP inhibits the
L-type inward calcium channel current (/Ca) by stimula¬
tion of adenosine 3',5'-cyclic monophosphate (cAMP)
phosphodiesterase, but in rat ventricular myocytes
cGMP predominantly inhibits this calcium current by a
mechanism involving cGMP-dependent protein kinase,
independent of any effect on cAMP levels (13, 25). Fur¬
thermore, cGMP has both stimulatory and inhibitory ac¬
tions on different phosphodiesterases in rat cardiac my¬
ocytes and under certain experimental conditions has a
stimulatory effect on ^Ca (13). Over the short time course
of our experiments methylene blue, an inhibitor of gua¬
nylate cyclase, reversed the effects of NO from sodium
nitroprusside. However, superfusion with methylene blue
for prolonged periods >30-60 min caused the cells to
contract much more strongly before fibrillating. Whether
this represents an action mediated by changes in cGMP
or some toxic action of methylene blue was not demon¬
strated in our system.
An alternative explanation of the effect of NO on car¬
diac myocytes is that the elasticity of proteins forming
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the cytoskeleton, rather than the actin-myosin myo¬
fibrils, is modified by NO. Important changes in cytosk-
eletal proteins occur in ischemia (24) and in cardiomy¬
opathy (18), but these changes probably evolve over a
long time course. Whether NO can cause transient
changes in cellular ultrastructure has not been described.
That NO affects cardiac myocyte contractility may
have important consequences. It may be that in normal
hearts, capillary endothelium produces EDRF, which has
a tonic effect on contraction of nearby myocytes. With
the development of cardiac hypertrophy or dilatation in
disease states, the normal architecture and relationship
between microvasculature and myocytes becomes dis¬
turbed with increased diffusion distance between endo¬
thelial cell and cardiac myocyte. Subsequent loss or at¬
tenuation of the tonic influence of NO on myocyte
contractility may then be detrimental to myocardial func¬
tion. It is of interest that sodium nitroprusside, but not
the organic and more commonly used nitrates, ISDN and
GTN, was metabolized to generate NO within cardiac
myocytes. In vivo, this could be masked by the wide¬
spread hemodynamic changes after nitrovasodilator ad¬
ministration. In patients with unstable angina, sodium
nitroprusside showed no difference with respect to hemo¬
dynamic changes when compared with GTN (3); it may
be that vascular smooth muscle is more sensitive than
cardiac muscle to the actions of sodium nitroprusside,
and thus vasodilator effects are seen before changes in
myocardial contractility develop.
In conclusion, our results show that the contraction of
isolated cardiac myocytes is reduced by NO derived from
either endothelium or sodium nitroprusside or adminis¬
tered directly. Because the coronary microcirculation is
in such close proximity to cardiac myocytes, endotheli-
um-derived NO may have an important effect on myo¬
cardial contractility.
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Brady, Adrian J. B., Philip A. Poole-Wilson, Sian E.
Harding, and John B. Warren. Nitric oxide production
within cardiac myocytes reduces their contractility in endotox¬
emia. Am. J. Physiol. 263 (Heart Circ. Physiol. 32): H1963-
H1966, 1992.—We investigated whether increased nitric oxide
(NO) synthase activity within cardiac myocytes contributes to
the depressed cardiac contractility observed in endotoxic shock.
Isolated ventricular myocytes were studied to examine the ef¬
fects of substrates and inhibitors of NO synthase on myocyte
contractility. When stimulated electrically, the resting length of
myocytes from control animals shortened by 5.3 ± 0.3% (means
± SE, n = 32). Baseline contraction of myocytes from endo-
toxin-treated animals was reduced to 3.0 ± 0.3% (n = 17, P <
0.001). The NO synthase inhibitor iVG-nitro-l-arginine methyl
ester (l-NAME, 10-4 M) had no effect on myocytes from con¬
trol animals, but it increased the contraction of myocytes from
endotoxin-treated animals by 40% (fractional shortening in¬
creased to 4.3 ± 0.4%, P < 0.01). Similar results were obtained
with ArG-methyl-l-arginine. The effect of l-NAME could be
reversed by excess l-arginine, but not d-arginine. The effect of
endotoxin was abolished by dexamethasone pretreatment. Me¬
thylene blue also reversed the effects of endotoxin but had toxic
effects on myocytes. Agents that either prevent synthesis or the
effects of NO reverse the depression of myocyte contraction
seen following endotoxin treatment.
lipopolysaccharide; nitric oxide synthase; /VG-nitro-l-arginine
methyl ester; endotoxic shock
endotoxic shock is characterized by profound sepsis,
hypotension, multiple organ failure, and extremely high
mortality. In the early stages cardiac output is increased
as peripheral resistance decreases, but later myocardial
contractility itself declines, for reasons that are not well
understood (4, 11, 13, 16). Recent evidence suggests that
the fall in peripheral resistance, which is refractory to
vasoconstrictors, is caused by the induction of nitric
oxide (NO) synthase (9). Two forms of NO synthase
have been identified (9). The first is the constitutive,
calcium-dependent enzyme, which synthesizes the ma¬
jor component of endothelium-derived relaxing factor.
The second, which is induced by endotoxin or cytokines,
predominates in vascular smooth muscle with much
lower levels in endothelium. This second form can be
inhibited by corticosteroids. In both patients with septic
shock (12) and in animal models (10, 15, 17, 19), it has
recently been demonstrated that inhibition of this en¬
zyme with the NO synthase inhibitors AIG-nitro-l-argi-
nine methyl ester (l-NAME) and /VG-monomethyl-l-
arginine (l-NMMA) causes dose-dependent increases in
blood pressure and systemic vascular resistance. Thus
induction of NO synthase may represent a common
pathway by which different inflammatory mediators in
endotoxic shock cause vasodilatation (10).
With the use of a citrulline assay, the inducible form
of NO synthase has been detected in cardiac ventricular
myocytes isolated from endotoxin-treated rats. Endo¬
toxin also caused a corresponding elevation in guanosine
3',5'-cyclic monophosphate (cGMP) content of the my¬
ocardium (14). Preliminary evidence from our labora¬
tory has shown that the contraction of normal cardiac
myocytes can be attenuated by nitric oxide derived from
either endothelium or from sodium nitroprusside (2, 3).
The hypothesis tested in the present study is that pro¬
duction of NO within the myocytes themselves contrib¬
utes to the reduced cardiac contractility seen in endo¬
toxic shock. This study was designed to examine
whether contractility of cardiac myocytes was reduced
by endotoxin treatment of animals, and if so, whether
inhibition of the synthesis or transduction of NO would
modify this attenuation.
methods
Guinea pig cardiac ventricular myocytes were isolated by en¬
zymatic digestion, as described previously (6). A drop of myo¬
cyte suspension was placed in a 200-pl perspex chamber on the
stage of an inverted microscope. The suspension was superfused
at 2 ml/min with 2 mM calcium Krebs-Henseleit (KH) buffer
(containing in mM: 119.1 NaCl, 4.7 KC1, 0.94 MgS04, 1.2
KH2P04, 25 NaHC03, and 11.5 glucose) and bubbled with 95%
02-5% C02 at 32 ± 0.5°C. Temperature was monitored by a
thermistor in the cell bath. Cells were electrically stimulated to
contract using a bipolar stimulator delivering 30 V/4 ms pulses
at 0.5 Hz.
Contractility of individual myocytes was determined as de¬
scribed in detail elsewhere (7). Briefly, contraction amplitude
and velocity of shortening of electrically stimulated myocytes
were recorded using a video microscopy-length detection system
and analyzed by computer-signal averaging. This system had a
time resolution of 20 ms and a spatial resolution of 1 in 256,
which allowed typically 10-15 sampling points within a single
contraction and relaxation. Six consecutive contractions were
signal averaged to produce data under each particular set of
conditions. Myocyte contraction amplitude was calculated as a
percentage of the resting length, and time to peak contraction
and time from peak contraction to return to 90% of resting
length (90% relaxation time) were recorded. Criteria were de¬
fined as previously described (6) to identify healthy, viable,
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isolated myocytes: 1) only rod-shaped cells without sarcolemmal
blebs were examined; 2) cells that exhibited spontaneous con¬
tractions were excluded; 3) cells that displayed a variable base¬
line contraction to electrical stimulation at 2 mM calcium were
rejected.
Animals treated with endotoxin (lipopolysaccharide, Escher¬
ichia coli serotype 055:B5; Sigma, Poole, Dorset, UK) were ad¬
ministered (4 mg/kg) intraperitoneally, 4 h before the animals
were killed. In some cases, an intravenous injection of dexa-
methasone (4 mg/kg; David Bull, Warwick, UK) was given 1 h
before injection of endotoxin.
Once stable contraction had been achieved, myocytes were
exposed for 10 min to NO synthase inhibitors and substrates,
and values obtained were compared with the mean of control
contractions measured both before and after exposure to each
drug. All recordings were made within 45 min of stabilization to
avoid the decline in myocyte contraction amplitude, which is
seen in experiments lasting longer than 2-3 h. Some experi¬
ments were performed in the presence of the guanylate cyclase
inhibitor, methylene blue (David Bull Laboratories). In these
experiments, recordings were made after 15 min of exposure and
compared with baseline before administration. The NO syn¬
thase inhibitors l-NAME and l-NMMA and substrates l-argi-
nine and d-arginine were obtained from Sigma.
Statistical differences between contraction of control myo¬
cytes and myocytes from endotoxin-treated animals, and differ¬
ences between baseline contraction and contraction under dif¬
ferent pharmacological conditions, were tested using Student's
two-tailed t test for paired data. Values are expressed as means
± SE.
results
Effect of endotoxin treatment on contraction amplitude
of cardiac myocytes. Figure 1 shows the effect of endo¬
toxin treatment on myocyte shortening. The contraction
amplitude of myocytes isolated from endotoxin-treated
animals was reduced by 46% (P < 0.001) compared with
cells from control animals. The reduced contractility of
myocytes from endotoxin-treated animals was partly re¬
versed by the nitric oxide synthase inhibitor l-NAME,
whereas l-NAME had no effect on control cells. Pretreat-
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Fig. 1. Effect of endotoxin treatment on fractional shortening of cardiac
myocytes. LPS, lipopolysaccharide (4 mg/kg ip) injection 4 h before
death; l-NAME, JVG-nitro-l-arginine methyl ester 10~4 M; Dex, dexa¬
methasone (4 mg/kg iv) injection 5 h before death. Values are means ±
SE of 32 (normal), 17 (endotoxin-treated animals), and 7 (endotoxin +
dexamethasone) myocytes. ** P < 0.001; * P < 0.05, compared with
normal myocytes.
toxin. Addition of l-NAME to cells from animals treated
with both dexamethasone and endotoxin had no further
effect (fractional shortening 5.0 ± 0.9%; n = 7, P = NS,
compared with normal cells).
Exposure of cells from endotoxin-treated animals to 5
X 10"6 M methylene blue for 15 min increased contrac¬
tion amplitude substantially by 157 ± 27% (fractional
shortening increased from 2.3 ± 0.4% of cell length to 6.1
± 1.4% of cell length; n = 7, P < 0.005). Interestingly,
exposure of normal control myocytes to methylene blue
also increased contraction amplitude at 15 min (by 54 ±
11%, n = 8, P < 0.01). In experiments with myocytes
from both normal and endotoxin-treated animals, some
cells showed signs characteristic of calcium overload with
hypercontractility and fibrillation, after a 20-min super-
fusion with methylene blue. Four of seven myocytes from
endotoxin-treated animals and four of eight normal my¬
ocytes failed to return to baseline contraction after expo¬
sure to methylene blue.
Endotoxin treatment had no effect on either time to
peak contraction or 90% relaxation time compared with
normal controls. Time to peak contraction was 0.10 ±
0.02 vs. 0.12 ± 0.02 s, relaxation time 0.32 ± 0.02 vs. 0.30
± 0.03 s, and values are means ± SE of 9 normal controls
and 17 endotoxin-treated animals. Addition of l-NAME
had no effect on either of these parameters (data not
shown). Dexamethasone itself had no effect on myocyte
contraction in control studies of normal cells (data not
shown).
Effect of substrates and inhibitors of NO on myocyte
contraction amplitude. Figure 2 shows the effects of dif¬
ferent substrates and inhibitors on contraction of myo¬
cytes from endotoxin-treated guinea pigs. Addition of
10~4 M A^-nitro-l-arginine methyl ester (l-NAME) to
myocytes from endotoxin-treated animals increased con¬
traction amplitude by 40 ± 6.6% (P < 0.001, n = 17).
£3 l-name hl-name+l-arg
u1 l-name+d-arg □ lnmma
Fig. 2. Percentage change in contraction amplitude induced by sub¬
strates and inhibitors of nitric oxide (NO) synthase on cardiac myocytes
from endotoxin-treated guinea pigs. l-Arg, l-arginine 10-3 M; d-Arg,
d-arginine 10-3 M; l-NMMA, NG-monomethyl-l-arginine 10~4 M.
Values are means ± SE of 17 (l-NAME), 8 (l-arginine + l-NAME), 6
(d-arginine + l-NAME), and 5 (l-NMMA) experiments. ** P < 0.01;
* P < 0.05, compared with baseline measurements.
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Contractility returned to baseline within a 10-min wash¬
out period. M'-methyl-l-arginine gave similar results.
The effect of l-NAME was reversed by coadministration
of l-arginine (10~3 M) but not d-arginine. l-NAME
(10~4 M) had no effect on contraction of normal myo¬
cytes isolated from control animals (fractional shortening
differed by 0.2 ± 0.3%; n = 7, P = NS).
discussion
We have shown that endotoxin treatment of guinea
pigs causes a substantial reduction in the contractility of
isolated cardiac myocytes. About half of this reduction
can be reversed by specific NO synthase inhibitors, and
their effect can be overcome by an excess of l-arginine,
the l-isomer amino acid from which NO is generated, but
not by the inactive d-isomer. These results suggest that
NO is being produced within the myocytes themselves
and that this NO has an attenuating effect on myocyte
contraction.
Pretreatment with dexamethasone prevents the in¬
duction of inducible NO synthase within cardiac myo¬
cytes (14). In the present study prior administration
of dexamethasone prevented the reduction in contractil¬
ity caused by endotoxin, and subsequent addition of
l-NAME had no effect. This is further evidence for in¬
ducible NO synthase within the heart contributing sub¬
stantially to the reduction in contractility occurring in
endotoxic shock. Normal cardiac myocytes are reported
to contain detectable amounts of constitutive NO syn¬
thase (14), although this does not appear to generate
effective levels of NO, since in the present study and in a
previous one from our laboratory (1), NO synthase inhib¬
itors had no effect on contractility of cardiac myocytes
isolated from healthy animals.
NO acts within cells by stimulating soluble guanylate
cyclase to increase levels of cGMP, and this can be in¬
hibited by methylene blue. We have shown previously
that the contraction-attenuating effect of the NO donor
sodium nitroprusside on normal myocytes can be re¬
versed by methylene blue (3). Exposure to methylene blue
in the present study caused a large increase in contraction
amplitude of cells from endotoxin-treated animals. Inter¬
estingly, contraction of normal myocytes was also in¬
creased, although to a lesser extent. In both groups of cells
administration of methylene blue caused some of the my¬
ocytes to become hypercontractile, with contractions
characteristic of calcium overload. It may be that expo¬
sure to methylene blue causes progressive injury to car¬
diac myocytes, perhaps by increasing the permeability of
the cells to extracellular calcium. We recorded contrac¬
tion amplitude after a 15 min exposure to methylene blue,
because an appreciable inotropic effect was usually ob¬
served by this time. The explanation why contractility of
some of the cells did not return to baseline when meth¬
ylene blue superfusion was discontinued is not clear.
Whether the effect of methylene blue is limited to
changes in cGMP concentration, or whether methylene
blue has a direct toxic effect, is not explained by our
study.
NO synthase inhibitors did not completely reverse the
effect of endotoxin. This suggests that factors other than
NO might contribute, although we cannot be sure that
NO production was blocked completely by the NO syn¬
thase inhibitors. While endotoxin may itself be cytotoxic
to myocytes, many other inflammatory mediators are re¬
leased in endotoxic shock. Recent attention has focused
on the use of anti-tumor necrosis factor (TNF) antibodies
in septic shock, which appears to improve left ventricular
function in such patients (18). In our study the effect of
lipopolysaccharide was abolished by pretreatment with
dexamethasone. Steroids not only prevent the induction
of NO synthase by endotoxin but also prevent the gener¬
ation of many inflammatory cytokines, which might im¬
pair myocyte contractility. Such cytokines may them¬
selves act by induction of NO synthesis within the heart;
in a recent study the cytokines TNFa, interleukin-2, and
interleukin-6 inhibited myocardial papillary muscle con¬
traction by a NO-dependent mechanism (5).
In animal models of endotoxic shock, recent studies
have shown that NO synthase inhibitors were ineffective
in small doses, whereas larger doses caused intense pe¬
ripheral vasoconstriction and cardiovascular collapse (10,
19). It appears that at high doses inhibition of both the
normal, constitutive NO synthase and the inducible NO
synthase occurs, and complete inhibition of endogenous
NO synthesis then allows unopposed peripheral vasocon¬
striction, deleterious in endotoxic shock (10, 19). The
authors suggested that either coadministration of a NO
donor with a NO synthase inhibitor or selective inhibi¬
tion of the inducible form of NO synthase might be of
benefit in this condition.
Our study is the first to show direct loss of contractility
of cardiac myocytes in endotoxic shock, associated with
the induction of NO synthase and production of NO
within the myocytes. Contractility was restored partially
by NO synthase inhibitors in keeping with two recent
clinical case reports, where administration of NO syn¬
thase inhibitors was associated with a short-term in¬
crease in both blood pressure and cardiac ouput (12).
Methylene blue was shown in another case report to be of
short-term benefit in liver failure, and this benefit was
considered to be due to inhibition of NO in the circula¬
tion and also possibly within the heart (8). In the present
study we have found methylene blue to be toxic to myo¬
cytes after prolonged administration, although the rea¬
sons for this effect are not yet clear. The loss of contrac¬
tility after endotoxin exposure can be prevented by
pretreatment of animals with dexamethasone, but it is
generally accepted that steroid therapy is of no benefit to
patients with endotoxic shock. Until a specific inhibitor
of inducible NO synthase is available, careful titration of
a NO synthase inhibitor, perhaps combined with a NO
donor, may be a possible treatment in endotoxic shock,
not only by reducing the profound peripheral vasodilata¬
tion (19) but also by augmenting myocardial contraction.
In summary, we have shown that contractility of car¬
diac myocytes from endotoxin-treated animals is sub¬
stantially reduced. This appears to be due to induction of
NO synthase and subsequent production of NO within
the myocytes themselves, since inhibitors of NO and NO
synthase can reverse this reduction. Endotoxic shock is
associated with myocardial depression, exacerbating the
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profound hemodynamic changes that occur in this con¬
dition. NO production within cardiac myocytes may con¬
tribute to the contractile impairment in endotoxic heart
failure.
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Circulatory failure in septic shock
Nitric oxide: too much of a good thing?
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Septicaemia and accompanying septic shock
account for a substantial number of hospital
deaths, despite appropriate antibiotic and
supportive therapy. In the United States an
estimated 100 000 patients die from sepsis in
hospital each year.1 One of the characteristic
features of septic shock is profound hypoten¬
sion caused by a decrease in peripheral vascu¬
lar resistance. This hypotension is unusually
resistant to both volume replacement and
vasoconstrictor agents. In the earliest stages
of spetic shock stroke volume and cardiac
output are maintained or even increased;
later, ventricular dilatation develops with a
reduction in ejection fraction.M If patients
survive, ventricular size and function return
to normal as the infection is controlled and
circulatory function restored. Recently,
important advances have been made in our
understanding of the pathophysiology and
treatment of this frequently lethal condition.
Gram negative bacteria account for
approximately 30% of cases of septic shock.5
Bloodborne infection liberates endotoxin, the
lipopolysaccharide component of the bacterial
cell wall, into the circulation. Endotoxin and
the organisms themselves activate host
defense and inflammatory systems, including
the complement, kinin, and coagulation cas¬
cades; the interleukins; tumour necrosis fac¬
tor (TNF) and other endogenous mediators
of inflammation; leucocytes; and platelets.
These together generate the acute inflamma¬
tory response to bacteraemia. Although many
inflammatory mediators are themselves
vasoactive, recent work has shown that the
hypotension and cardiac depression of septic
shock are mediated by important changes




nitric oxide, modulate blood flow within the
vasculature (for review see Moncada et al).6
Nitric oxide, synthesised from the amino acid
L-arginine by a constitutive nitric oxide syn¬
thase enzyme, is present in endothelial cells.
It is released tonically in small amounts to act
on adjacent vascular smooth muscle, causing
relaxation and vasodilatation. This mecha¬
nism exists in health to regulate blood flow
within tissue.67 Endothelium-derived nitric
oxide also inhibits platelet adhesion and
aggregation, maintaining an antithrombotic
luminal surface.
Nitric oxide synthase is also constitutively
expressed in other cell types. These include
some neural tissues; circulating neutrophils,
mast cells and platelets; pancreatic islet ft
cells; and renal macula densa cells.68
Production of nitric oxide seems to be a fun¬
damental and important mechanism of inter¬
cellular signalling in these cell types. By its
nature, nitric oxide is an unstable free radical
with powerful oxidant properties when high
local concentrations are achieved. Macro¬
phages produce large amounts of nitric oxide
when activated and this accounts for much of
their cytotoxicity against micro-organisms
and tumour cells.8-10 Nitric oxide also dam¬
ages iron-containing enzymes, for example
NADH, and can inhibit DNA synthesis in
some tumour cells.8
Abnormalities of nitric oxide production
in endotoxic shock
In endotoxic shock the presence of dissemi¬
nated foreign antigen, together with the
inflammatory response, causes an inducible
nitric oxide synthase to be generated in many
other cell types which do not normally
express this enzyme, including hepatocytes,
fibroblasts, and vascular smooth muscle.68
Subsequent production of large quantities of
nitric oxide leads not only to haemodynamic
instability but also to widespread production
of nitric oxide-based free radicals which have
the potential to cause considerable damage to
tissues. Evidence from clinical studies sup¬
ports this. Patients with endotoxic shock"
and cancer patients receiving interleukin-2
(IL-2) chemotherapy, a cytokine which acti¬
vates other endogenous cytokines to induce
nitric oxide synthase,12 excrete high concen¬
trations of nitric oxide metabolites.
Vascular smooth muscle is itself not a
source of nitric oxide in health. In endotoxic
shock production of nitric oxide occurs with¬
in the muscle layer of the vessel wall and this
causes excessive vasodilatation and hence a
reduction in peripheral vascular resistance.6
Analogues of the substrate L-arginine have
been developed that act as substrate
inhibitors of nitric oxide synthase. These
cause systemic vasoconstriction and a pressor
response in healthy animals by inhibiting con¬
stitutive nitric oxide production by the
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endothelium. In animals with experimental
endotoxic shock inhibitors of nitric oxide syn¬
thase reverse hypotension but also cause a
sustained increase in systemic vascular resis¬
tance, and at higher doses a decrease in car¬
diac output.13"15 A reduction in cardiac output
has also been seen with these agents in
healthy animals.131617 Whether this fall in car¬
diac output is secondary to the rise in vascu¬
lar resistance or to a direct effect of nitric
oxide synthase inhibitors on cardiac contrac¬
tility was not established by these studies.
Cardiac failure in endotoxic shock
Global deterioration of myocardial contractile
function in patients with endotoxic shock has
been established by clinical and radionuclide
studies.2"1 In healthy volunteers administra¬
tion of purified endotoxin causes reversible
depression of left ventricular function, in
addition to the expected reduction in sys¬
temic vascular resistance.18 Until recently, the
cause of myocardial depression in endotox-
aemia was considered to be a direct effect of
endotoxin or an inflammatory mediator on
myocardial tissue. The existence of a specific
circulating myocardial depressant substance
in endotoxic shock has been postulated but
not proven.4 Whereas coronary perfusion
abnormalities in patients with coexisting car¬
diac or coronary disease and endotoxic shock
may account for segmental abnormalities of
left ventricular function, in patients with
global myocardial impairment and endotoxic
shock the loss of function cannot be wholly
explained by changes in coronary flow.4 As in
the peripheral vasculature, multiple factors
exist which depress cardiac function in endo¬
toxic shock. However, there may be a com¬
mon pathway for such mediators to impair
myocardial contraction.
Overproduction of nitric oxide in the
peripheral vasculature accounts for the
vasodilatation and loss of vascular control in
endotoxic shock. The hypothesis that over¬
production of nitric oxide within cardiac
muscle contributes to impaired function has
now been tested. Studies of papillary muscles
and individual cardiac myocytes isolated from
healthy animals have shown that nitric-oxide-
donating drugs19 20 or nitric oxide itself
released from adjacent endocardium or
endothelium19 21 22 can modulate the contrac¬
tility of adjacent cardiac myocytes. In health
cardiac myocytes do not produce appreciable
amounts of nitric oxide.23 24 In experimental
endotoxaemia, or after administration of
inflammatory cytokines to isolated myocytes,
nitric oxide synthase enzyme is induced with¬
in cardiac myocytes.25 This activity and the
subsequent generation of nitric oxide within
the myocytes themselves25 is accompanied by
a substantial loss of contractile function,
compared with myocytes from healthy ani¬
mals.24 Both the generation of nitric oxide by
myocytes25 and their depression of contractil¬
ity24 can be reversed by specific inhibitors
of the nitric oxide synthase enzyme.
Pretreatment of animals with high dose corti¬
costeroids prevents the induction of this
enzyme and blocks completely the impair¬
ment of contraction.24 25 The cytokine TNFa
and the interleukins IL-6 and IL-2 can cause
marked depression of cardiac contraction in
isolated papillary muscles.26 This effect is
mediated by nitric oxide generation within
the cardiac muscle itself.26 Furthermore, there
is overproduction of nitric oxide within the
coronary microcirculation in experimental
endotoxic shock.27 This may not only perturb
coronary blood flow in the microvasculature
but may also depress cardiac contraction,
since current work has shown a moderating
influence of nitric oxide derived from vascular
endothelium on adjacent cardiac myocyte
contraction.22
Thus there seems to be a common mecha¬
nism in endotoxic shock contributing to both
cardiac and vascular dysfunction. As in the
peripheral vasculature, overproduction of
nitric oxide within the myocardium, at least
in experimental models, contributes impor¬
tantly to the loss of contractility seen in
patients with endotoxic shock.
Therapeutic strategies for the future
The cornerstones of treatment in septic shock
are appropriately selected antibiotics and
intensive support therapy. Molecular
approaches to treatment accompanied by
greater understanding of the pathophysiologi¬
cal mechanisms involved in endotoxic shock
have generated important additions to exist¬
ing therapy. Experimentally, pretreatment of
animals with corticosteroids prevents the
induction of the nitric oxide synthase enzyme
within the heart and the vasculature.2425 28 In
the clinical setting patients present with
established infection, too late for steroids to
be of benefit. This may explain in part the
results of previous clinical trials which
showed no benefit from corticosteroids in this
condition.5 29 30
New developments in the treatment of
endotoxic shock include a specific human
monoclonal IgM antibody to the lipid A
domain of endotoxin,31 although distribution
of this agent has recently been suspended
worldwide pending further clinical trials.
Another new therapy is TNF antibody. In a
pilot study inhibition of this mediator of
inflammation was shown to improve left ven¬
tricular function in patients with septic
shock.32 Whether there is also improvement
in mortality has not been demonstrated.
Excess nitric oxide in the cardiovascular
system seems to have a central role in endo¬
toxic shock, but existing inhibitors of the
nitric oxide synthase enzyme are not specific
for the inducible form of the enzyme which
accounts for this overproduction. In animal
models of endotoxic shock a small dose of
inhibitor blocked the excess production of
nitric oxide but higher doses inhibited nor¬
mal, endogenous nitric oxide production as
well,13-15 causing intense vasoconstriction and
cardiovascular collapse. The vasoconstriction
can be modulated by coadministration of
nitric-oxide-donating agents (drugs which act
like sodium nitroprusside) to replace the
nitric oxide normally present in the vascula¬
ture. An inhibitor specific for the inducible
nitric oxide synthase enzyme would be a
potential treatment but is not available.
Widespread inhibition of nitric oxide has
potentially serious side effects, for example
impairment of the normal anticoagulant
status of endothelium, and alteration of neuro¬
transmission. Moreover, a degree of vaso¬
dilatation may in fact be valuable, allowing
washout of toxic oxides of nitrogen from
tissues.6
Encouraging results have been described in
two recent clinical reports in which the non¬
specific inhibitors were used.33 34 In two
patients with septic shock, administration of
L-arginine analogues (drugs which compete
with L-arginine for the nitric oxide synthase
enzyme) caused short-term increases in blood
pressure. Cardiac output was increased in
one patient and decreased in the other.33 A
further intriguing report described short-lived
improvement in a patient with hepatic failure
after administration of methylene blue, an
agent that inhibits the effects of nitric oxide
on vascular tone.34 Methylene blue does not
inhibit the cytotoxic effects of nitric oxide.
Placebo controlled studies of nitric oxide syn¬
thase inhibitors in patients with septic shock
are underway.
Conclusion
One of the principal mechanisms causing car¬
diovascular depression in endotoxic shock is
an excessive production of nitric oxide both
in the heart and in the vasculature. Research
into the basic mechanisms of disease, in this
case endotoxic shock, has led the way to
potentially major advances in clinical prac¬
tice. Results from current trials are awaited.
AJBB is a Medical Research Council Clinical Training
Fellow. This work was supported by the British Heart
Foundation.
1 Parrillo JE, Parker MM, Natanson C, Suffredini AF,
Danner RL, Cunnion RE, et al. Septic shock in humans.
Advances in the understanding of pathogenesis, cardio¬
vascular dysfunction, and therapy. Ann Intern Med
1990;113:227-42.
2 MacLean LD, Mulligan WG, McLean APH, Duff JH.
Patterns of septic shock in man—a detailed study of 56
patients. Ann Surg 1967;166:543-62.
3 Parker MM, Shelhamer JH, Bacharach SL, Green MV,
Natanson C, Frederick TM, et al. Profound but
reversible myocardial depression in patients with septic
shock. Ann Intern Med 1984;100:483-90.
4 Ellrodt AG, Riedinger MS, Kimchi A, Berman DS,
Maddahi J, Swan HJC, et al. Left ventricular perfor¬
mance in septic shock: Reversible segmental and global
abnormalities. Am Heart J 1985;110:402-9.
5 Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz
CA, Balk RA, et al. A controlled clinical trial of high-
dose methylprednisolone in the treatment of severe sep¬
sis and septic shock. N Engl J Med 1987;317:653-8.
6 Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physi¬
ology, pathophysiology and pharmacology. Pharmacol
Rev 1991;43:109-42.
7 Vallance P, Collier J, Moncada S. Effects of endothelium-
derived nitric oxide on peripheral arteriolar tone in man.
Lancet 1989;ii:997-1000.
8 Nathan C. Nitric oxide as a secretory product of mam¬
malian cells. FASEBJ 1992;6:3051-64.
9 Lancaster JR, Hibbs JB. EPR demonstration of iron-nitro-
syl complex formation by cytotoxic activated
macrophages. Proc Natl Acad Sci USA 1990;87:1223-7.
10 Pellat C, Henry Y, Drapier J-C. IFN-gamma-activated
macrophages: detection by electron paramagnetic reso¬
nance of complexes between L-arginine-derived nitric
oxide and non-heme iron proteins. Biochem Biophys Res
Commun 1990;166:119-25.
11 Ochoa JB, Udekwu AO, Billiar TR, Curran RD, Cerra
FB, Simmons RL, et al. Nitrogen oxide levels in patients
after trauma and during sepsis. Ann Surg 1991 ;214:
621-6.
12 Hibbs JB, Westenfelder C, Taintor R, Vavrin Z, Kablitz
C, Baranowski RL, et al. Evidence for cytokine-
inducible nitric oxide synthesis from L-arginine in
patients receiving interleukin-2 therapy. J Clin Invest
1992;89:867-77.
13 Klabunde RE, Ritger RC. NG-monomethyl-L-arginine
(NMA) restores arterial blood pressure but reduces car¬
diac output in a canine model of endotoxic shock.
Biochem Biophys Res Commun 1991; 178:1135-40.
14 Nava E, Palmer RMJ, Moncada S. Inhibition of nitric
oxide synthesis in septic shock: how much is beneficial?
Lancet 1991;338:1555-7.
15 Wright CE, Rees DD, Moncada S. Protective and patho¬
logical role of nitric oxide in endotoxin shock.
Cardiovasc Res 1992;26:48-57.
16 Kilbourn RG, Jubran A, Gross SS, Griffith OW, Levi R,
Adams J, et al. Reversal of endotoxin-mediated shock by
NG-methyl-L-arginine, an inhibitor of nitric oxide syn¬
thesis. Biochem Biophys Res Commun 1990;172:1132-8.
17 Aisaka K, Gross SS, Griffith OW, Levi R. NG-methylargi-
nine, an inhibitor of endothelium-derived nitric oxide
synthesis, is a potent pressor agent in the guinea pig:
does nitric oxide regulate blood pressure in vivo.
Biochem Biophys Res Commun 1989;160:881-6.
18 Suffredini AF, Fromm RE, Parker MM, Brenner M,
Kovacs JA, Wesley RA, et al. The cardiovascular
response of normal humans to the administration of
endotoxin. N EnglJ Med 1989;321:280-7.
19 Smith JA, Shah AM, Lewis MJ. Factors released from
endocardium of the ferret and pig modulate myocardial
contraction. J Physiol 1991;439:1-14.
20 Brady AJB, Warren JB, Poole-Wilson PA, Williams TJ,
Harding SE. Differential metabolism of nitrovasodila-
tors by cardiac myocytes: sodium nitroprusside reduces
myocyte contractility [abstr]. Br J Pharmacol 1992;105:
96P. "
21 Shah AM, Henderson AH. Effects of endocardial damage
on myocardial contraction. In: Parratt JR, ed.
Myocardial response to acute injury. Basingstoke:
Macmillan, 1992; 153-69.
22 Brady AJB, Warren JB, Poole-Wilson PA, Williams TJ,
Harding SE. Nitric oxide attenuates cardiac myocyte
contraction. Am J Physiol (in press).
23 Amrani M, O'Shea J, Allen NJ, Harding SE, Jayakumar J,
Pepper JR, et al. Role of basal release of nitric oxide on
coronary flow and mechanical performance of the isola¬
ted rat heart. J Physiol 1992;456:681-7.
24 Brady AJB, Poole-Wilson PA, Harding SE, Warren JB.
Nitric oxide production within cardiac myocytes
reduces their contractility in endotoxemia. Am J Physiol
1992;263:H 1963-6.
25 Schulz R, Nava E, Moncada S. Induction and potential
biological relevance of a Ca2 " -independent nitric oxide
synthase in the myocardium. Br J Pharmacol
1992;105:575-80.
26 Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler
BG, Simmons RL. Negative inotropic effects of
cytokines on the heart mediated by nitric oxide. Science
1992;257:387-9.
27 Smith REA, Palmer RMJ, Moncada S. Coronary vasodila¬
tation induced by endotoxin in the rabbit isolated per¬
fused heart is nitric oxide-dependent and inhibited by
dexamethasone. BrJ Pharmacol 1991;104:5-6.
28 Rees DD, Cellek S, Palmer RMJ, Moncada S.
Dexamethasone prevents the induction by endotoxin of
a nitric oxide synthase and the associated effects on vas¬
cular tone: an insight into endotoxin shock. Biochem
Biophys Res Commun 1990;173:541-7.
29 Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard
MA, Long WM, et al. The effects of high-dose cortico¬
steroids in patients with septic shock. N Engl J Med
1984;311:1137-43.
30 The Veterans Administration Systemic Sepsis Cooperative
Study Group. Effect of high-dose glucocorticoid therapy
on mortality in patients with clinical signs of systemic
sepsis. N EnglJ Med 1987;317:659-65.
31 Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC,
Foulke GE, et al. Treatment of gram-negative bac¬
teremia and septic shock with HA-1A human mono¬
clonal antibody against endotoxin. N Engl J Med
1991;324:429-36.
32 Vincent J-L, Bakker J, Marecaux G, Schandene L, Kahn
RJ, Dupont E. Administration of anti-TNF antibody
improves left ventricular function in septic shock
patients. Chest 1992;101:810-5.
33 Petros A, Bennett D, Vallance P. Effect of nitric oxide
synthesis inhibitors on hypotension in patients with sep¬
tic shock. Lancet 1991;338:1557-8.
34 Midgley S, Grant IS, Haynes WG, Webb DJ. Nitric oxide
in liver failure. Lancet 1991;338:1590.
Clinical Science (1992) 83, 511-518 (Printed in Great Britain)
Editorial Review
511
Inflammatory injury in myocardial ischaemia
Adrian J. B. BRADY*t, Frances M. WILLIAMS* and Timothy j. WILLIAMS*
Departments of *Applied Pharmacology and fCardiac Medicine, National Heart and Lung
Institute, London, U.K.
INTRODUCTION
The presence of inflammatory cells in infarcted
myocardium was first described more than 50 years
ago [1], The importance of inflammatory processes
in successful healing after myocardial infarction was
revealed more recently when methylprednisolone
given to post-infarction patients caused a substantial
increase in both infarct size and deaths from ventri¬
cular rupture due to poor scar formation [2], This
indicated that inflammatory mechanisms are necess¬
ary for optimal repair after infarction. However, the
possibility exists that such inflammatory processes
may also damage nearby healthy or reversibly
injured myocardium. Since thrombolysis and angio¬
plasty have become so successful in relieving acute
myocardial ischaemia, the role of acute inflam¬
mation in these early stages of myocardial injury
has become the subject of intensive study.
There are experimental data to support the
hypothesis that restoration of arterial flow to ischae-
mic myocardium may in fact contribute to, or
hasten, cell death of some of the injured myocardial
cells. However, not all authors agree that injury
caused by ischaemia -reperfusion can be divided
reliably into that caused by the initial ischaemic
insult, and that resulting from subsequent inflam¬
matory processes. The possibility that such inflam¬
matory responses may bring about repair 'at a cost',
i.e. that viable myocardial tissue is consumed by the
early repair process, will be discussed in this review.
Current understanding of the underlying mecha¬
nisms will be described, in particular the contri¬
bution to myocardial injury of neutrophils, oxygen
free radicals and complement factors. The concept
of injured myocytes signalling their own destruction
will be discussed, and an outline of possible therapy
to augment the benefits of thrombolysis or acute
intervention will be considered.
NATURAL HISTORY OF INJURY INDUCED BY
ISCHAEMIA AND ISCHAEMIA-REPERFUSION
After irreversible coronary occlusion the earliest
manifestations of necrosis can be demonstrated in
myocyte organelles and contractile elements by elec¬
tron microscopy within 1 h [3], although gross and
microscopic changes do not become apparent until
6-8 h after the onset of ischaemia [4]. The features
of coagulative necrosis then appear: after about 8h
infiltration by neutrophils occurs, with the develop¬
ment of a zone of granulation tissue at the margin
of the infarct [1, 5], The infarct heals by digestion
of necrotic tissue by macrophages with subsequent
scar formation, and the infarct zone is replaced
gradually by fibrous tissue.
If reperfusion occurs after irreversible myocyte
injury, a characteristic pattern of contraction-band
necrosis appears rapidly, with myocyte swelling and
condensation of myofibrillar protein, disruption of
the sarcolemma and deposition of calcium within
the mitochondria [6-9], Ionic changes with a mas¬
sive influx of calcium into the cytoplasm occur and
the myocytes are killed both by cellular disruption
from hypercontraction, as well as loss of normal
aerobic metabolism. Large numbers of neutrophils
accumulate in the dead myocardium [10], although
whether they are involved in killing myocytes alive
at the time of reperfusion is uncertain.
After periods of up to 3 h of ischaemia, reperfused
myocardium is characterized by the early accumu¬
lation of neutrophils, first within the blood vessels
and then later within the injured myocardium
[11, 12]. There is recovery of some of the injured
myocytes and herein lies the central controversy of
recovery after a short period of ischaemic injury:
does the process of reperfusion with delivery of
acute inflammatory components cause irreversible
injury of myocytes which might have regained
normal function, or does reperfusion merely hasten
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the death of cells irretrievably injured? This
question remains unresolved, but in the next section,
evidence is presented that interference with some of
these inflammatory processes reduces ultimate
infarct size.
Short periods of myocardial ischaemia are accom¬
panied by a reduction in contractile function,
termed myocardial 'stunning' [13]. This appears to
be due to alteration in the contractile function of
myocytes, without evidence of microvascular
obstruction by damaged endothelium or trapped
neutrophils. There is recovery from myocardial
stunning, and the time course of this recovery is
related to the duration of ischaemia. After 1 min of
coronary occlusion active shortening in the affected
area returns within 20 s, and is complete by 30 min
[13]. Regional loss of myocardial function after
15 min of ischaemia may take 60 min to recover.
Even after prolonged ischaemia, some return of
myocardial function in the affected area may be
seen as late as 1-2 weeks after the event. For
laboratory studies of reperfusion injury, periods of
ischaemia of 30-90 min are usually employed so that
a moderate degree of myocardial injury is achieved.
PATHOGENESIS OF INFLAMMATORY INJURY
AFTER MYOCARDIAL ISCHAEMIA
There is abundant evidence implicating neutro¬
phils as important mediators of injury in ischaemia-
reperfusion damage. Depletion of circulating neutro¬
phils by means of cytotoxic agents [14], anti-
neutrophil antibodies [15] or leucocyte filters [16]
are all reported to reduce myocardial infarct size in
experimental models. The protective action of
agents such as ibuprofen and prostacyclin in models
of myocardial infarction [17, 18] is also associated
with a reduction in neutrophil accumulation.
It should be borne in mind, however, that in a
few studies some of these interventions have been
reported to be without effect [11, 19]. This discre¬
pancy in results may be due to methodological
differences, for instance the manner in which tissue
viability was assessed or whether myocardial blood
flow was measured. Measurement of myocardial
blood supply is of particular importance in canine
models, which have been used for a large propor¬
tion of these studies. In this species, the myo¬
cardium has a variable, but often substantial, colla¬
teral blood supply. It is therefore of importance to
measure the blood flow within the ischaemic region.
In contrast, other animals, such as the rabbit, have
virtually no collateral circulation, which is more
akin to the situation in patients presenting with
acute myocardial infarction in the absence of a long
prior history of angina pectoris. Much of the con¬
troversy over interpretation of experimental findings
from canine studies in vivo is due to dispute over
the contribution made by collateral arteries.
Role of inflammatory mediators in neutrophil activation
and accumulation
The role of inflammatory mediators in eliciting
neutrophil infiltration into myocardial tissue after
ischaemic injury has been the subject of consider¬
able interest. Identification of the relevant mediators
would provide an obvious target for modulation of
neutrophil function. To date, a definitive role for
any one mediator has not been assigned, although
there is evidence implicating two well-established
neutrophil chemoattractants, the complement frag¬
ment, C5a, and the eicosanoid, leukotriene B4
(LTB4).
There is a large body of experimental evidence
indicating that activation of the complement path¬
way occurs after episodes of myocardial ischaemia,
including alterations in the concentration of circu¬
lating complement components [20, 21]. This acti¬
vation is central to the inflammatory response, since
C5a which is generated during this process is one of
the most potent neutrophil chemoattractants in vivo.
The complement components C3, C4 and C5 have
been detected immunohistochemically on the surface
of myocytes in necrotic areas of baboon myo¬
cardium [22], whereas the terminal complement
complex C5b-9 has been identified in the marginal
zones of human infarcts [23]. Accumulation of
radiolabeled Clq has also been reported in
infarcted dog myocardium. Interestingly, co-
localization of neutrophils in the same region of
myocardium was observed in this study [24],
Evidence implicating complement activation in
the inflammatory response has been provided by
studies carried out using cobra venom factor, which
depletes circulating complement. In experimental
models of myocardial infarction, the use of cobra
venom factor has resulted in a reduction in both
myocardial infarct size and in the accumulation of
neutrophils [22, 25]. More recently, a soluble form
of complement receptor 1 (sCRI) has been deve¬
loped, which inhibits complement activation by
binding the C3 and C5 convertases, resulting in
proteolytic inactivation of C3b and C4b. In a rat
model of myocardial infarction, sCRI also reduced
infarct size and neutrophil infiltration [26]. Treat¬
ment with cobra venom factor is also reported to
reduce the neutrophil chemoattractant activity of
coronary sinus blood after myocardial ischaemia,
suggesting that a product of complement activation
is involved [27]. Furthermore, neutrophil chemo¬
attractant activity in post-ischaemic cardiac lymph
can be neutralized by antibodies to C5a [28],
The eicosanoid LTB4 also acts as a neutrophil
chemoattractant in vivo [29, 30]. LTB4 is a product
of neutrophil activation and has been detected in
increased quantities in infarcted myocardium [31].
In this study peak concentrations of the eicosanoid
preceded maximal accumulation of neutrophils, sug¬
gesting that there may be a causal relationship.
Experimental studies in which drugs inhibiting the
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enzyme 5-lipoxygenase and consequently the gene¬
ration of LTB4 were administered have provided
support for this proposal. Reduction in infarct size,
as well as neutrophil accumulation, was observed in
a number of models of coronary artery occlusion
and reperfusion [31, 32]. However, many of these
agents possess other properties such as free-radical-
scavenging activity. More recently, compounds with
LTB4 receptor antagonistic activity have become
available. However, the results reported with these
agents have so far been mixed: one LTB4 antagonist
was reported to be effective in a rat model of
ischaemia and reperfusion [33], whereas another
was ineffective in a canine model of myocardial
infarction [34].
Although there is evidence that both C5a and
LTB4 are involved in causing neutrophil infiltration,
this does not preclude a role for other inflammatory
mediators. The cytokine interleukin-8 (IL-8) is a
recently identified inflammatory mediator [35, 36],
which can also elicit neutrophil infiltration in vivo
[37]. We have found that a homologue of IL-8 is
generated in vivo, subsequent to the appearance of
C5a, in a model of acute inflammation in the rabbit
[38]. As yet there is no evidence for a role for IL-8
in myocardial infarction; however, it remains a
potential candidate. Platelet-activating factor (PAF)
is another possible mediator of inflammation. In a
model of intestinal ischaemia and reperfusion, admi¬
nistration of a PAF receptor antagonist is reported
to reduce leucocyte adhesion and extravascular mig¬
ration [39], Although PAF antagonists are also
reported to reduce myocardial infarct size [40, 41],
in a rabbit model of myocardial ischaemia we found
WEB 2086, a potent PAF antagonist, to be without
effect on neutrophil accumulation [42].
Mechanisms of tissue damage by neutrophils
Neutrophils have been suspected as the agents of
tissue injury in a number of pathological states,
such as rheumatoid arthritis and acute respiratory
distress syndrome, as well as in myocardial infarc¬
tion. This suspicion hinges partly on their ability to
release a number of potentially injurious agents
when activated. These fall into two main groups:
reactive oxidizing chemicals and proteolytic
enzymes.
The first of these are products of the membrane-
bound NADPH oxidase enzyme, which catalyses
the production of superoxide anions, hydrogen per¬
oxide and hydroxyl radicals. Although these radicals
are themselves able to react with a number of
biological substrates, it is thought that another
product of oxidative metabolism is of greater
importance in vivo. Hydrogen peroxide combines
with the enzyme myeloperoxidase, one of the major
constituents of neutrophil granules, to form an
enzyme-substrate complex that oxidizes halides, and
in particular Cl~, to produce highly reactive toxic
products such as hypochlorous acid (HOC1) [43],
HOC1 is now thought to be the major product of
oxidative metabolism by neutrophils [44], These
free radicals are able to cause direct cellular injury,
for instance by oxidizing membrane phospholipids,
thereby increasing the fluidity and permeability of
the membrane and reducing its integrity. In addi¬
tion, they also affect the activity of neutrophil
proteolytic enzymes as described below.
Neutrophils possess a number of enzymes stored
within granules. Three of these have been of particu¬
lar interest with respect to tissue damage: the serine
proteinase, elastase, and the two metalloproteases,
collagenase and gelatinase. These enzymes are able
to degrade key components of the extracellular
matrix. Using endothelial monolayers in vitro, elas¬
tase has been shown to alter barrier properties and
to cause detachment or even lysis of cells [45—47].
However, inhibitors of serine proteinases are present
in the extracellular fluid in high concentrations in
order to prevent inappropriate elastase activity.
Furthermore, the metalloproteases are secreted in
an inactive form [48]. Despite these safeguards,
there is evidence to suggest that these enzymes are
able to function at sites of inflammation [49].
Chlorinated oxidants are thought to inactivate
o^-proteinase inhibitor, thus destroying the anti-
proteinase shield [50]. It has also been shown that
activation of collagenase is dependent on the
presence of a functional NADPH oxidase system
[51]. It would appear therefore that by releasing
free radicals in addition to proteolytic enzymes, the
potential of neutrophils to cause tissue injury is
considerably enhanced.
It has been reported recently that the collagen
content of myocardial tissue decreases by 50% after
3h of ischaemia in a rat model [52], Whether this is
due to neutrophil-derived proteases or to tissue
procollagenase enzymes has yet to be determined.
So far little work has been carried out into the effect
of elastase or other proteases on myocardial injury.
As selective and potent inhibitors become available
this situation will no doubt change.
Tissue damage by oxygen free radicals
Since the 1970s it has been accepted that re-
oxygenation of ischaemic myocardium may be asso¬
ciated with immediate and extensive ultrastructural
damage, and the damage is caused, at least in part,
by oxygen free radical species derived from the
administered oxygenated medium [53], Neutrophils
also generate these reactive radicals, although to
what extent oxygenated blood and neutrophils each
contribute to the amount of free-radical damage has
not been quantified. The role of oxygen free radicals
in myocardial infarction has been the subject of a
large number of studies using agents which can
scavenge these radical species. As with studies into
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the role of neutrophils the results of intervention to
reduce free-radical damage have been mixed. Of 32
studies of interventions to reduce free-radical
damage in animal models of myocardial injury, 16
showed benefit and 16 did not [54]. Although the
scavenging agents catalase and superoxide dismu-
tase can neutralize oxygen free radicals in the
extracellular space, they are large molecules and do
not readily enter cardiac myocytes [55]. Yet within
myocytes, free radicals generated by the mito¬
chondria cause damage to contractile proteins [56].
This may explain the modest protection afforded by
scavenging agents in the published studies.
Effects of ischaemia on coronary microvasculature
One of the consequences of ischaemia is injury to
the coronary microvasculature itself. Successful
reperfusion of the large coronary arteries may not
always be accompanied by restoration of blood flow
within the area of injured myocardium. This has
been termed the 'no-flow' phenomenon [57], and it
appears to follow endothelial injury after periods of
ischaemia greater than 60-90 min. Plugging of the
microvessels by neutrophils during reperfusion con¬
tributes substantially to the no-reflow phenomenon,
and is likely mediated both by neutrophil adhesion
to damaged endothelium, together with neutrophils
wedging in the microvessels. Such physical trapping
occurs because activated neutrophils are less
deformable, and hence their ability to squeeze
through capillary lumina is impaired [58], In the
clinical situation, the no-reflow phenomenon occurs
when restoration of patency is achieved by
thrombolysis or angioplasty, yet reperfusion of myo¬
cardium in the ischaemic area remains impaired.
Such impairment of myocardial perfusion is asso¬
ciated with a worse outcome, measured in terms of
left ventricular ejection fraction, than patients in
whom microvascular and hence myocardial tissue
reperfusion is achieved [59].
Ultrastructural studies suggest that endothelium
tolerates hypoxia better than cardiac myocytes,
since zones of no-reflow are found only within areas
of myocardial necrosis [60]. Endothelial cell swell¬
ing is seen as a result of ischaemic damage, but it
only appears together with irreversible myocyte
injury [57]. However, there is accumulating evi¬
dence that important alterations in endothelial func¬
tion may occur much earlier in ischaemia, without
evidence of morphological damage. Recent studies
have shown that brief periods of ischaemia cause
loss of endothelium-dependent vasodilatation and
enhanced coronary vasoconstrictor responses [61],
together with increased permeability of the coronary
endothelium [62]. These functional changes occur
without evidence of structural injury. Furthermore,
administration of pharmacological agents which
mimic endothelial products, including nitric oxide
[63], iloprost (a stable analogue of prostacyclin)
[64] and adenosine [65], has been shown to reduce
experimental infarct size, probably both by replen¬
ishing protective endogenous autocoids lost during
the ischaemic episode and also by inhibiting
neutrophil-endothelial interactions. Such inter¬
ventions may become clinically important, since
limiting the no-reflow phenomenon may allow
better myocardial perfusion after epicardial coron¬
ary artery occlusion-reperfusion.
MYOCARDIAL RESPONSE TO ACUTE ISCHAEMIA:
CELLULAR EVENTS AND INTERCELLULAR
SIGNALLING
Neutrophils have the potential to damage myo¬
cardium by their release of toxic products. Whether
such toxins are liberated in a random fashion by
activated neutrophils within an area of injured
myocardium, or whether they are targeted towards
injured myocytes in particular has not yet been
determined. However, emerging evidence suggests
that injured cardiac myocytes may signal their own
destruction by activating such mechanisms at their
cell surface.
Neutrophil-endothelial adhesion
For neutrophils to reach the interstitium and then
the myocytes they have to adhere to and then
traverse the endothelial barrier. At sites of inflam¬
mation neutrophils roll along endothelium by
engaging and disengaging to the endothelial cells by
adhesive interactions involving the neutrophil glyco¬
protein L-selectin (formerly termed LAM-1, Mel-14,
LECAM-1, Leu-8) [66]. Tethering of neutrophils at
sites of inflammation occurs via the expression of
the endothelial glycoprotein P-selectin (formerly
GMP-140, PADGEM, CD62), which appears on
cell surfaces within minutes of endothelial activation
by inflammatory mediators [67]. The rapid expres¬
sion of P-selectin suggests that it may mediate early
neutrophil adhesion to activated or injured endo¬
thelium, since it is expressed from intracellular or
cell membrane stores without the need for synthesis
of new proteins [67]. P-selectin interacts with its
carbohydrate ligand CD15 on the neutrophil [68].
It appears that the neutrophils undergo an early
change in the expression of their adhesion molecule
presentation, with L-selectin exhibiting a rapid
increase in affinity followed by down-regulation of
its expression and the activation of the CD 18
adhesion glycoprotein complex [69, 70].
Migration of neutrophils across the endothelial
layer follows adhesion, and requires contact between
the neutrophil integrin CD 18 complex and the
endothelial adhesion molecule, intercellular adhesion
molecule-1 (ICAM-1) [71], Activated endothelium
synthesizes and expresses the adhesion glycoproteins
ICAM-1 and E-selectin (formerly endothelial-
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leucocyte adhesion molecule-1). ICAM-1 is present
constitutively on endothelium at low levels, but its
expression is increased substantially by inflam¬
matory mediators [72]. Monoclonal antibodies to
the CD 18 antigen have been shown to be very
effective in reducing neutrophil infiltration into
ischaemic-reperfused myocardium [42] and in
reducing myocardial infarct size [73]. In the latter
study a monoclonal antibody to ICAM-1 was also
protective.
E-selectin only appears on the endothelium after
stimulation [74] and requires protein synthesis de
novo. The corresponding ligand for E-selectin on the
neutrophil has been identified recently as another
carbohydrate, sialylated Lewis X tetrasaccharide
[75]. Both E-selectin and ICAM-1 mediate neutro¬
phil adhesion to and migration through activated
endothelium. It may be envisaged that after early
initiation of neutrophil adhesion to ischaemic-
reperfused endothelium by endothelial expression of
P-selectin, further neutrophil-endothelial adhesion
to damaged myocardium may be promoted by the
ICAM-1/CD18 and E-selectin/sialylated Lewis X
tetrasaccharide mediated interactions. This hypo¬
thesis is supported by current research. Very
recently, increased production of messenger RNA
(mRNA) for both P- and E-selectin has been
demonstrated in the endothelium of blood vessels
from the injured segments of ischaemic-reperfused
hearts [76a, 76b].
Neutrophil-cardiac myocyte interactions
Once neutrophils have reached the extravascular
space they can directly attack cardiac myocytes.
Whether this damage is directed specifically towards
previously injured myocytes is not known, but
current research indicates that activated myocytes
appear to exhibit signals which activate neutrophil
wound repair mechanisms. Recent studies indicate
that cardiac myocytes, as well as endothelial cells,
express ICAM-1 in response to activation by inflam¬
matory mediators [76c]. Neutrophils bind to
ICAM-1 on activated myocytes by a process involv¬
ing their adhesion molecule complex CD 18 [77],
and this receptor-mediated adhesion appears to be
the main mechanism of neutrophil adherence to
cardiac myocytes. Furthermore, mRNA for ICAM-1
can be induced in both endothelial cells and cardiac
myocytes by post-ischaemic cardiac lymph [78], and
recent data suggest that direct neutrophil-mediated
injury of cardiac myocytes requires adhesion by the
CD18/ICAM-1 mechanism [28]. However, expres¬
sion of ICAM-1 by myocytes requires protein syn¬
thesis de novo [77]. Since it has been shown that
complement activation products are present on the
surface of myocytes after ischaemia, a possible
mechanism of early neutrophil attachment is via a
CD lib/CD 18 (complement receptor 3) interaction
with iC3b.
It is possible therefore that administration of
monoclonal antibodies to CD18 or ICAM-1 is able
to confer protection in models of myocardial ischae¬
mia by inhibiting direct neutrophil-cardiac myocyte
interactions as well as by inhibiting neutrophil
migration through the endothelium. These recently
published and ongoing studies provide exciting new
evidence that injured myocardium plays an active
role in the inflammatory response to ischaemic
injury.
Myocardial defence against ischaemic injury
Poorly understood endogenous defence mecha¬
nisms exist within the heart which offer some myo¬
cardial protection against periods of ischaemia.
Ischaemic preconditioning, where brief periods of
ischaemia afford protection against a subsequent,
more prolonged ischaemic episode, is a well-
recognized phenomenon [79], The tolerance to
ischaemia is associated with reduced energy utiliza¬
tion during ischaemia [80], although whether this
accounts for all the protection is not clear. The
purine nucleoside adenosine, released by catabolism
of ATP, appears to have a role in ischaemic pre¬
conditioning, since the beneficial effect of pre¬
conditioning can be abolished by adenosine
antagonists [81].
Adenosine may also have other protective roles in
ischaemic-reperfusion injury. Adenosine has wide¬
spread actions on endothelium, vascular smooth
muscle, cardiac myocytes, neutrophils and platelets,
in addition to its therapeutic pharmacological effects
on conducting tissue. Adenosine possesses a number
of actions which are likely to be protective during
myocardial ischaemia. These include vasodilatation
in response to hypoxia, which may improve local
blood flow in ischaemic areas [82], as well as
protecting against free-radical injury [82, 83].
Adenosine inhibits both the adhesion to endo¬
thelium and the release of superoxide anions by
neutrophils [84, 85]. It has also been reported to
inhibit platelet aggregation in ischaemic myo¬
cardium [86]. Some agents which reduce infarct size
in experimental models are thought to act by
augmentation of adenosine release [87] and admi¬
nistration of adenosine reduces myocardial reper¬
fusion injury in dogs [88]. Endogenous adenosine is
quickly washed out during reperfusion; therefore
agents which mimic or augment adenosine release
are of potential value in myocardial injury.
Heat shock proteins, induced by a prior exposure
to hyperthermia and other stressful stimuli, are
protective against subsequent ischaemic episodes
[89]. However, the requirement for protein synthesis
de novo [90] precludes a major role for these
fascinating proteins in the immediate endogenous
protection against myocardial ischaemia-reperfusion
injury. It seems unlikely therefore that they are
involved in ischaemic preconditioning.
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CONCLUSIONS AND STRATEGIES FOR THE
FUTURE
This review began with a description of the
disasters caused by interference with healing pro¬
cesses after myocardial infarction [2], Our under¬
standing of the behaviour of inflammatory mecha¬
nisms has increased greatly since the study of
Roberts et al. [2] was published. Early reperfusion
is essential for effective tissue salvage after coronary
occlusion. However, it is likely that reperfusion
carries its dangers, in that blood defensive cells,
notably the neutrophil in early stages, are pro¬
grammed to target injured tissue cells. Therapeutic
intervention is possible in order to abolish the
accumulation of neutrophils. This may be beneficial
in the short-term; however, the long-term effects (as
indicated by the trial with anti-inflammatory ster¬
oids) are likely to be deleterious. This is because the
acute inflammatory events trigger the process of
tissue healing and remodelling, events that are
necessary in order to conserve important physical
properties of the ventricular wall. For this reason a
detailed knowledge is required of the mechanisms
involved in the inflammatory events occurring in
ischaemia and reperfusion of the myocardium. Only
with this knowledge will it be possible to design a
rational intervention.
One possible strategy may be to attenuate neutro¬
phil accumulation for a brief period at the start of
reperfusion to disengage the phase of re-oxygenation
from the initial phase of neutrophil accumulation.
While some possible therapeutic agents, such as
monoclonal antibodies to neutrophil adhesion mole¬
cules, are available, the size and cost of a carefully
conducted, randomized trial would be substantial.
Thrombolysis in myocardial infarction is successful,
and the mortality in the large trials so low (10-11%
[91]), that additional benefit over current strategies
would require the study of many thousands of
patients to test the ultimate efficacy and safety of
such a therapy. When the cost of producing such
agents in large quantities becomes economic, such
studies may well be performed.
Encouragingly, however, new low-molecular-mass
carbohydrate agents which bind to the oligo¬
saccharide moieties of adhesion receptors, thus
blocking their action, are cheaper to produce, easier
to manufacture and potentially more readily admi¬
nistered to patients, and are nearing clinical trials.
Another potential agent to reduce inflammation in
myocardial injury is the sCRl receptor, already
shown to be of benefit in animal studies [26].
Prostacyclin analogues which switch off neutrophil
function are another area of therapeutic interest,
although hypotension is a problem [92], In the near
future, results of trials using drugs which act either
as analogues of adenosine or stimulants of its
release are expected, and these and other early
modulations of the inflammatory response may offer
important gains in the management of myocardial
ischaemia.
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